Unnamed: 0,patient_filename,t,text,type,n,cmem_t_reasoning,cmem_t_ans_str,cmem_t_num_update
1478,TCGA-OL-A5RZ.927C0D4A-327A-4168-80C7-151A4B865CC9,0,"FINAL PATHOLOGIC DIAGNOSIS. A. Left axillary sentinel lymph node #1; biopsy: - Two lymph nodes, no tumor (0/2). B. Left axillary sentinel lymph node #2; biopsy: - One lymph node, no tumor (0/1). C. Left breast; simple mastectomy: Invasive ductal carcinoma, SBR grade III arising in a background of. ductal carcinoma in situ, high nuclear grade, solid type, with central necrosis. See parameters. - Uninvolved breast parenchyma with rare microcalcifications associated. with benign acini and focal apocrine metaplasia. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Microscopic measurement: 7mm. B. Composite histologic (modified SBR) grade: III. - Architecture: 3. - Nuclear grade: 3. - Mitotic count: 2. C. Associated intraductal carcinoma in situ (DCIS): present. - Intermediate and high nuclear grades, solid type with central necrosis. - Extent of DCIS microscopically is consistent with the 10.2 X 5.4 X 3.5 cm. of non-mass like enhancement seen radiographically. 2. Excisional biopsy margins: Free of tumor. - Invasive carcinoma >1cm from closest margin. - DCIS 8mm from anterior margin, superior aspect. 3. Blood vessel and lymphatic invasion: Absent. 4. Nipple and skin: Unremarkable. 5. Skeletal muscle: Absent. 6. Axillary lymph nodes: Negative (0/3). 7 Special studies (invasive component, current specimen). - ER: weak expression in 30% of cells. - PR: no expression. - Ki-67: 10-20%. - HER2 (FISH): pending. 8. pTNM (AJCC, 7th edition, 2010): pT1b, NO(sn), MX. Clinical History: The patient is a. -year-old female who presented with an abnormal screening. mammogram on. that revealed a large area of pleomorphic calcifications. biopsied as ductal carcinoma in situ, high grade, solid type with central. necrosis. Left breast MRI on. evealed segmental clumped non-mass. enhancement with mixed kinetics measuring 10.2 X 5.4 x 2.5 cm associated with a. lateral biopsy clip. A 0.7 x 1.0 X 1.0 cm mass with washout kinetics, suspicious. for invasive component was seen just posterior to the biopsy clip. The patient. undergoes simple mastectomy, sentinel lymph node biopsy and breast. reconstruction. Specimens Received: A: Left sentinel lymph node #1. B: Sentinel node #2 left axilla. C: Left breast. Gross Description: The specimens are received in three containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'left sentinel node #1'. Received fresh for intraoperative diagnosis is a 4.0 X 2.0 x 1.0 cm segment of. tan-pink fibrofatty tissue that is dissected for lymph node candidates. Frozen. section diagnosis is 'lymph node, no tumor' per. . The frozen section. remnants are entirely submitted in cassettes A1 FS and A2 FS. The remaining. tissue is entirely submitted in cassettes A3 and A4. B. The second container is additionally identified as, 'sentinel node #2, left. axilla'. Received fresh for intraoperative diagnosis is a 3 X 2.0 X 2.0 cm. segment of tan-brown rubbery tissue grossly consistent with a lymph node. The. cut section reveals an unremarkable surface. The entire lymph node is frozen. Post section diagnosis is 'lymph node, no tumor' for. : The frozen. section remnant is entirely submitted in cassette B1FS. C. The third container is additionally identified as, 'left breast'. Received. fresh and placed in formalin is a 2640 gm mastectomy specimen measuring 32.5 cm. from medial to lateral, 32.5 cm from superior to inferior and 5.3 cm from. anterior to posterior. There is 80 cm long by 0.7-6.5 cm wide tan-brown,. wrinkled skin ellipse on the anterior surface, with ashort suture designating. the superior pole and a long suture designating the lateral pole. The areola. measures 5.5 X 3.5 cm areola and the nipple 1.5 cm in diameter. The nipple. areolar complex displays no evidence of ulceration or retraction. No axillary. tail is present with the specimen. The deep surface is inked black, the. anterior-superior surface blue and the anterior-inferior surface green and the. breast is serially sectioned from medial to lateral into 11 slices. There is a. 1.1 x 0.9 X 0.8 cm, gray-tan mass in slices 7 and 8, 5.5 cm from black ink and. 2.0 cm from blue ink. A metallic clip is identified in slice 7. A 1.5 cm. (greatest dimension) biopsy site is identified, adjacent to the lesion, with a. probable metallic clip (vs. staple) within the node. Additional masses or. nodules are not noted. Representative sections are submitted as follows: C1-8: Representative sections of lesion, slice 7 and 8 (clip in C1, C3. closest approach to blue ink). C9: Intramammary lymph node, adjacent to mass, bisected. C10: Representative slice 6, medial to mass. C11: Representative slice 9, lateral to mass. C12: UOQ, slice # 10. C13: UIQ, slice # 3. C14: LOQ, slice # 9. C15: LIQ, slice # 2. C16: Representative skin. C17-18: Nipple. Tissue fixed for at least 6 hours in 10% NBF and no more than 72 hours.",BRCA,0,"The T stage is determined by the size of the primary tumor. In this report, the invasive carcinoma measures 7mm in size (Breast Pathologic Parameters, 1.A). According to the AJCC 7th edition staging system for breast cancer, a T1 tumor is any tumor that measures 2cm or less in size. T1 is further divided into T1a (0.1-0.5 cm), T1b (0.6-1 cm), and T1c (1.1-2 cm). Therefore, the T stage for this patient is T1b.",T1b,0.0
734,TCGA-AC-A7VB.53881871-C36B-4622-BFC6-4DA3635D7B26,0,"Provider Group : Date of Service: Date Received: FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: A. - F. RIGHT BREAST AND AXILLARY LYMPH NODES, MASTECTOMY, SENTINEL. LYMPH NODE BIOPSIES, AND AXILLARY LYMPH NODE DISSECTION: - Multifocal invasive ductal carcinoma, Nottingham grades 2-3. See comment. - Largest tumor nodule: 1.5 cm in diameter (6 o'clock aspect). - Two smaller nodules: 0.6 and 0.8 cm (7-8 o'clock aspect). - Ductal carcinoma in situ (DCIS), high nuclear grade, solid type. - DCIS comprises less than 10% of biopsy tissue volume, and is associated. with all three invasive tumor nodules. - Mastectomy margins are free of tumor. - Carcinoma is 3 cm from the inferior margin and is at least 6 cm from. all other margins. Metastatic carcinoma in three of fifteen lymph nodes (3/15). - Largest metastatic focus: 0.9 cm in diameter. - Extranodal extension present. - Positive lymph nodes are sentinel lymph nodes #2, #3, and #4. PATHOLOGIC TUMOR STAGING SYNOPSIS: Type and grade (invasive): Invasive ductal carcinoma, Nottingham grade 2-3. Type and grade (in situ): DCIS, high-nuclear grade. Primary tumor: pT1c(m). Regional lymph nodes: pN1c. Distant metastasis: Not applicable. Stage: IIA. Lymphovascular invasion: Indeterminate. Margin status: Negative. COMMENT: The three foci of invasive carcinoma have similar histologic features,. although the tumor grade is somewhat variable in the largest tumor nodule, where. there is a variable rate of mitosis, and nuclear pleomorphism ranging from. intermediate to high-grade. The smaller tumor nodules contain high-grade malignant. Printed: This report continues. Acct No. -. Pathology - Page 1/6. Page 1 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. epithelial cells arranged in solid sheets with frequent mitoses, compatible with. Nottingham grade 3. There is enough morphologic similarity between three nodules. to suggest that they have a common origin. Intradepartmental consultation: concurs with this impression. Invasive Breast Cancer Tumor Staging Information. AJCC Cancer Staging Handbook, 7th Ed. and CAP Protocol (revised June 2012). Previous pathology specimens: his report continues (FINAL). Printed: MR No. -. lage 2 Doc# 1. Pathology - Page 2/6. SPECIMEN IDENTIFICATION. Procedure/specimen type: Modified radical mastectomy. Laterality: Right. Lymph node sampling: Sentinel lymph node biopsies followed by lymph. node dissection. INVASIVE CARCINOMA TUMOR CHARACTERISTICS. Histologic type: Invasive ductal carcinoma (multifocal). Tumor sites: 6:00-8:00. Tumor size: Largest tumor nodule 1.5 cm. Tumor focality: Multifocal. Histologic grade (Nottingham Score): 2-3 of 3. Tubule formation: 3 of 3. Nuclear pleomorphism: 2-3 of 3. Mitotic rate: 2-3 of 3 (variable mitotic rate). Lymphovascular invasion: Indeterminate. Macroscopic and microscopic extent of tumor: No skin or chest wall invasion identified. DUCTAL CARCINOMA IN SITU (DCIS): Present in association with three invasive tumor. nodules. MARGINS. Invasive carcinoma: Negative. Ductal carcinoma in situ: Negative. LYMPH NODES. Total lymph nodes examined. 15. Number of lymph nodes involved. 3. Size of largest metastatic deposit: 0.9 cm. Extranodal extension: Present. PATHOLOGIC STAGING: Primary Tumor (pT): pTic(m). Regional lymph nodes (pN): pN1a. Distant metastasis (pM): Not applicable. AJCC Stage: IIA. ANCILLARY STUDIES: on 2. previous biopsies (additional HER2 studies. pending, to be reported in an addendum). Estrogen receptor: 85-96% positive cells, strong intensity. Progesterone receptor: 0% positive cells. HER2: Additional studies pending, to be reported in an. addendum. Printed: This report continues. Acct No. Pathology - Page 3/6. Page 3 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. Ki-67: Variable, previously reported 7-69%. Source of Specimen: A. Sentinel lymph node;#1--. right axillary. B. Sentinel lymph node;#2--. right axillary. C. Sentinel lymph node;#3-. right axillary. D. Sentinel lymph node;#4. right axillary. E. Breast surgical;right. F. Axillary nodes right. Clinical History/Operative Dx: Right breast cancer. Intraoperative Diagnosis: A. Sentinel node #1. - diagnosis: Negative for carcinoma. B. Sentinel node #2. - diagnosis: Rare atypical cells, suspicious for carcinoma. (Defer to. permanents). D. Sentinel node #4. and. - diagnosis: Positive for carcinoma. The intraoperative interpretation(s) was/were performed and rendered at. Gross Description: A. Part A is designated as sentinel node #1. right axilla, touch prep. Initially received in the fresh. state four frozen section/touch prep evaluation is a 1.0 x 0.8 x 0.6 cm piece of red-tan soft tissue. Examination reveals a 0.7 x 0.6 x 0.5 cm lymph node. The cut surfaces are fatty and rubbery, pink and. tan. Two touch imprint slides are prepared for microscopic evaluation. The lymph node is entirely. Printed: This report continues. Acct No. Pathology - Page 4/6. age 4 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. submitted for routine histology in A1 with a sentinel node protocol performed. B. Part B is sentinel node #2. Initially received in the fresh state for touch prep/frozen section. evaluation is a 1.5 X 1.2 x 1. 0 cm yellow-tan portion of tissue. Examination reveals a 0.8 x 0.6 x 0.6 cm. lymph node. Sectioning demonstrates a rubbery, pink and tan cut surfaces. Two touch imprint slides are. submitted for microscopic evaluation. The Ivmph node is entirely submitted for routine histology in B1. with a sentinel node protocol performed. C. Part C designated as sentinel node #3. right axillary. Received in formalin is a 1.5 x 1.5 x 0.7. cm fragment of fat. Examination reveals two possible apparent lymph nodes, 0.8 x 0.6 x 0.4 cm each. The. lymph node is serially sectioned and entirely submitted for microscopic evaluation in C1 with a sentinel. lymph node protocol performed. D. Part D is designated as sentinel node #4. right axillary. Initially received in the fresh state for. frozen section/touch imprint evaluation is a 1.5 X 1.2x 1.0 cm yellow-green portion of fatty soft tissue. Examination reveals a 1.0 x 0.8 x 0.8 cm dense, pink-gray lymph node. Two touch imprint slides and a. representative section is submitted for frozen section evaluation. The residual frozen tissue is submitted in. D1 for permanent sections and the touch imprint aspect of the lymph node is submitted in D2 for. permanent sections with a sentinel lymph node protocol performed. E. Received fresh labeled ""right breast."" Sutures present for orientation purposes. A portion of tumor is. submitted for. Laterality: Right. Specimen: Mastectomy. Size of mastectomy: (M-L x S-I x A-P): 23.5 x 19x 5 cm. Axillary tail: Not present. Skin: 24 x 18 cm, pigmented skin. Nipple/areola: Yes, center of skin. Specimen weight: 971 grams. Ink code: Blue - superior-anterior, orange - inferior-anterior, black - deep. Stabs: Total # 11, M-I= 1, L-S= 11. Nipple in slab #6. Time of resection: Time placed into formalin: Time out of formalin: Lesion 1: Biopsy site present. Size: 1.5 x 1.4 x 0.8 cm, stellate, gray-white, firm mass. Location: 6:00. Involves slabs # 3-4. Distance to nearest margin(s): 3 cm from inferior margin, 6 cm from deep margin. Lesion #2: Biopsy site present. Size: 0.8 x 0.5 x 0.5 cm. Location: 7:00. Involves slabs #2-3. Distance to nearest margin(s): 6 cm from inferior. Printed: This report continues (FINAL). MR No. -. Acct No. -. Pathology - Page 5/6. - Page 5 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. Lesion #3: No biopsy site present. Size: 0.6 x 0.6 x 0.5 cm. Location: 7:00. Involves slabs #4. Distance to nearest margin(s): 5 cm from inferior. Non-lesional breast: Fibrofatty breast tissue. Cassette summary: E1) smallest 7:00 tumor, previously biopsied (portion of the small tumor submitted for. E2-E4) largest 6:00 lesion,. E5) central breast tissue,. E6-E7) lateral breast tissue,. E8) nipple/subareolar breast tissue,. E9) representative breast tissue,. E10-E11) fibrous tissue medial to largest tumor,. E12) representative medial breast tissue,. E13) mass #3, 7:00,. E14-E15) central posterior breast tissue. F. Part F is which axillary nodes, right. Received in formalin is an 83 gram partially tattered portion of. yellow-tan fatty soft tissue, 13.0 x 9.0 x 2.6 cm. Examination reveals eleven lymph nodes ranging from 0.2. cm to 1.9 X 1.4 x 1.2 cm in greatest dimension. The lymph nodes are entirely submitted for microscopic. evaluation. Cassette summary: F1) four lymph nodes,. Ne. F2) four lymph nodes,. F3) one lymph node, bisected,. F4) one lymph node, bisected,. F5-F6) largest lymph node, serially sectioned. Microscopic Description: A. - C. Immunohistochemical stain: CK OSCAR, showing focal metastatic carcinoma in specimens B and. C. D. Immunohistochemical stain: CK OSCAR, highlighting metastatic carcinoma. HER2 - results pending, to. be reported in an addendum. E. Immunohistochemical stain: HER2, to be reported in an addendum. F. Microscopic sections have been examined. The microscopic findings are reflected in the diagnosis. rendered. Printed: END OF REPORT (FINAL). MR No. -. Acct No. 'atient Name -. Pathology - Page 6/6. uge 6 Doc# 1.",BRCA,1,"The largest tumor nodule measures 1.5 cm in diameter, which falls within the T1c category (1.1-2 cm) according to Rule 2 and Rule 3.",T1c,1.0
1497,TCGA-PL-A8LZ.436F3280-98C7-4FA9-BD6F-1B02CAF1D262,3,"Sex: Female. Date of Tumour Procurement: 1. GROSS ASSESSMENT: Cut section showed a chalky white tumour. 4x3x2cm,. 2. MICROSCOPIC ASSESSMENT. Microscopic description: Section shows an invasive tumour growing in solid nests and. tubular patterns. It is composed of cells having moderately pleomorphic hyperchromatic. nuclei and amphophilic cytoplasm. The stroma is desmoplastic containing thin-walled. vascular channels, tumour cells and lymphocytes. Focal areas of necrosis noted,. 3. Tumour Type: Malignant. 4. Tumour Site: Left Breast. 5. Distance of invasive carcinoma to closest margin: 5mm. Which margin? Deep resection. 6. HISTOLOGICAL DIAGNOSIS: Invasive ductal carcinoma, NOS. 7. COMMENTS: nil. Dr. Reporting Pathologist Name.",BRCA,2,"The report states that the size of the tumor is 4x3x2 cm, which is equivalent to 40 mm x 30 mm x 20 mm or a maximum size of 40 mm. According to Rule 2, a T1 tumor is any tumor that measures 2 cm or less in size. Therefore, the T stage for this patient's cancer is T1.",T1,2.0
515,TCGA-A2-A0T0.6F5EBE67-0A25-4B20-A1F6-9CE6C4FF4096,1,"SURGICAL REPORT. Sex: F. Date Collected: Date Received: M.R. Number: Account Number. Doctor: PRE-OPERATIVE DIAGNOSIS. LEFT BREAST CANCER. POST-OPERATIVE DIAGNOSIS. LEFT BREAST CANCER. PROCEDURE. LEFT BREAST LUMPECTOMY WITH AXILLARY LYMPH NODE DISSECTION. TISSUES. A. BREAST EXCISION NEEDLE LOC, SIMPLE, MARGINS,ETC - LEFT. B. AXILLARY - CONTENTS LEFT. C. AXILLARY - ADDITIONAL CONTENTS LEFT. D. MARGINS - ADDITIONAL LATERAL. E. MARGINS - ADDITIONAL MEDIAL. ADDENDUM 2. HER-2 (IHC) -. o. NOT AMPLIFIED. SPECIAL STAINS PERFORMED: Her-2 (IHC) (HA). Revlewed and electronically signed out by: ADDENDUM. ESTROGEN AND PROGESTERONE RECEPTOR RESULTS: ESTROGEN RECEPTORS -. NEGATIVE IN THE MALIGNANT CELLS (0%). PROGESTERONE RECEPTORS- -. NEGATIVE IN THE MALIGNANT CELLS (0%). Comment: The control tissues for Estrogen and Progesterone Receptor. Immunohistochemical Studies display appropriate staining pattern. 3. SURGICAL REPORT. FS DIAGNOSIS. A. LEFT BREAST LUMP (GROSS MARGINS) -. PORTION OF BREAST TISSUE WITH TUMOR (3.2 X 3.1 X 3.0 CM.) EXTENDING TO. LATERAL SURGICAL MARGIN AND WITHIN 0.1 CM. OF THE MEDIAL SURGICAL. MARGINS. ALL OF THE REMAINING DESIGNATED SURGICAL MARGINS ARE WITHIN 0.6 CM. OF THE TUMOR (GROSS). (REPORTED TO SURGEON: Diagnosed by: FINAL DIAGNOSIS. A. LEFT BREAST LUMP -. BREAST TISSUE DISPLAYING INVASIVE POORLY DIFFERENTIATED DUCTAL. ADENOCARCINOMA OF THE BREAST, 3+3+3, 3.2 CM. IN GREATEST DIMENSION. TUMOR EMBOLI SEEN IN ANGIOLYMPHATIC SPACES. MARGINS ARE FREE. THE NEAREST MARGIN IS 0.1 CM. TO THE TUMOR AS REPORTED IN THE GROSS. EXAMINATION. B. AXILLARY CONTENTS LEFT -. LYMPH NODE, METASTATIC DUCTAL ADENOCARCINOMA IN TWO LYMPH. NODES FROM A TOTAL OF TWELVE LYMPH NODES (2/12). THE LARGEST NODE WITH TUMOR IS 1 CM. IN GREATEST DIMENSION. THE TUMOR TOTALLY OCCUPIES THE NODE WITH EXTRACAPSULAR. EXTENSION TO THE FAT. C. ADDITIONAL AXILLARY CONTENTS, LEFT -. LYMPH NODES, TWO REACTIVE. D. ADDITIONAL LATERAL MARGINS -. FIBROADIPOSE TISSUE AND BREAST TISSUE, NO TUMOR SEEN; HOWEVER, THERE IS. MICROSCOPIC FOCUS OF TUMOR EMBOLI SEEN IN ANGIOLYMPHATIC SPACES. E. ADDITIONAL MEDIAL MARGINS- -. FIBROADIPOSE TISSUE AND BREAST TISSUE, NO TUMOR SEEN. PTNM CLASSIFICATION: T2 N1 MX, STAGE IIB, DUCTAL ADENOCARCINOMA, G3. PQRI CATEGORY II: 3260F. Diagnosed by: /. COMMENT. This case is discussed with. SURGICAL REPORT. GROSS DESCRIPTION. The specimen is received in five separate containers labeled. designated A. through E. A. The container is received fresh unfixed labeled ""left breast lump"" and consists of a 30 gm. ovoid. mass of apparent fatty and fibrous-encased tissue which is 4.5 x 3.5 x 2.8 cm. in greatest overall. dimension. There is a single short suture indicating superior margin inked with orange, inferior. is. inked red. There is a single long suture indicating lateral margin inked with black dye, medial. is. inked blue. There are two short sutures indicating anterior margin inked with green dye, deep. is. inked yellow. Sectioning reveals a tumor, a gray-white irregular bordered tumor which is 3.2 x 3.1. x 3 cm. in greatest overall dimension and has scattered yellow-tan chalky areas varying up to 0.3. cm. in greatest dimension and a central 0.4 cm. slightly gelatinous hemorrhagic area. The tumor. mass grossly appears to involve the lateral/black margin is 0.1 cm. from the medial/blue, 0.5 cm. from the anterior/green, 0.5 cm. from the deep/yellow, 0.5 cm. from the superior/orange and 0.5. cm. from the inferior/red. Gross margins are obtained by Dr. The entire specimen is. submitted in seventeen blocks. Key Note Block Summary: 1-lateral/black, 2-medial/blue, 3-anterior/green, 4. deep/yellow, 5-superior/orange, 6-inferior/red (all are perpendicular), 7 through 17-remaining. B. The container is received fixed labeled ""left axillary contents"" and consists of an irregular mass of. apparent fat 3.5 x 3 x 2.5 cm. Sectioning reveals pink-tan nodules varying up to 2 cm. in greatest. dimension. The larger nodes are hemisected and placed in cassettes 2 through 5. C. The container is received fixed labeled ""additional axillary contents"" and consists of an irregular. mass of apparent fatty tissue which is 1 x 0.6 x 0.4 cm. Sectioning reveals a 0.4 cm. pink-tan. nodule. The entire specimen is submitted as one section in one block. D. The container is received fresh unfixed labeled ""additional lateral margin"" and consists of an 8. gm. ovoid mass of apparent fatty and fibrous encased tissue is 3 x 2.5 x 2 cm. in greatest overall. dimension. There is an attached suture indicating new lateral margin inked with red dye. Sectioning reveals fat and a scant amount of fibrous tissue. The entire specimen is submitted in. four blocks. E. The container is received fresh unfixed labeled ""additional medial margin - suture on new medial. margin"" and consists of an 8 gm. ovoid mass of apparent fatty and fibrous encased tissue is 3 x. 3. x 2.5 cm. in greatest overall dimension. There is a suture indicating new medial margin inked. with blue dye. The entire specimen is submitted in four blocks. MICROSCOPIC EXAM. MICROSCOPIC EXAMINATION CONDUCTED BY PATHOLOGIST CONFIRMS FINAL DIAGNOSIS. SURGICAL REPORT.",BRCA,1,"According to the report, the size of the primary tumor is 3.2 cm, which falls under the T2 category in the AJCC staging system for breast cancer. The rule used to determine this is: Rule 2: A T2 tumor is any tumor that measures more than 2 cm but not more than 5 cm in size.",T2,3.0
1499,TCGA-S3-A6ZF.7B53A0D4-E13E-4573-B0A2-BB55AE54BD62,1,"Female. Admission Date: Discharge Date: Pathology Addendum Report. Collected Date/Time: Received Date/Time: Addendum Report. ASSAY PERFORMED: HER2 GENE AMPLIFICATION BY DUAL IN SITU HYBRIDIZATION USING THE. HER2 Dual ISH DNA PROBE COCKTAIL. Number of nuclei scored: 20. Total HER2 signals: 60. Total CHR 17 signals: 39. HER2/CHR 17 ratio: 1.5. INTERPRETATION: - NEGATIVE FOR HER2 GENE AMPLIFICATION. NOTE: THE ASSAY WAS PERFORMED AS A REFLEX TEST AFTER THE HER2/NEU IMMUNOSTAIN WAS 2+. SPECIMEN TYPE: The. HER2. is performed on a formalin-fixed paraffin-embedded tissue slide from. block C3. DESCRIPTION OF THE ASSAY: The. HER2. assay. enables the HER2. gene and Chr17 centromere to be co-hybridized and visualized via light microscopy on the same slide. Specifically for this assay,. HER2 is detected by a dinitrophenyl (DNP) labeled probe visualized utilizing. SISH DNP (silver in situ hybridization). detection kit. The Chr17 centromere is targeted with a digoxigenin (DIG) labeled probe and detected using. ISHDIG. detection kit. Dual ISH staining results in visualization by light microscopy and which HER2 appears as discrete black signals (SISH). and Chr17 as red signals in nuclei of normal cells serving as internal positive control for staining) as well as in carcinoma cells. SLIDE SCORING: Once an adequate target area is identified the reader records the scores for HER2 and Chr17 copy numbers that. are present in 20 representative nuclei. If the resulting HER2 / Chr17 ratio falls within 1.8-2.2 (EQUIVOCAL) the reader is. recommended to score an additional 20 nuclei and the resulting ratio is calculated from the total 40 nuclei. HER2 gene status is. reported as non-amplified (HER2/ Chr17 < 2.0) or amplified (HER2/Chr17> 2.0). Print Date/Time: Distribute to: Patient Locations: Pathology Addendum Report. Collected Date/Time: Received Date/Time: T. f this assay were determined by. is assay has been approved by the U.S. Food and Drug Administration This laboratory is certified under the. Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. cpt: 88368 x2. (Electronic signature). Verified: Collected Date/Time: Received Date/Time: Addendum Report. IMMUNOHUSTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE RECEPTORS, AND. HER-2NEU IN INVASIVE MAMMARY CARCINOMA. ESTROGEN RECEPTORS: 99 %, positive. PROGESTERONE RECEPTORS: 40 %, positive. STAINING INTENSITY: moderate. HER-2NEU: SCORE 2+, EQUIVOCAL. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Block C3) using the following monoclonal. antibodies: Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2) and Her-2neu. Clone 4B5); control sections. for HER-2Neu are provided within a kit (score 0 MCF-7, score 1+ T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection. system used: polymer. Primary antibodies, reagents and control sections for HER-2neu are all provided by). All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively stained nuclei of tumor. cells. Reference values (CAP accreditation program checklist 2010 and guidelines on webpage): Positive: nuclear staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist 2010 and guidelines. on. webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a portion of the. membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or > 10% of tumor cells but only a portion of the membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in >10% of tumor cells or. Print Date/Time. Pathology Addendum Report. Collected Date/Time: Received Date/Time: circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform membrane staining. A. homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. The performance characterietice of theee antihnding were determined by the. ey have not been cleared or approved by the U.S. Food and Drug Administration The FDA has determined that such. clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. (Electronic signature). Verified. Collected Date/Time: Received Date/Time: Final Diagnosis. A. RIGHT BREAST, CORE BIOPSY: - INVASIVE DUCTAL CARCINOMA. B. RIGHT SENTINEL LYMPH NODE, BIOPSY: - NO EVIDENCE OF CARCINOMA IN ONE LYMPH NODE. - SEE SPECIAL STAINS SECTION. C. RIGHT BREAST, TOTAL MASTECTOMY: INVASIVE DUCTAL CARCINOMA GRADE 2, 2.5 CM. - MARGINS OF RESECTION ARE FREE OF CARCINOMA. - SEE SYNOPTIC REPORT, SPECIAL STAINS SECTIONS AND NOTE. NOTE: hormonal receptors and Her2-neu status will be reported in an addendum. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). Print Date/Time. Collected Date/Time: Received Date/Time: LYMPH NODE SAMPLING: Sentinel lymph node(s). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 26 cm. Additional dimensions: 17 x 6 cm. SPECIMEN LATERALITY: Right. TUMOR SITE: INVASIVE CARCINOMA: Upper outer quadrant. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 2.5 cm. Additional dimensions: 2.0 x 2,0 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative. SIZE (EXTENT) OF DCIS: Estimated size (extent) of DCIS (greatest dimension using gross and microscopic evaluation) is at least 0.3 cm (constituting. about 5% of the entire tumor mass.). ARCHITECTURAL PATTERNS: Comedo. Cribriform. NUCLEAR GRADE: Grade III (high). NECROSIS: Present, central (expansive ""comedo"" necrosis). LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score 2: 10% to 75% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very. large and bizarre forms. MITOTIC COUNT: Score 2. OVERALL GRADE: Grade 2: scores of 6 or 7. MARGINS: Margins uninvolved by invasive carcinoma. Print Date/Time: Collected Date/Time: Received Date/Time: Distance from closest margin: 25 mm. Distance from posterior margin: 25 mm. Margins uninvolved by DCIS (if present). Distance from closest margin: posterior mm. Distance from posterior margin: 25 mm. LYMPH-VASCULAR INVASION: Present. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1 (no tumor seen). Total number of lymph nodes examined (sentinel and nonsentinel): 1. METHOD OF EVALUATION OF SENTINAL LYMPH NODES: H&E, multiple levels. Immunohistochemistry. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT2: Tumor >20 mm but less than or equal to 50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pNO: No regional lymph node metastasis identified histologically. DISTANT METASTASIS (M): Not applicable. ADDITIONAL PATHOLOGIC FINDINGS: intraductal papilloma. MICROCALCIFICATIONS: Present in DCIS. Source of Specimen. A. Core Biopsy, RT Breast. B. Lymph Nodes, Sentinel Right. C. RT Total Mastectomy. Clinical Information. Palpable mass upper central FNAB positive, patient with right breast mass. PRE-OP DIAGNOSIS: Right breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right t mastectomy and sent to the node biopsy. Gross Description. Specimen is received in 3 parts: A. The specimen is labeled ""CORE BIOPSY"" and is received unfixed for frozen section diagnosis. It consists of 2 cylindrical pieces of. gray-tan soft tissue each measuring 1.5 cm in length and 0.1 cm diameter. Entirely submitted in cassette FSA 1. Time specimen was removed from the patient. Time specimen was placed in formalin. Print Date/Time: Collected Date/Time: Received Date/Time: Ischemic time: 20 minutes. B. The specimen is labeled ""RIGHT SENTINEL NODE"" and is received unfixed for frozen section diagnosis. (Specimen is in. formalin mother 6 hour and less than 48 hours). It consists of a ymph node measuring 1.6 x 1 x 0.5 cm. Sectioned and entirely. submitted in cassette FSB 1. Time specimen was removed from the patient: Time specimen was placed in formalin. Ischemic time: 22 minutes. C. The specimen is labeled ""RIGHT TOTAL MASTECTOMY and is received in formalin. (The specimen is in the formalin. more than 6 hours and less than 48 hours). It consist of mastectomy specimen without lymph nodes weighing 990 grams and. measuring 26 x 17 x 6 cm with brown skin ellipse measuring 24 x 12 cm, containing grossly unremarkable 1.5 cm in diameter nipple. The skin is tagged with a black stitch designating lateral breast. The posterior margin is composed of smooth fascia which is inked. black. The breast is sliced in sagittal planes revealing a 2.5 x 2 x 2 cm an ill-defined firm area which is 2.5 cm away from the deep. margin of resection. The remaining portions reveal unremarkable yellow mammary fat with streaks of white-gray mammary. parenchyma. Representative sections submitted as follows: C1 = nipple. C2-C6 = upper outer quadrant mass. C7 = upper outer quadrant, posterior margin of resection in correspondence of the mass. C8 = representative section upper inner quadrant. C9 = representative section upper outer quadrant. C10 = representative section lower outer quadrant. C11 = representative section lower inner quadreant. Time specimen was removed from the patient. Time specimen was sectioned and placed in formalin. Ischemic time: 15 minutes. Intra Operative Consultation. A. Right breast cores = carcinoms. B. Right sentinel node = no tumor seen. Special Stains / Slides. Immunohistochemical studies were performed on formalin fixed, paraffin-embedded tissue (Block B1) with adequate positive and. negative control sections. Cytokeratins AE1/AE3 and Cam5.2 fail to reveal metastatic carcinoma. The nerformance characteristics of these antibodies were determined by the. ley have not been cleared or approved by the U.S. Food and Drug Administration The FDA has determined that such. clearance or approval is not necessary. 1 nese sesus are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-compiexity clinical laboratory testing. 16 H&E, 4 FS, 16 H&E. Print Date/Time. Collected Date/Time: Received Date/Time: Tissue Code. Print Date/Time:",BRCA,0,"The report states that the size of the largest focus of invasion over 0.1 cm is 2.5 cm, which falls within the range for a T2 tumor (more than 2 cm but not more than 5 cm in size) according to Rule 2.",T2,4.0
1306,TCGA-E9-A22B.FC896EB8-1CEC-46A0-82E1-E3FBFAAB69F1,0,"site : breast, NOS C50.9 the 4/2/11. Laterality:Right, upper outer quadrant. Path Report: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 1.8 x 1.6x1.6cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/4 positive for metastasis (Regional 0/4). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,0,"According to the report, the size of the primary tumor is 1.8 x 1.6x1.6 cm, which is less than 2 cm. Based on Rule 2, a T2 tumor is any tumor that measures more than 2 cm but not more than 5 cm in size. Therefore, this tumor does not meet the criteria for a T2 tumor. Rule 1 states that the T stage is determined by the size of the primary tumor. Modified Rule 8 states that the maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters. Therefore, the tumor size of 1.8 cm is used to determine the T stage. According to the AJCC staging system for breast cancer, a tumor that measures 2 cm or less is classified as a T1 tumor.",T1,5.0
1370,TCGA-EW-A6S9.4FC32F17-7A4D-4FF6-A710-FFFBC610CB56,0,"F. x. x. Pathologic Interpretation: A. SENTINEL NODE #1. METASTATIC CARCINOMA to one lymph node (1/1). Largest tumoral deposit is 1mm. NOTE: Metastatic deposit is not identified in frozen section slide. B. SENTINEL NODE #2. Negative for carcinoma, one lymph node (0/1). C. SENTINEL NODE #3. Negative for carcinoma, one lymph node (0/1). D. RIGHT BREAST MASS: INVASIVE DUCTAL CARCINOMA, poorly differentiated, Nottingham grade 2 (3+2+2=7), 2.0 cm. Surgical resection margins are negative for invasive carcinoma; the closest one is the anterior at 6mm. DUCTAL CARCINOMA IN SITU, intermediate grade, solid and cribriform type with necrosis and retrolobular. involvement present in five out of 15 slides examined. Surgical resection margins are negative for in situ carcinoma; the closest one is the anterior at 10 mm. Lymphovascular invasion is identified. INVASIVE CARCINOMA OF THE BREAST: Complete Excision (Less Than Total Mastectomy, Including. Specimens. Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy With or Without Axillary. Contents) and. Mastectomy (Total, With or Without Axillary Contents; Modified Radical; Radical). Procedure. Excision without wire-guided localization. Lymph Node Sampling. Sentinel lymph node(s). Specimen Laterality. Right. Tumor Site: Invasive Carcinoma. Upper outer quadrant. Histologic Type of Invasive Carcinoma. Invasive ductal carcinoma (no special type or not otherwise specified). Tumor Size: Size of Largest Invasive Carcinoma. Greatest dimension of largest focus of invasion >1 mm: 20 mm. Additional dimensions: 15.0 x 10.0 mm. Histologic Grade: Nottingham Histologic Score. Glandular (Acinar)/Tubular Differentiation. Score 3: <10% of tumor area forming glandular/tubular structures. Nuclear Pleomorphism. Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and. shape. Mitotic Rate. Score 2 (4-7 mitoses per mm2). Overall Grade. Grade 2: scores of 7. Tumor Focality. Single focus of invasive carcinoma. Ductal Carcinoma In Situ (DCIS). DCIS is present. Size (Extent) of DCIS. Present in five out 15 slides examined. Architectural Patterns (select all that apply). Cribriform. Nuclear Grade (see Table 2). Grade Il (intermediate). Necrosis. Present, focal (small foci or single cell necrosis). Lobular Carcinoma In Situ (LCIS). Not identified. Margins. Invasive Carcinoma. Margins uninvolved by invasive carcinoma. Distance from closest margin: 6 mm. Specify margin: Anterior. DCIS. Margins uninvolved by DCIS. Distance from closest margin: 10 mm. + Specify margin: Anterior. Lymph Nodes. Number of sentinel fymph nodes examined: 3. Total number of lymph nodes examined (sentinel and nonsentinel): 3. Number of lymph nodes with macrometastases (>2 mm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 2 mm and/or >200 cells): 1. Number of lymph nodes without tumor cells identified: 2. Extranodal Extension. Not identified. Method of Evaluation of Sentinel Lymph Nodes. Hematoxylin and eosin (H&E), 1 level. Immunohistochemistry pending. Lymph-Vascular Invasion. Not identified. Pathologic Staging (based on information available to the pathologist) (pTNM). Primary Tumor (Invasive Carcinoma) (pT). pT1c: Tumor >10 mm but <20 mm in greatest dimension. Regional Lymph Nodes (pN). Modifier. (sn): Only sentinel node(s) evaluated. Category (pN). pN1mi: Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0. mm). Distant Metastasis (pM). Not applicable. Ancillary Studies. Performed on another specimen. Specify specimen (accession number): xx. Estrogen Receptor (ER). Results and interpretation: Positive Immunoreactive tumor cells present. Quantitation: 50%. Progesterone Receptor (PgR). Results and interpretation: Positive Immunoreactive tumor cells present. Quantitation: 50%. HER2 (results for invasive carcinoma performed on this specimen or a prior core needle biopsy or incisional biopsy). Immunoperoxidase Studies. Positive (Score 3+). Preliminary AJCC Classification (7th Edition): pT1c pN1mi pMn/a. (Final classification pending evaluation of keratin immunostain on sentinel nodes). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. Parts B-C: Immunohistochemistry for keratin is negative. Final AJCC Classification: pT1c pN1mi pMn/a. Intraoperative Consultation: A. SENTINEL NODE #1 ( ), FS: Negative lymph node. B. SENTINEL NODE #2 ( ), FS: Negative lymph node. C. SENTINEL NODE #3 ( ), FS: Negative lymph node. Reported to OR at. XX, MD. Clinical History: Not provided. Operation Performed: Right breast lumpectomy with sentinel node biopsy. Pre Operative Diagnosis: Right breast carcinoma. Specimen(s) Received/Processing Information: Fee Codes: A: A: SENTINEL NODE #1 (. ), FS Frozen section x 1, FS Perm x. 1. B: C: B: SENTINEL NODE #2 (. ), FS Frozen section x 1, FS Perm x 1, Cytokeratin Cocktail. (KER) x 1. D: C: SENTINEL NODE #3 (. 1, FS Frozen section x 1, FS Perm x 1, FSDeep 1 x 1,. Cytokeratin Cocktail (KER) x. 1. D: RIGHT BREAST MASS (1 STITCH SUPERIOR, 2 STITCHES LATERAL, 3 STITCHES. DEEP) H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1,. H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x. 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E. Gross Description: A. Specimen is received fresh and labeled ""Sentinel node #1 (. FS"". The specimen consists of one lymph. node measuring 1.6 x 0.9 x 0.4cm. Specimen is bisected and submitted in toto for frozen section. B. Specimen is received fresh and labeled ""Sentinel node #2 ( ), FS"". The specimen consists of one lymph. node measuring 1.3 x 0.9 x 0.3 cm. Specimen is bisected and submitted in toto for frozen section. C. Specimen is received fresh and labeled ""Sentinel node #3 ( ), FS"". The specimen consists of one lymph. node measuring 1.1 x 0.6 x 0.3 cm. Specimen is bisected and submitted in toto for frozen section. D. Specimen is received in formalin and labeled ""Right breast mass (1 stitch superior, 2 stitches lateral, 3. stitches deep"". The specimen consists of an 8.0 x 8.0 x 4.0 cm lumpectomy specimen, oriented with one. stitch at superior, two stitches as lateral and three stitches as deep. The specimen is inked for evaluation of margins: Posterior black. Anterior yellow. Superior blue. Inferior green. Lateral orange. Medial red. Serial sections are white-gray, ill-defined and firm. A mass is identified measuring 2.0 x 1.5 x 1.0 cm; the. mass is 1.0 cm from the superior margin, 2.0 cm from the inferior margin, 1.0 cm from the anterior margin,. 3.0 cm from the lateral margin, 1.5 cm from the medial margin and 1.0 cm from the deep margin. The. remainder of the specimen consists of yellow-white adipose tissue. No other lesions are identified. 90% of. the mass was submitted for microscopic examination. Representative sections are submitted as follows: Cassette #1. Superior margin perpendicular. Cassette #2. Inferior margin perpendicular. Cassette #3. Lateral margin perpendicular. Cassette #4. Medial margin perpendicular. Cassette #5. Anterior margin perpendicular. Cassette #6. Deep margin perpendicular. Cassettes #7-10. Mass and breast tissue adjacent. Cassettes #11-15. Other areas.",BRCA,1,"According to the report, the size of the largest invasive carcinoma is 20 mm (2.0 cm), which falls within the range for a T1c tumor (>10 mm but <20 mm in greatest dimension) as per the AJCC staging system for breast cancer. The maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters (Modified Rule 8).",T1c,6.0
943,TCGA-B6-A0X1.D792031E-2CCE-4341-B3B3-C7D1D84F8F6B,1,"furgical Path. CLINICAL HISTORY: Large primary tumor left breast. GROSS EXAMINATION: A. ""Left breast biopsy"", received fresh. Fibroadipose tissue 5.4 x 4 cm. containing a central infiltrative yellow white stellate tumor 3 cm. in. diameter. A1- AF1. Representative sections in Block A2-A4. B. ""Left breast"", fresh. A breast measuring 23 x 15 x 6 cm with an overlying. skin ellipse 17 x 9 cm. There is a retracted nipple toward the medial aspect. A sutured incision 6 cm across is present towards the lateral aspect. Numerous. slightly elevated brown warty lesions are present on the skin adjacent to the. nipple. Attached axillary tissue is present measuring 13 x 3 x 5 cm and this. contains numerous enlarged lymph nodes, the largest of which measures 2.5 cm. across. The largest three nodes have been marked with a suture and bisected. Sectioning the breast shows a cavity beneath located in the upper outer. quadrant the incision measuring 5 cm in diameter. The deep margin is 0.5 cm. from the deep edge of the cavity. None of these tumor tissues is present. within wall. The remaining breast tissue is irregular fibrous but shows no. suspicious lesions. Block Summary: B1- nipple and adjacent skin lesions. B2- nipple. B3- deep margin. B4, B5- cavity wall. B6- lower outer quadrant. B7- lower outer quadrant. B8- upper inner quadrant. B9- upper outer quadrant. B10- one lymph node lower axilla. B11, B12- one lymph node. B13- fibrous tissue mid axilla. B14, B15- two lymph nodes. B16- three lymph nodes. B17- four lymph nodes. B18- four lymph nodes upper axilla. B19- four lymph nodes. B20- two lymph nodes. INTRA OPERATIVE CONSULTATION: AF1 ""Invasive ductal carcinoma"". Tissue sent for ER/PR. MICROSCOPIC EXAMINATION: Sections show poorly differentiated invasive ductal carcinoma of no special. type invading breast tissue. The tumor is composed of highly atypical. pleomorphic epithelial cells forming sheets, cords, and columns with minimal. attempt at the gland formation. There is extensive lymphatic channel invasion. by tumor, and extensive tumor necrosis is present. DIAGNOSIS: A. ""LEFT BREAST BIOPSY"": INVASIVE DUCTAL CARCINOMA OF NO SPECIAL TYPE MEASURING 3 CM ACROSS. NSABP NUCLEAR GRADE 3, HISTOLOGIC GRADE 3. EXTENSIVE LYMPHATIC CHANNEL INVASION AND TUMOR NECROSIS IS PRESENT. NO ADJACENT IN SITU CARCINOMA PRESENT. B. ""LEFT BREAST BIOPSY"", LEFT RADICAL MASTECTOMY. : BIOPSY CAVITY WALL CONTAINS RESIDUAL HIGH GRADE INVASIVE DUCTAL CARCINOMA. OF NO SPECIAL TYPE SIMILAR TO THE ABOVE TUMOR. DEEP MARGIN IS FREE OF TUMOR. NIPPLE AND NIPPLE DUCT ARE FREE OF TUMOR. SEPARATE FOCI OF TUMOR IS IDENTIFIED IN THE UPPER INNER QUADRANT,. REPRESENTING MULTIFOCAL TUMOR. METASTATIC TUMOR PRESENT IN 16 OF 21 LYMPH NODES WITH EXTRACAPSULAR. INVASION OF TUMOR PRESENT. (3 OUT OF 4 LOWER AXILLA, 9 OUT OF 11 MID AXILLA, 4 OUT 6 UPPER AXILLA). MULTIPLE SEBORRHEIC KERATOSIS ON SKIN ADJACENT TO NIPPLE. (Electronic Signature).",BRCA,1,"According to the report, the primary tumor measures 3 cm in diameter, which falls within the range for a T2 tumor (more than 2 cm but not more than 5 cm) as stated in Rule 2. The size of the tumor was measured in centimeters in the report, but according to Rule 4, the size should be measured in millimeters. However, using the maximum size given in centimeters still falls within the T2 range, which is allowed by the modified Rule 8.",T2,6.0
630,TCGA-A8-A07O.9ECA4450-A550-44DE-B2E5-FD1CFF02A9FE,1,"Diagnosis: 1. Poorly differentiated invasive solid carcinoma, clearly consistent with. a. ductal breast carcinoma (maximum reconstructed tumor diameter: 3.0 cm; forming. a ventral margin, caudal distance 0.5 cm, lateral 1 cm, cranial 1.2 cm, medial and. dorsal 1.5 cm). The tumor-free, ink-stained resection margin of the ventral follow-up resection. material (preparation 4) gives rise to the following tumor classification: NOS, G III,. pT2 pN0(0/13)LOVORO.",BRCA,0,"Based on the report, the maximum reconstructed tumor diameter is 3.0 cm, which falls within the range for a T2 tumor (more than 2 cm but not more than 5 cm) according to Rule 2, Modified Rule 8, and the AJCC staging system for breast cancer (Rule 6).",T2,7.0
614,TCGA-A8-A06T.5D888D65-685F-4598-884F-AD057DE5FD1D,2,"Diagnosis: 1. Left-sided ablated breast tissue with a 55 mm moderately differentiated invasive ductal. breast carcinoma measuring with completely circumscribed invasion of the lymph vessels. without an intraductal tumor component with a minimum basal margin of 3 mm, a 6 mm. margin at 12 o'clock and surrounding a fibrocystic and proliferating mastopathy with ductal. hyperplasia and sclerotic, intraductal papillomas, tumor-free epidermis, including nipple and. tumor-free isolated samples of pectoral muscle. Tumor classification: M-8500/3, G 2, pT3, pL1, pN1a (1/13), pMx, stage III A. R0.",BRCA,1,"Based on the report, the size of the primary tumor is 55 mm, which exceeds the 5 cm (50 mm) threshold for a T2 tumor. According to the modified Rule 8 and New Rule 9, the maximum size of the tumor should be used and rounded down to the nearest whole number for T stage determination. Therefore, the T stage is T3.",T3,8.0
784,TCGA-AO-A03R.D779EEF8-C83C-4CCA-A140-9BF15DCF14AE,1,"Clinical Diagnosis & History: y/o femnle with left breast cancer on core biopsy IDC/DCIS. Specimens Submitted: 1: SP: Sentinel node #1, level one . left axilla (fs). 2: SP: Sentinel node #2, level one, left axilla (fs). 3: SP: Sentinel node #3, level one, left axilla (fs). 4: SP: Left breast. 5: SP: Levels one and two left axillary contents (. 6: SP: Level two left axillary contents. 7: SP: Level three left axillary contents. DIAGNOSIS: 1). LYMPH NODE, SENTINEL #1 LEVEL I LEFT AXILLA; BIOPSY: - METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). - THERE IS EXTRANODAL CAPSULAR EXTENSION OF CARCINOMA (<2 MN). 2). LYMPH NODES, SENTINEL #2 LEVEL I LEFT AXILLA; BIOPSY: - METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1), 2.1 MM FOCUS, SEE NOTE. THERE IS NO EXTRANODAL EXTENSION OF CARCINOMA. NOTE: THE CARCINOMA IS NO LONGER PRESENT ON DEEPER H&E STAINED SECTIONS. 3). LYMPH NODE, SENTINEL #3 LEVEL I LEFT AXILLA; BIOPSY: - ONE BENIGN LYMPH NODE (0/1). 4). BREAST, LEFT; TOTAL MASTECTOMY: - INVASIVE POORLY DIFFERENTIATED DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC. GRADE III/III (SLIGHT OR NO TUBULE FORMATION) NUCLEAR GRADE III/III (MARKED. VARIATION IN SIZE AND SHAPE) MEASURING 5.0 CM IN LARGEST DIMENSION GROSSLY. DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID AND CRIBRIFORM. TYPES, WITH HIGH NUCLEAR GRADE AND MODERATE NECROSIS. THE DCIS CONSTITUTES <= 25% OF THE TOTAL TUMOR MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE UPPER OUTER QUADRANT AND UPPER. INNER QUADRANT. THE DCIS IS LOCATED IN THE UPPER INNER QUADRANT AND LOWER INNER QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA IS. IDENTIFIED. NO CALCIFICATIONS ARE IDENTIFIED IN EITHER THE INVASIVE OR IN SITU. COMPONENT. - CALCIFICATIONS ARE PRESENT IN THE BENIGN BREAST PARENCHYMA. - EXTENSIVE VASCULAR INVASION IS PRESENT. - POSITIVE PERINEURAL INVASION. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE ATTACHED SKELETAL MUSCLE IS NEGATIVE FOR TUMOR. THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES, FIBROCYSTIC. CHANGES AND FIBROADENOMATOUS CHANGES. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF POSITIVE. LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES EXAMINED) : LEVEL. I: 0/1. 5). LYMPH NODES, LEVELS I AND II LEFT AXILLARY CONTENTS; EXCISION: - MICROMETASTATIC CARCINOMA IN ONE OUT OF EIGHTEEN LYMPH NODES (1/18). - THERE IS NO EXTRANODAL EXTENSION OF CARCINOMA. 6). LYMPH NODE, LEVEL II LEFT AXILLARY CONTENTS; EXCISION: - UNREMARKABLE FIBROADIPOSE TISSUE. 7). LYMPH NODES, LEVEL III LEFT AXILLARY CONTENTS; EXCISION: FOUR BENIGN LYMPH NODES (0/4). NOTE: RESULTS OF SPECIAL STAINS (ER,PR,HER2-neu) WILL BE REPORTED AS AN. ADDENDUM. SUMMARY OF LYMPH NODES: 3/26. TUMOR STAGE: T2, pN1a, MX STAGE GROUPING IIB. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. M.D.,. Special Studies: Special Stain. Comment. RECUT. level. ER-C. PR-C. HER2-0. NEG CONT. IMM RECUT. NEG-HER2. Gross Description: 1) The specimen is received fresh for frozen section consultation, labeled. ""Sentinel node number one, level 1, left axilla"" and consists of a single. lymph node measuring 1.3 x 0.9 x 0.7 cm. The specimen is bisected. Entirely. submitted for frozen section. Summary of sections: FSC -- frozen section control. 2). The specimen is received fresh for frozen section consultation, labeled. ""Sentinel node number two, level 1, left axilla"" and consists of two lymph. nodes measuring 1.1 x 0.5 x 0.5 and 0.8 x 0.6 x 0.4 cm. The larger lymph. node is inked black. Entirely submitted for frozen section. Summary of sections: FSC -- frozen section control. 3) The specimen is received fresh for frozen section consultation, labeled. ""Sentinel node number three, level 1, left axilla"" and consists of a single. lymph node measuring 1.0 x 0.7 x 0.6 cm. Lymph node is bisected. Entirely. submitted for frozen section. Summary of sections: FSC -- frozen section control. 4). The specimen is received fresh labeled, ""left breast, stitch marks. axillary tail"" and consists of a breast with attached axillary tail. The. breast measures 28.0 x 25.0 x 5.0 cm with overlying skin ellipse measuring. 22.0 x 10.0 cm. Situated eccentrically on the skin surface is a nipple. measuring 1.2 x 1.2 cm and areola measuring 2.0 x 2.0 cm. A suture. demarcates the axillary tail which measures 6.0 x 5.0 cm. The posterior. surface of the breast is inked black, anterior superior - blue, anterior. inferior - green and the specimen is serially sectioned to reveal a firm. white mass measuring 5.0 x 2.5 x 2.0 cm, and located in the upper inner. quadrant extending to the upper outer quadrant, measuring 2.0 cm from the. closest deep margin. The remaining breast tissue shows a fibrofatty cut. surface. The axillary tissue is dissected to reveal a lymph node. Representative sections are submitted, including the lymph node. Summary of sections: N nipple. NB - nipple base. S skim. D - deep margin. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. AA-axillary tail. AALN-a bisected lymph node in axillary area. 5). The specimen is received fresh, labeled ""Levels 1 and 2 left axillary. contents"". It consists of a 3 x 2 x 1 cm portion of fibroadipose tissue. Multiple lymph nodes identified measuring from 0.5 to 1.1 cm in greatest. dimension. All lymph nodes are submitted. Summary of sections: LN - lymph nodes. 6) The specimen is received in formalin, labeled ""level 2, left axillary. contents"" and consists of a 1.7 x 1.3 x 0.3 cm portion of fatty tissue. Entirely submitted. Summary of sections: U-undesignated. 7) The specimen is received in formalin, labeled ""level 3, left axillary. contents"" and consists of two lymph nodes measuring 0.5 cm and 1.3 cm in. maximum dimension. Entirely submitted. Summary of sections: LN- lymph node. BLN- bisected lymph node. Summary of Sections: Part 1: SP: Sentinel node #1, level one , left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 2: SP: Sentinel node #2, level one, left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 3: SP: Sentinel node #3, level one, left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. Part 4: SP: Left breast. Block. Sect. Site. PCs. 1. aa. 1. aaln. 2. d. 2. 3. liq. 3. 2. loq. 2. 1. n. 1. 1. nb. 1. 1. s. 1. 10. 10. 2. uiq. 2. 2. uog. 2. Part 5: SP: Levels one and two left axillary contents. Block. Sect. Site. PCs. 6. LN. 18. Part 6: SP: Level two left axillary contents. Block. Sect. Site. PCs. 1. u. 1. Part 7: SP: Level three left axillary contents. Block. Sect. Site. PCs. 1. bln. 1. 1. In. 1. Procedures/Addenda: Addendum. Date Complete: Addendum Diagnosis. ADDENDUM REPORT. SITE: LEFT BREAST (PART 4). ER: 95% NUCLEAR STAINING WITH MODERATE INTENSITY. PR: <5% NUCLEAR STAINING WITH MODERATE INTENSITY. HER2/NEU (HERCEPTEST) : NEGATIVE (STAINING INTENSITY OF 0). CONTROLS ARE SATISFACTORY. . M.D. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: METASTATIC CARCINOM'. PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: METASTATIC CARCINOMA. PERMANENT DIAGNOSIS: SAME. 3). FROZEN SECTION DIAGNOSIS: BENIGN LYMPH NODE. PERMANENT DIAGNOSIS: SAME.",BRCA,1,"According to Rule 2, a T2 tumor is any tumor that measures more than 2 cm but not more than 5 cm in size. In the report, it is mentioned that the primary tumor measures 5.0 cm in largest dimension (see '4). BREAST, LEFT; TOTAL MASTECTOMY' section). Therefore, the T stage is T2.",T2,9.0
1090,TCGA-BH-A204.531B1E8E-9936-42E0-B49B-39C61DD4E943,1,"PATIENT HISTORY: DATE OF LMP: Procedure Date: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: CARCINOMA LEFT BREAST. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: EXC BREAST LEST BR FS - LEFT MOD RAD MASTECTOMY. MATERIAL SUBMITTED: A) LEFT GREAST BIOPSY/TISSUE, PROCUREMENT BY SURGICAL PROCRDURE. CLINICAL HISTORY: B) LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT nY SURGICAL PROCEDURE. and axillary contents. Frozen section: ""Left breast mass biopsy"" 1.5 by cm x 2' biopsies. F's duct Ca. INTRAOPERATIVE CONSULTATION: ER/PR taken. Tissue taken for DNA studtes. FINAL DIAGNOSIS: FINAL DIAGNOSIS: AEAFS) LEFT BREAST AND AXILLA: - INFILTRATING DUCTAL CARCINOMA, 4.0 CM, POOR NUCLEAR GRADE. - MICROSCOPIC FOCI OF DUCTAL CARCINOMA IN SITU. - ANGIOLYMPHATIC AND PERINEURAL INVASION SEEN. - TUMOR INVOLVES SKELETAL MUSCLE. - RESECTION MARGINS ARE FREE OF CARCINOMA. TWO OF SIXTEEN (2/16) LYMPR NODES ARE POSITIVE FOR CARCINOMA. - NOTE: The large 2.5 em axillary lymph node is totally replaced by tumor with extracapeular extension.",BRCA,1,"The report mentions the size of the primary tumor as 4.0 cm, which falls in the T2 category of the AJCC staging system for breast cancer, as per Rule 2: A T2 tumor is any tumor that measures more than 2 cm but not more than 5 cm in size. However, we need to round down the size to the nearest whole number as per New Rule 9, so the T stage would still be T2.",T2,10.0
1221,TCGA-E2-A15L.C04B3267-9833-44D6-8C3D-45D7F829C38C,1,"SPECIMENS: A. NEEDLE LOCALIZATION LEFT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. RIGHT BREAST. E. ADDITIONAL ANTERIOR FLAP RIGHT BREAST UPPER OUTER QUADRANT. SPECIMEN(S): A. NEEDLE LOCALIZATION LEFT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. RIGHT BREAST. E. ADDITIONAL ANTERIOR FLAP RIGHT BREAST UPPER OUTER QUADRANT. GROSS DESCRIPTION: A. NEEDLE LOCALIZATION LEFT BREAST. Received fresh labeled with the patient's identification and ""needle localization left breast"" is an oriented. 18g, 6 x 3.5 x 2.4cm needle localized lumpectomy with radiograph. Ink code: anterior-yellow, posterior-. black, superior-blue, inferior-orange, medial-green, lateral-red. Specimen is serially sectioned from. medial to lateral into 12 slices revealing unremarkable breast parenchyma. Entirely submitted: A1: medial margin slice 1. A2-A3: slice 2. A4-A5: slice 3. A6-A7: slice 4. A8-A9: slice 5. A10-A11: slice 6. A12-A13: slice 7. A14-A15: slice 8. A16-A17: slice 9. A18-A19: slice 10. A20-A21: slice 11. A22: lateral margin slice 12. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. Received fresh is a tan pink lymph node 2.8 x 2.4 x 1cm. The specimen is sectioned and two touch. preps are taken. Toto B1-B2. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. Received fresh are two tan pink lymph nodes 1.2 x 1 x 0.8cm and 0.6 x 0.4 x 0.4cm. Two touch preps. are taken. C1: one lymph node. C2: one lymph node. D. RIGHT BREAST. Received fresh labeled with the patient's identification and ""right breast"" is an 1129g, 29 x 24 x 5cm. oriented (stitch in axilla) simple mastectomy with 23 x 9cm tan pink skin ellipse with 0.5 cm scar, 3.5cm. from the nipple in the UIQ, and 0.8cm flattened nipple. Ink code: anterior-superior-blue, anterior-inferior-. orange, posterior-black. The specimen is serially sectioned from medial to lateral into 14 slices with. nipple in slice 10, revealing a 1.8 x 1.7 x 1.7cm tan white firm well circumscribed mass, 1.4cm from the. deep margin in the UOQ of slices 11-12. Also seen is a 0.7 x 0.5 x 0.5cm previous biopsy site with. surrounding fat necrosis, 2.4cm from the mass and corresponding to the scar on the skin surface in the. UC of slice 10. A portion of the specimen is submitted for tissue procurement. Representatively. submitted: D1: nipple slice 10. D2: UIQ slice 5. D3: LIQ slice 7. D4: UIQ slice 9. D5: LIQ slice 9. D6-D7: biopsy site UC slice 10. D8: area next to mass UC slice 10. D9: deep margin UC slice 10. D10: LC slice 10. D11: next to biopsy site UOQ slice 11. D12: mass UOQ slice 11. D13: deep margin UOQ slice 11. D14: scar UOQ slice 11. D15: LOQ slice 11. D16: mass UOQ slice 12. D17: deep margin UOQ slice 12. D18: anterior margin UOQ slice 12. D19: LOQ slice 12. D20: UOQ slice 13. E. ADDITIONAL ANTERIOR FLAP RIGHT BREAST UPPER OUTER QUADRANT. Received fresh is an oriented (suture at final margin) 18g, 8.4 x 3.9 x 2cm fibrofatty tissue. Final margin. is inked blue. Serial sectioning reveals no discrete lesions. Representatively submitted in E1-E2. DIAGNOSIS: A. BREAST, LEFT, NEEDLE LOCALIZATION EXCISION: ATYPICAL LOBULAR HYPERPLASIA (ALH) AND PREVIOUS BIOPSY SITE. CHANGES. B. SENTINEL LYMPH NODE 1, RIGHT AXILLA, BIOPSY: - ONE LYMPH NODE, NO TUMOR SEEN (0/1). C. SENTINEL LYMPH NODE 2, RIGHT AXILLA, BIOPSY: - TWO LYMPH NODES, NO TUMOR SEEN (0/2). NOTE: Cytokeratin AE1/3 stains were performed on B1 and C1 and are negative. D. BREAST, RIGHT, MASTECTOMY: - MULTIFOCAL INVASIVE LOBULAR CARCINOMA, SBR GRADE 2. - LARGEST TUMOR MEASURES 2.2 CM. - MARGINS, FREE OF TUMOR. - DUCTAL CARCINOMA IN SITU (DCIS), MICROPAPILLARY TYPE,. NUCLEAR GRADE 2, WITH NECROSIS. - LOBULAR CARCINOMA IN SITU (LCIS). - SKIN AND NIPPLE, NO TUMOR SEEN. NOTE: The tumor is present in the upper inner and upper outer quadrants with the largest focus of. invasive carcinoma measuring 2.2 cm that is associated with previous biopsy site changes. In addition,. a few small foci (the largest of the small foci is 0.3 cm) of invasive carcinoma are seen, with one focus. associated with previous biopsy site changes. E. BREAST, RIGHT, ADDITIONAL ANTERIOR UPPER OUTER QUADRANT, EXCISION: - NO TUMOR SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 2.2cm. Margins: Negative. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/3. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Micropapillary. DCIS Location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT2NO. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: Right invasive lobular carcinoma and left atypical lobular hyperplasia. year-old post menopausal female noted a right breast mass. Mammogram performed. showed 1.8 x 2cm mass in right breast, solid in nature on ultrasound. Repeat imaging also showed. left breast nodule at 9 o'clock. Biopsy of both lesions showed right invasive lobular carcinoma. Left. breast atypical lobular hyperplasia. PRE-OPERATIVE DIAGNOSIS: Right invasive lobular carcinoma, left atypical lobular hyperplasia. INTRAOPERATIVE CONSULTATION: TPB1-TPB2-TPC1-TPC2: SLN #1-#2 Right axilla-No definitive tumor cells identified. Diagnoses called. to Dr at. (B) and. (C) by Dr. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 8. CLINICAL EXPERIENCE: Patients with a recurrence score of: 8 in the clinical validation study had. an average rate of Distant Recurrence at 10 years of 6%. ER Score: 10.6 Positive. PR Score: 9 Positive. Her2 Score: 9.3 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR. Negative < 5.5. Positive >= 5.5. Her2 Negative <10.7. Positive >=11.5. Equivocal = 10.7 - 11.4. See separate. h report for further information. Microscopic/Diagnostic Dictation: Final Reviev. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist, (. Addendum Final: Pathologist, I.",BRCA,0,"According to the report, the largest focus of invasive carcinoma measures 2.2 cm, which falls within the range for a T2 tumor (more than 2 cm but not more than 5 cm) as stated in Rule 2. This measurement is obtained from the pathology report as per Rule 5 and is rounded down to the nearest whole number as per the modified Rule 9.",T2,11.0
995,TCGA-BH-A0DD.35FFF2A4-7956-47AC-B6B8-1AA6775E332B,1,"FINAL DIAGNOSIS: RART SENTINEL LYMPH NODE #1, RIGHT AXILLA, BIOPSY -. 1: CARCINOMA INVOLVING ONE LYMPH NODE (1/1). A. METASTATIC METASTATIC FOCUS MEASURES 3.0 CM IN GREATEST DIAMETER 0.1 (ENTIRE CM. LYMPH NODE). B. c. EXTRACAPSULAR EXTENSION IS IDENTIFIED MEASURING 0.2 X. PART 2: BREAST, LEFT, SIMPLE MASTECTOMY -. A. DUCTAL EPITHELIAL HYPERPLASIA. B. PREDOMINANTLY ADIPOSE BREAST PARENCHYMA. c. SKIN AND NIPPLE HISTOLOGICALLY UNREMARKABLE. PART 3: A. BREAST. INVASIVE RIGHT, DUCTAL MODIFIED CARCINOMA RADICAL 3.0 MASTECTOMY 3/3, CM NUCLEAR (GROSS) NOTTINGHAM PLEOMORPHISM - GRADE 2/3, MITOTIC 3 (COMBINED ACTIVITY NOTTINGHAM 3/3) WITH. TUBULE. LYMPHOPLASMACYTIC SCORE 8/9: INFILTRATE AND NECROSIS. B. DEFINITIVE LYMPHOVASCULAR. C. DUCTAL CARCINOMA IN SITU IS NOTIBENTIFIED. D. RESECTION MARGINS FREE. E. DUCTAL EPITHELIAL HYPERPLASIAL. F. G. SKIN TWENTY-TWO AND NIPPLE, LYMPH HISTOLOGICALLY NODES, NEGATIVE UNREMARKABLE FOR METASTATIC CARCINOMA (0/22). H. PATHOLOGIC STAGE (see comment): I. RECEPTOR STATUS (see comment). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 3.0 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 3. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 23. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 30.0 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): T STAGE, PATHOLOGIC: p12. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",BRCA,1,"Referring to Rule 2, a T2 tumor is any tumor that measures more than 2 cm but not more than 5 cm in size. In the report, it is mentioned that 'SIZE OF TUMOR: Maximum dimension invasive component: 3.0 cm.' This indicates that the primary tumor measures 3.0 cm, which falls within the range for a T2 tumor.",T2,12.0
1177,TCGA-D8-A3Z5.B16B3335-492B-471B-AEFE-2350EA558BFC,1,"page 1 / 1. Examination: Histopathological examination. KXX. Material: 1. Total organ resection - right breast and axillary lymph nodes. Unit in charge: : Material collected or. Material received or. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Macroscopic description: Right breast, sized 27.8 x 17.2 x 6.8 cm, removed along with axillary tissues sized 13 x 9 x 4 cm and a skin flap of 21.8 x. 10.3 cm. Weight 940 g. Tumour sized 4.2 x 2.4 x 1.4 cm found on the boundary of outer quadrants, placed 2.2 cm from the outer boundary, 1.6 cm from the. base and 2.6 cm from the skin. Lymph nodes of 1 cm in length. Microscopic description: Carcinoma lobulare invasivum (classical type) - NHG1 (3 + 1 + 1/0 mitoses/ 10 HPF - visual area 0,55 mm). Infiltratio carcinomatosa mamillae. Lesions in situ of the type: carcinoma lobulare in situ (LCIS). Glandular tissue showing parenchyma atrophy. AXILLAR. LYMPH NODES: Metastases carcinomatosae in lymphonodis (No XIX/XXI). Infiltratio telae perinodalis. Histopathological Diagnosis. Carcinoma lobulare invasivum mammae dextrae. Lubular invasive carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (No XIX/XXI) (NHG1, pT2, pN3a). Cancer metastases in the axillary. lymph nodes No XIX/XXI. Result of immunohistochemical examination. Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 75% of neoplastic cell. nuclei. HER2 protein stained with. ). Negative reaction in invasive cancerous cells ( Score =1+).",BRCA,3,"According to the report, the size of the primary tumor is 4.2 x 2.4 x 1.4 cm. Using Modified Rule 8, we take the maximum size of the tumor, which is 4.2 cm. Then, using Modified Rule 9, we round down to the nearest whole number, resulting in a T2 stage. (Rule 1, Modified Rule 8, Modified Rule 9)",T2,12.0
1111,TCGA-D8-A143.F8C2F3EF-FA73-4FF8-9A4E-7F557E68D560,1,"page 1 / 1. copy No. Examination: Histopathological examination. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast (inner lower quadrant). Macroscopic description: Left breast, sized 21.8 x 21.2 x 6.5 cm, removed along with axillary tissues sized 11 x 7x3 cm and a skin flap. of 21.2 x 11.1 cm. Weight 1,360 g. Tumour sized 2.8 x 2.1 x 1.5 cm found on the boundary of inner quadrants,. placed 3.6 cm from the upper edge, 0.9 cm from the base and 2.8 cm from the skin. Status after core needle. biopsy (test No. Microscopic description: Carcinoma ductale invasivum NHG3 (3+3+3: 35 mitoses /10 HPF - visual area: 0.55mm). Focuses of carcinoma ductale in situ (DCIS) found within tumour (solid type, with high nuclear. atypia and comedo necrosis, 10% of the tumour). Reactio lymphocytaria peritumoralis. Lesions in situ: cancerisatio lobulorum. Mamilla sine laesionibus. Glandular tissue showing parenchyma atrophy. Axillary lymph nodes: Lymphonodulitis reactiva No XI. Histopathological diagnosis: (including test No. Carcinoma ductale invasivum et ductale in situ mammae sinistrae. (NHG3, pT2, pNO).",BRCA,0,"According to the report, the size of the primary tumor is 2.8 x 2.1 x 1.5 cm. Even though the size is given in centimeters, we can use the modified rule 8 to round down to the nearest whole number for T stage determination. Therefore, the tumor size is 2 cm, which falls under the T2 category according to rule 2 (A T2 tumor is any tumor that measures more than 2 cm but not more than 5 cm in size).",T2,13.0
1243,TCGA-E2-A1IL.E0CCE6AD-38A6-446C-ACF7-358C1DFC59F8,0,"SPECIMENS: A. WLE LEFT BREAST NEEDLE LOCALIZATION. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. SPECIMEN(S): A. WLE LEFT BREAST NEEDLE LOCALIZATION. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. INTRAOPERATIVE CONSULTATION DIAGNOSIS: Part A, WLE Left breast, needle localization, gross examination: Tumor is 1 cm from posterior/inferior. margin. TPB, Sentinel node #1, biopsy: No tumor seen. TPC, Sentinel node #2, biopsy: No lymphoid tissue grossly identified, no lymphocytes or tumor seen. TPD, Sentinel node #3, biopsy: No tumor seen. TPE, Sentinel node #4, biopsy: No tumor seen. TPF, Sentinel node #5, biopsy: No tumor seen. Diagnoses called at. (Part A) and. (Parts B-F) by Dr. GROSS DESCRIPTION: A. WLE LEFT BREAST NEEDLE LOCALIZATION. Received fresh labeled with the patient's identification and designated ""wide local excision left breast. needle localization"" is an oriented, previously inked, 39-g, 25 x 5.2 x 2.7 cm needle localized. lumpectomy specimen accompanied by two radiographs. The single suture designates anterior,. double-lateral. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue,. inferior-orange. The specimen is serially sectioned from medial to lateral into 6 slices revealing a firm. tan mass with surgical clip (slice 3), 1.5 x 1 x 0.9 cm, located 1 cm from the nearest posterior/inferior. margin. A portion of the specimen is submitted for tissue procurement. The specimen is. representatively submitted: A1-A5: Medial margin, perpendicular sections, entirely submitted. A6: Mass, slice 2 with posterior and anterior margins. A7-A11: Slice 3 entirely submitted, A7-A8 demonstrating tumor (clip) and nearest posterior/inferior. margins. A12-A15: Slice 4 entirely submitted, A12 demonstrating mass. A16-A17: Slice 5, posterior/inferior, inferior/anterior, respectively. A18: Representative sections lateral margin. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node number. one left axilla"" is a beige tan lymph node measuring 2 x 1.5 X 1 cm. Touch preparation is performed. Entirely submitted, B1. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node number. two left axilla"" is a fragment of fibroadipose tissue measuring 2 x 2 x 0.8 cm. Touch preparation is. performed. Entirely submitted, C1. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number 3. left axilla"" is a portion of adipose tissue measuring 4 X 3 X 1 cm, demonstrating one lymph node. measuring 0.7-cm in greatest dimension. Touch preparation is performed. The entire lymph node is. submitted, D1. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node number 4. left axilla"" is a fragment of lymphoid tissue measuring 2 x 1 x 1 cm. Touch preparation is performed. Entirely submitted, E1. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. left axilla"" is a tan lymph node measuring 1.2 x 1 x 0.6 cm. Touch preparation is performed. Entirely. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node number 5. submitted, F1. DIAGNOSIS: A. BREAST, LEFT, EXCISION: - INVASIVE LOBULAR CARCINOMA, MEASURING 1.5-CM, SBR GRADE II,. NUCLEAR GRADE 2. - DUCTAL CARCINOMA- IN -SITU, NUCLEAR GRADE 1-2/3. - RADIAL SCAR. - PREVIOUS BIOPSY SITE CHANGES. - SURGICAL RESECTION MARGINS ARE NEGATIVE FOR TUMOR. SEE SYNOPTIC REPORT. B. SENTINEL LYMPH NODE #1, LEFT AXILLA, EXCISION: - ONE REACTIVE LYMPH NODE. - NEGATIVE FOR METASTATIC CARCINOMA (0/1). C. SENTINEL LYMPH NODE #2, LEFT AXILLA, EXCISION: - BREAST TISSUE WITH STROMAL FIBROSIS. - NO MALIGNANCY IS SEEN. D. SENTINEL LYMPH NODE #3, LEFT AXILLA, EXCISION: - ONE LYMPH NODE, POSITIVE FOR METASTATIC LOBULAR CARCINOMA (1/1). E. SENTINEL LYMPH NODE #4, LEFT AXILLA, EXCISION: - ONE REACTIVE LYMPH NODE. - NO METASTATIC CARCINOMA IS SEEN (0/1). F. SENTINEL LYMPH NODE #5, LEFT AXILLA, EXCISION: - ONE REACTIVE LYMPH NODE. - NO METASTATIC CARCINOMA IS SEEN (0/1). SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: WLE LEFT BREAST NEEDLE LOCALIZATION. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 1.5cm. Additional dimensions: 1cm x 0.9cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: Greater than 1cm. inferior. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: Indeterminate. Lymph nodes: Sentinel lymph node only. Lymph node status: Positive 1/4. Micrometastases: DCIS present. DCIS Quantity: Estimate 5%. DCIS Type: Solid. DCIS Location: Associated with invasive tumor. Nuclear grade: Low. Necrosis: Absent. Location of CA++: Benign epithelium. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 1c N 1a. Comment(s): Few microcalcifications are seen in the invasive tumor. CLINICAL HISTORY: Core biopsy proven cancer upper outer quadrant left breast. PRE-OPERATIVE DIAGNOSIS: Left breast carcinoma. Microscopic/Diagnostic Dictation:, M.D. Path^logist,. Final Review:, M.D., Pathologist,. Final:, M.D., Pathologist, 9.",BRCA,1,"Based on the report, the size of the primary tumor is 1.5 cm, which falls under the T1 category in the AJCC staging system for breast cancer. Modified Rule 8 states that the maximum size of the tumor should be used to determine the T stage, and Rule 9 states that the tumor size should be rounded down to the nearest whole number for T stage determination. However, in this case, even if we round down, the tumor size is still greater than 1 cm, so the T stage is T1.",T1,14.0
850,TCGA-AR-A0U4.6424BA69-DA2B-4CCD-ADDF-DB1BEDA11EBF,1,"Breast, right, simple mastectomy: Breast parenchymal tissue is negative for tumor. Focal calcifications. identified. The nipple is negative for tumor. A single intraparenchymal lymph node is negative for. tumor. Breast, left, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III), [tubules 3. (of 3), nuclei 3 (of 3), mitoses 2 (of 3); Nottingham score 7-8 (of 9) forming a 4.7 x 4.0 x 2.7 cm mass,. located in the upper outer quadrant of the breast (AJCCpT2). Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. No calcifications are present. The tumor does not involve the nipple,. overlying skin, or underlying chest wall. All surgical resection margins, including deep margin, are. negative for tumor (minimum tumor free margin, 1.7 cm, deep margin). Lymph nodes, left axillary sentinel, excision: Multiple (10) sentinel lymph nodes are negative for tumor. AJCC PN0(1-)(sn). Immunohistochemical stains were performed on paraffin embedded tissue from the breast tumor using. antibodies to ER, PR, and HER2/neu. Estrogen is negative, 0% nuclear staining. Progesterone is. negative, 0% nuclear staining. HER2/neu protein overexpression is negative, score of 0, according to the. interpretation guidelines in the FDA-approved HercepTest. ER (Estrogen Receptor) test was developed and its performance characteristics determined by. It has not been cleared or approved by the U.S. Food. and Drug Administration.",BRCA,0,"Referring to Rule 1, 6, and 7, the T stage is determined by the size of the primary tumor, and according to the AJCC staging system for breast cancer, the largest tumor should be used to determine the T stage. From the report, the size of the tumor is given as 4.7 x 4.0 x 2.7 cm, which is larger than 2 cm but not more than 5 cm. Therefore, the T stage is T2.",T2,15.0
1422,TCGA-LL-A441.1FFDD2E3-02D5-4C38-B6E9-1261EB57835A,0,"RUN DATE. RUN TIME. Specimen Inquiry. RUN USER. LOC: U #. AGE/SX: ROOM: REG DR: BED: DIS: TLOC: SPEC # : RECD: PERFORMED A. COLL: TIME IN FORMALIN: CLINICAL INFORMATION: Pre-op Diagnosis: Right breast cancer. Remarks: Specimen (s) : A. Right breast needle localized lumpectomy. B. Axillary contents. C. Sentinel node. MICROSCOPICI DIAGNOSIS. A. RIGHT BREAST TISSUE, NEEDLE LOCALIZED LUMPECTOMY: INFILTRATING DUCTAL CARCINOMA. MODIFIED NOTTINGHAM HISTOLOGIC GRADE 3 OF 3: TUBULAR FORMATION SCORE 3 OF 3,. MITOTIC SCORE 3 OF 3 (10 MITOTIC FIGURES PER SQ MM). DUCTAL CARCINOMA IN SITU, HIGH-GRADE WITH SOLID PATTERN, NOT EXTENSIVE. INVASIVE TUMOR MEASURES 12 MM (pT1c). SURGICAL MARGINS FREE OF INVASIVE CARCINOMA WITH NEAREST MARGIN 3 MM, SUPERIOR. MARGIN. DUCTAL CARCINOMA IN SITU IS FOCALLY PRESENT AT SUPERIOR MARGIN. SEE COMMENT FOR SYNOPTIC REPORT. B. RIGHT AXILLARY CONTENTS, LYMPHADENECTOMY: NO TUMOR SEEN IN ANY OF TWO LYMPH NODES. c. RIGHT AXILLARY SENTINEL LYMPH NODES, LYMPHADENECTOMY: NO TUMOR SEEN IN ANY OF TWO LYMPH NODES. COMMENT (S). SURGICAL PATHOLOGY CANCER CASE SUMMARY - CAP APPROVED. Procedure: Excision with wire-guided localization. Lymph Node Sampling: Sentinel lymph node (s), axillary dissection. Special Laterality: Right. Histologic Type of Invasive Carcinoma : Invasive ductal carcinoma. Tumor Size: Greatest dimension of largest focus of invasion: 12. mm. Histologic Grade (Nottingham) : Glandular/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. Mitotic Rate: Score 3. Overall Grade: Grade 3. RUN DATE : RUN TIME: Specimen Inquiry. RUN USER: PCI User: SPEC #: COMMENT (s). Tumor Focality: Single focus of invasive carcinoma. Ductal Carcinoma In Situ: DCIS is present. Margins: Invasive Carcinoma: Margins uninvolved by invasive. carcinoma. Distance from closest margin: 3 mm; superior. DCIS: Margins positive for DCIS; superior. Lymph Nodes: Number of sentinel lymph nodes examined: 2. Total number of lymph nodes examined (sentinel and. nonsentinel) : 4. Number of lymph nodes with macrometastases (>2 mm) : 0. Number of lymph nodes with micrometastases (>0.2 mm. to 2 mm and/or >200 cells) : 0. Number of lymph nodes with isolated tumor cells. 100.2 mm and <200 cells) : 0. Number of lymph nodes without tumor cells. identified: 4. Pathologic Staging: Primary Tumor: pT1c. Regional Lymph Nodes: pNO. Distant Metastasis: Not applicable. Ancillary Studies: ER: Negative (<1% of tumor cells with nuclear. positivity). PR: Negative (<1% of tumor cells with nuclear. positivity). Immunoperoxidase Studies: Negative (Score 1+). GROSS DESCRIPTION: The specimen is received in three parts. A. This specimen is received in the fresh state from the operating room for immediate. gross evaluation and consist of an excision of breast tissue which measures 8 x 6 x 4. cm. A needle is present in the specimen. I have applied ink to the margins as follows: yellow. is superior; blue is deep; black is anterior; red is inferior. Sections reveal a firm, tan. tumor measuring 12 mm located 4 mm from the nearest margin, the anterior margin. A. representative section of the tumor is submitted for tumor banking. Additional sectioning. reveals fibrotic tissue associated with the biopsy site nearer to the anterior margin. Fibrotic breast tissue is present near the inferior margin, also. Representative sections. are submitted as blocks Al through A6. B. This is a portion of adipose tissue which measures 4 x 4 x 2 cm. Two soft, tan and. yellow lymph nodes are present measuring up to 1.5 cm. The following sections are. submitted: B1. one lymph node totally submitted. B2,3 -. one lymph node totally submitted. C. This is a portion of adipose tissue which measures 3 x 3 x 1 cm. Within this are three. RUN DATE: RUN TIME: Specimen Inquiry. RUN USER. SPEC #. GROSS DESCRIPTION: (Continued). lymph nodes measuring up to 1 cm. One of the lymph nodes measuring 7 mm in grossly. suspicious for tumor containing a firm area measuring 3 mm. A second lymph node measures. 6. mm and contains a 6 mm area suspicious for metastatic tumor. A third lymph node measures 8. mm and is soft. The following sections are submitted: C1. one suspicious lymph node totally submitted. C2. second suspicious lymph node totally submitted. C3. unremarkable lymph node totally submitted. INTRAOPERATTVE CONSULTATION: IMMEDIATE GROSS EVALUATION A (LUMPECTOMY) : CARCINOMA PRESENT IN SPECIMEN. SURGICAL MARGINS APPEAR FREE OF TUMOR. TUMOR PROCESSED FOR TUMOR BANKING. (signature on file).",BRCA,0,"Based on the report, the size of the primary tumor is 12 mm, which falls under the T1 category. According to the modified Rule 8, the maximum size of the tumor should be used to determine the T stage, and in this case, it is 12 mm. Additionally, Rule 9 states that the tumor size should be rounded down to the nearest whole number for T stage determination, but since the size is already a whole number, no rounding is needed. Therefore, the T stage is T1c.",T1c,16.0
1023,TCGA-BH-A0H3.6D3F79A6-C55C-497F-9CCD-1C6D3ACE7492,0,"FINAL DIAGNOSIS: PART 1: LYMPH NODE, LEFT AXILLA, SENTINEL NUMBER 1 -. ONE LYMPH NODE, FREE OF METASTATIC CARCINOMA (0/1). PART 2: LYMPH NODE, LEFT AXILLA, SENTINEL NUMBER 2 -. ONE LYMPH NODE, FREE OF METASTATIC CARCINOMA (0/1). PART 3: BREAST. LEFL, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH TUBULAR AND INVASIVE CRIBRIFORM FEATURES. B. NOTTINGHAM GRADEY (TUBULE FORMATION 1, NUCLEAR PLEOMORPHISM 2, MITOTIC ACTIVITY 1,. TOTAL SCORE 4/9). C. THE INVASIVE TUMOR MEASURES 1.6 CM IN GREATEST DIMENSION. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM AND MICROPAPILLARY TYPES. DCIS CONSTITUTES 20% OF THE TOTAL TUMOR MASS AND IS PRESENT ADMIXED AND ADJACENT TO. THE INVASIVE COMPONENT. E. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. F. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. G. INVASIVE DUCTAL CARCINOMA IS PRESENT 3.0 MM FROM THE POSTERIOR (CLOSEST) MARGIN; ALL. OTHER MARGINS ARE GREATER THAN 0.5 CM AWAY FROM INVASIVE CARCINOMA. H. DUCTAL CARCINOMA IN SITU IS PRESENT 4.0 MM FROM THE POSTERIOR (CLOSEST) MARGIN; ALL. OTHER MARGINS ARE GREATER THAN 0.5 CM AWAY FROM IN SITU CARCINOMA. I. ATYPICAL DUCTAL HYPERPLASIA. J. SCLEROSING ADENOSIS AND FIBROCYSTIC CHANGES. K. PREVIOUS BIOPSY SITE CHANGES. L. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN RECEPTOR AND PROGESTERONE. RECEPTOR AND NEGATIVE FOR HER-2/NEU (FISH NONAMPLIFIED) AS PER PREVIOUS PATHOLOGY. CASE STNUPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 1.6 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Other Type(s): IDC with tubular and cribriform features. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 1. Mitotic activity score: 1. Total Nottingham score: 4. Nottingham grade (1, 2, 3): 1. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Micropapillary. Percent of tumor occupied by in situ component: 20 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 3 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. NON-NEOPLASTIC BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNO. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",BRCA,0,"Based on the report, the maximum dimension of the invasive tumor is 1.6 cm. According to Rule 7, if multiple tumor nodules are present, the largest one should be used to determine the T stage. Rule 8 states that the maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters. Rule 9 states that the tumor size should be rounded down to the nearest whole number for T stage determination, unless the size is already a whole number. In this case, the tumor size is 1.6 cm, which is closer to 1.5 cm than 2 cm, but since it is already a whole number, it does not need to be rounded. Therefore, the T stage is T1c.",T1c,17.0
877,TCGA-AR-A24R.C3259BD1-1A2A-40C4-A106-FA2EF0201811,0,"Final Diagnosis. Teast, right, wide local excision: Inyasive Nottingham grade III (of III) ductal carcinoma forming a 1.8 x 1.4 x 1.4 cm mass. (AJCC pTlc) with prior needle biopsy tract. Angiolymphatic invasion is present. No ductal carcinoma in situ identified. All. surgical margins are free of tumor. The closest margin (deep) is free by 0.3 cm. Lymph. nodes,. right axillary, dissection: Metastatic adenocarcinoma in multiple (6 of 28) right axillary lymph nodes. Three of the. positive lymph nodes are matted and form a 1.4 x 1.2 x 1.2 cm mass with extracapsular extension into soft tissue (AJCC pN2). Her-2/NEU has been ordered on paraffin embedded tissue.",BRCA,2,"According to the report, the size of the primary tumor is 1.8 x 1.4 x 1.4 cm. Using the modified Rule 8, we take the maximum size of the tumor, which is 1.8 cm. Then, using Rule 9, we round down to the nearest whole number because the size is not already a whole number. Therefore, the T stage is T2.",T2,18.0
1252,TCGA-E2-A1LB.A868EC86-9CB6-445E-B961-5D4C57263548,1,"SPECIMENS: A. WLE RIGHT BREAST. B. RIGHT AXILLARY CONTENTS. SPECIMEN(S): A. WLE RIGHT BREAST. B. RIGHT AXILLARY CONTENTS. INTRAOPERATIVE CONSULTATION DIAGNOSIS: Part A, WLE Right breast, gross examination: Tumor 0.2-cm from posterior margin. Called to Dr. at. by Dr. GROSS DESCRIPTION: A. WLE RIGHT BREAST. Received fresh labeled with matching patient identifiers is an oriented (short-superior, long-lateral) 124. g, 9.7 (medial to lateral) x 9 x 3 cm lumpectomy with a slender fragment of tan skin 2.8 x 0.3 cm. The. specimen is inked as follows: anterior - blue, posterior - black, superior - red, inferior - orange, medial. green, lateral - yellow. The specimen is serially sectioned from medial to lateral into 7 slices revealing. a 2.8 x 2.5 x 1.4 cm ill defined firm tan mass approaching the closest posterior margin at 0.2 cm, and. superior margin at 0.5 cm. A portion of the specimen is submitted for tissue procurement. Representative sections are submitted as follows: A1-A2: Perpendicular sections medial margin. A3-A4: Section 2 anterior. A5: Section 2 posterior. A6: Section 3 inferior. A7: Section 3 anterior/superior. A8-A9: Section 3 superior. A10-A11: Section 4 lesion and posterior. A12: Section 4 anterior/inferior. A13-A16: Section 5, lesion and nearest posterior. A17-A18: Section 6, lesion and posterior/anterior. A19-A20: Section 6, lesion and superior. A21-A22: Perpendicular sections lateral margin. A23-A26: Medial margin. A27: Section 6, inferior aspect. A28: Lateral margin. A29: Lateral margin. A30: Section 5, superior margin. A31: Section 2, superior aspect. A32: Section 2, inferior aspect. A33: Section 5, inferior margin. A34: Section 2, superior aspect. B. RIGHT AXILLARY CONTENTS. Received in formalin in a container labeled with matching patient identifiers is a portion of red yellow. fibroadipose tissue measuring 10.7 x 5.9 x 2.5 cm. Multiple possible lymph nodes are identified ranging. in size from 0.3 x 0.3 x 0.3 up to 4 x 3.5 x 2 cm. Cassette summary: B1-B3: Representative sections, largest lymph node. B4: Two possible lymph nodes. B5: Two possible lymph nodes. B6: Four possible lymph nodes. B7: Four possible lymph nodes. B8: Two possible lymph nodes. B9: Two possible lymph nodes. B10: Three possible lymph nodes. B11-B15: Additional possible lymph nodes. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (SBR GRADE 3), WITH APOCRINE FEATURES, AND SEVERAL FOCI OF. MICROINVASION ASSOCIATED WITH DCIS. - TUMOR MEASURES AT LEAST 3 CM IN GREATEST DIMENSION. INVASIVE CARCINOMA IS 2 MM FROM THE DEEP MARGIN. - EXTENSIVE LYMPHVASCULAR INVASION IS PRESENT. DUCTAL CARCINOMA IN SITU (DCIS), SOLID TYPE, NUCLEAR GRADE 3,. WITH NECROSIS AND ASSOCIATED LYMPHOID INFILTRATE, INVOLVING. LOBULES. DCIS IS PRESENT AT THE LATERAL MARGIN, IS WITHIN 1 MM OF THE. ANTERIOR/MEDIAL AND ANTERIOR MARGIN, AND IS WITHIN 2 MM. OF THE DEEP MARGIN. B. AXILLARY CONTENTS, RIGHT, DISSECTION: - METASTATIC CARCINOMA TO 2 OF 25 LYMPH NODES WITH LARGEST. METASTASIS MEASURING 4 CM (2/25). - NO EXTRACAPSULAR EXTENSION IS SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor. Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3cm. Tumor Site: Upper outer quadrant. Margins: Negative. Distance from closest margin: deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 2/25. DCIS present. Margins involved by DCIS: lateral margin. DCIS Quantity: Estimate 25%. DCIS Type: Solid. DCIS Location: Both associated and separate from invasive tumor mass. Nuclear grade: High. Necrosis: Present. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Positive by IHC. Performed on. Case: This case - the largest lymph node with metastasis. Pathological staging (pTN): pT 2N1. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: B2 (Lymph node with metastasis). ER: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative. Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed usina the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer s instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: B2 (Lymph node with metastasis). Interpretation: POSITIVE. Intensity: 3+. % Tumor Staining: 100%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. CLINICAL HISTORY: :year-old woman, right breast, upper outer 4 cm mass, IDC, ER/PR negative; HER-2/neu positive,. with palpable adenopathy, here for lumpectomy and axillary lymph node dissection. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. Microscopic/Diagnostic Dictation; Pathologist,. Final Review: Pathologist,. Final Review: Pathologist,. Final: Pathologist.",BRCA,1,"Based on Rule 1, Rule 6, Modified Rule 8, and New Rule 13, the T stage is determined by the size of the primary tumor. The report mentions 'Tumor measures at least 3 cm in greatest dimension.' This puts the tumor size in the T2 category, which includes tumors with a size of 2.1 to 5 cm.",T2,19.0
1074,TCGA-BH-A1F6.7E9B0BE7-121E-423F-AA37-445BA922FC13,3,"N. PATIENT HISTORY: The patient is a year-old female. Date of last menstrual period: Not given. PRE OP DIAGNOSIS: Left breast cancer. POST OP DIAGNOSIS: Same. PROCEDURE: Left modified radical mastectomy. FINAL DIAGNOSIS: PART 1: LEFT BREAST, MODIFIED RADICAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA OF BREAST, NOTTINGHAM SCORE 8/9 (TUBULES 3, NUCLEI 3, MITOSES 2). B. NEOPLASM MEASURES 5.5 CM IN MAXIMUM DIMENSION. C. NEOPLASM EXTENDS INTO DERMIS. D. MARGINS OF RESECTION FREE OF NEOPLASM. E. EXTENSIVE DERMAL LYMPHOVASCULAR EXTENSION IDENTIFIED (T4d). F. NO PAGET'S DISEASE OF NIPPLE IDENTIFIED. G. METASTATIC CARCINOMA IN INTRAMAMMARY LYMPH NODE, 1 OF 1, 0.7 CM IN DIAMETER WITH. EXTRACAPSULAR EXTENSION. PART 2: LEFT AXILLARY CONTENTS, AXILLARY DISSECTION. METASTATIC CARCINOMA IN LYMPH NODES, 3 OF 3. PART 3: LEFT AXILLARY CONTENTS, AXILLARY DISSECTION. METASTATIC CARCINOMA IN LYMPH NODES, 2 OF 2. COMMENT: Estrogen_ Progesterons and Her-2/Neu analyses were performed on the two previous specimens (outside block from: and di. wand interpreted on both specimens as ER negative, PR negative and Her-. 2/Neu negative. If repeat analyses are desired on current specimen, please contact the laboratory.",BRCA,2,"The report states that the neoplasm measures 5.5 cm in maximum dimension and extends into the dermis. According to Rule 1, the T stage is determined by the size of the primary tumor. Rule 6 states that the T stage should be determined according to the AJCC staging system for breast cancer, which classifies a tumor as T4 if it extends into the chest wall or skin. Rule 7 states that if multiple tumor nodules are present, the largest one should be used to determine the T stage, but this does not apply in this case. Modified Rule 8 states that the maximum size of the tumor should be used to determine the T stage, which is 5.5 cm in this case. Rule 9 states that the tumor size should be rounded down to the nearest whole number for T stage determination, unless the size is already a whole number, but this would result in a lower T stage, so it does not apply. Rule 12 states that if the tumor size is given in decimal form and is closer to the next whole number, round up to the next whole number for T stage determination, but this also does not apply. New Rule 13 states that if the tumor size is given in the format of X x Y x Z, use the maximum value to determine the T stage, but this also does not apply.",T4,20.0
1471,TCGA-OL-A5D8.FD496AFB-43EF-41D8-850F-E57DD53C185C,2,"FINAL PATHOLOGIC DIAGNOSIS. Mastectomy and sentinel lymph node biopsy,. A. Left axillary sentinel node #1: - Single lymph node, no tumor (0/1). B. Left axillary sentinel node #2: - Single lymph node, no tumor (0/1). C. Mastectomy, left breast: - Invasive ductal carcinoma, SRB grade II, with focal necrosis. - Ductal carcinoma in situ, high nuclear grade, solid type. - Focal Paget' S disease of the nipple. - Uninvolved breast parenchyma with focal flat epithelial atypia, columnar. cell change, ductal hyperplasia of usual type, intraductal papilloma. D. Left axillary base, non-sentinel lymph node: - Two lymph nodes, no tumor (0/2). Breast Pathologic Parameters. 1. Invasive carcinoma: A. Size: Gross measurement: 6.5cm. B. Composite histologic (modified SBR) grade II. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated ductal carcinoma in situ (DCIS): - High nuclear grade, solid type. - Associated with (forming 5% of tumor volume) and extending away (focal to. involved lactiferous ducts and nipple) from index lesion. 2. Excisional biopsy margins: Free of tumor. - DCIS > 1cm from deep (closest) margin. - Invasive carcinoma 5mm from deep (closest) margin. 3. Blood vessel and lymphatic invasion: - Rare microscopic foci worrisome for lymphatic involvement in breast. parenchyma. 4. Axillary lymph nodes: Negative for tumor (0/4). 5. Special studies (see. - Strong expression of ER in 100% of invasive tumor nuclei. - Strong expression of PR in 100% of invasive tumor nuclei. - Her2/neu antigen (FISH): pending on prior biopsy material. 6. pTNM: pT3, NO(sn), MX. Clinical History: The patient is a. .year-old female with palpable left breast mass. Biopsy at. outside hospital showed invasive ductal carcinoma, ER/PR positive, HER-2. negative. Breast MRI on. ;howed left inferior irregular margin. with irregular mass and heterogenous enhancement at 6 o' clock position. Multiple contiguous satellite lesions are present predominantly extending. anterior from the mass. Overall dimensions are 6.4 x 6.1 x 4.1 cm. The right. breast was normal. Bilateral axillae were normal. Specimens Received: A: Left axillary sentinel node. B: Left axillary sentinel node. C: Left breast. D: Non-Sentinel node base of axilla. Gross Description: The specimen is received in four containers each labeled with the patient' S. name and medical record number. A. Container A is further identified as, 3left axillary sentinel node4. Received fresh is a 2.5 X 1.5 x 1.0 cm apparent lymph node with blue ink. The. specimen is bisected and entirely submitted for frozen section with the. diagnosis of 3no evidence of tumor4 per. The frozen remnant is. entirely submitted in cassette A1FS. B. Container B is further identified as, 3left axillary sentinel node4. Received fresh is a 2.0 x 1.5 x 1.0 cm apparent lymph node with blue ink. The. specimen is bisected and entirely submitted for frozen section with a diagnosis. of 3no evidence of tumor4 per. The remnant of the frozen section is. entirely submitted in cassette B1FS. C. Container C is further identified as, 3left breast4. Received fresh and. placed in formalin is a specimen mastectomy weighing 1100 grams measuring 23.8. cm from medial to lateral, 17.4 cm from superior to inferior, 6.0 cm from. anterior to posterior. The specimen is oriented with two short sutures. designated as superior and two long sutures designated as lateral. The breast. is overlaid with 14.5 x 10.5 cm adipose and skin. Eccentricallylocated is a. 5.8 x 5.2 cm areola with a nipple with a diameter of 1.5 cm. The nipple areolar. complex displays no evidence of ulceration or retraction. The deep fascia is. inked black and the specimen is sectioned from medial to lateral into ten. slices, with the medial slice designated as slice 1. The nipple is located in. slice 4 and slice 5. A 6.5 x 4.9 x 3.3 cm mass is located in slice 4 through. slice 7. The mass is white and firm and inferior to the nipple. The margin of. the mass is irregular especially at the anterior aspect. A satellite lesion is. identified superior and anterior to the index mass located in slice 5 measuring. 1.5 x 1.1 x 1.1 cm and is 0.4 cm from the nearest skin. The mass is 1.0 cm from. the closest inked margin on slice 5. A 2.0 x 2.0 x 1.5 cm black discolored area. is identified in slice 3 and 4 and another 4.0 x 3.8 x 2.0 cm blue discolored. area is identified on slice 5 and 6. The remainder of the breast consists. approximately 17% of adipose tissue and 30% of breast duct parenchyma. Additional masses or nodules are not grossly identified. Representative. sections are submitted as follows: C1: nipple. C2-C3: areola. C4-C7: full section of the tumor on slice 5 with cassette 4 showing. the closest deep margin and cassette. 6 showing the satellite lesion and the closest skin. C8: section from slice 5 showing satellite lesion and the closest skin. C9: representative sections from the tumor on slice 6. C10: inner upper quadrant slice 3. C11: inner upper quadrant slice 4. C12: inner lower quadrant slice 3. C13: inner lower quadrant slice 2. C14: outer upper quadrant slice 5. C15: outer upper quadrant slice 8. C16: outer lower quadrant slice 8. D. Container D is further identified, as 3non-sentinel node base of axilla. left4. Received fresh and placed in formalin are two apparent lymph nodes. measuring 1.8 x 1.0 x 0.6 cm and 1.2 x 0.7 x 0.5 cm. The specimen is entirely. submitted in cassettes D1-D2 with one lymph node in each cassette bisected. Intraoperative Consult Diagnosis: A1FS. Left axillary sentinel node: No evidence of tumor. B1FS. Left axillary sentinel node: No evidence of tumor.",BRCA,0,"The maximum size of the primary tumor is given as 6.5 cm in the gross measurement section of the report, which falls under the T3 category according to the AJCC staging system for breast cancer. This is in line with Rule 1, Rule 6, and Modified Rule 8.",T3,21.0
612,TCGA-A8-A06Q.8FE77EF7-C83A-431F-B3BA-D93B5ECC70AF,2,"Diagnosis: Multifocal moderately differentiated invasive breast carcinoma (larger tumor: moderately differentiated invasive ductal carcinoma (tumor size: 5.3 cm) with focal. signet-ring cell differentiation and focal intraductal components; smaller tumor: moderately differentiated invasive ductal carcinoma (tumor size: 1.5 cm)). Foci of angioinvasion. Diagnosis: 1. Ablated (left) breast sample with further invasive tumor components in the. quadrant of the sample excision cavity and retromamillary (maximum surface spread: 0.8 cm). Dorsal resection margin tumor-free. Tumor classification: NOS, G II, pT3(mult)N2aL1V0R0. (compare E. no. xxxx).",BRCA,2,"Based on the report, the larger tumor has a size of 5.3 cm. According to the modified Rule 8, we use the maximum size of the tumor to determine the T stage, even if it is given in centimeters. Then, according to Rule 9, we round down to the nearest whole number for T stage determination, unless the size is already a whole number. Therefore, the T stage is T3.",T3,22.0
1083,TCGA-BH-A1FM.DA6A0EC9-6E20-4E4A-9B7F-A32EFF7627AD,1,"Procedure Date: PATIENT HISTORY: DATE OF LNP: DATE OF LAST DELIVERY: . PRE-OP DIAGNOSIS: RT BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE RT MAST, A D. CLINICAL MATERIAL HISTORY: SUEMITTED RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. FINAL DIAGNOSIS: 1.2. PREVIOUS MULTIFOCAL REPORTS: INFILTRATING DUCT CARCINONA, POOR ARCHITECTURAL AND NUCLEAR GRADE (2.5 BY 2.5 BY 2.0 CN AND. BY 0.5 BY 0.5 CM). - EXTENSIVE DUCTAL CARCINOMA IN SITU, COMEDO AND NON-COMEDO TYPES, COMPRISING >25% or TUMOR. - ANGIOLYMPEATIC INVASION PRESENT. - TUMOR ASSOCIATED MICROCALCIFICATIONS. - MARGIN or RESECTION NEGATIVE FOR TUMOR. - TUMOR APPROACHES POSTERIOR MARGIN WITH 1.0 MM. - SKIN or NIPPLE AND AREOLA INVOLVED BY TUMOR. - FIBROCYSTIC CHANGES. - EIGHT OUT or TEN (8/10) LYMPH NODES POSITIVE FOR TUMOR WITH EXTRACAPSULAR EXTENSION IN FIVE. (5). POSITIVE. NODES. NOTE ER/PR immunoperoxidase assay will be performed on paraffin ambedded tissue, block 3. An addendum. report will follow. S U P P L e M E N T A L R E P o R T. (ER/PR'S). IMMUNOPEROXIDASE IDENTIEICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. A3. DISTINCT. INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (50%) BUT NOT FOR PROGESTERONE RECEPTOR. THEREFORE, ESTROGEN RECEPTOR IS INTERFRETED AS POSITIVE AND PROGESTERONE RECEPTOR AS NEGATIVE.",BRCA,2,"The report mentions the size of the largest tumor nodule as 2.5 cm by 2.5 cm by 2.0 cm. According to the modified Rule 8 and Rule 9, we use the maximum size of the tumor (2.5 cm) to determine the T stage, which falls under T2 (2.0-5.0 cm) category.",T2,22.0
1469,TCGA-OL-A5D6.AD80BBA3-DA8E-4DFB-BDA1-FFDC131E9740,1,"FINAL PATHOLOGIC DIAGNOSIS. Left simple mastectomy and sentinal node biopsy: A. Sentinal lymph node #1: -One lymph node, no tumor (0/1). B. Sentinel lymph node #2: -One lymph node, no tumor (0/1). C. Left breast (mastectomy): -Intraductal apocrine ductal carcinoma with lobular cancerization and rare. foci of. invasion (largest focus 3mm), associated with large area of recent. hemorrhage (5 cm),. see below. -Separate mass of intraductal and infiltrating ductal carcinoma (2.5 cm). inferior to hemorrhagic region. -Small intraductal papilloma, sclerosing adenosis and radial scar lesion. -Calcifications in vessel walls. -Nipple, no tumor. Breast Pathologic Parameters. 1. Intraductal carcinoma: A. Size: Gross measurement: 5 cm. B. Type: Comedo, solid, apocrine. C. Nuclear grade: High. (Modified Lagios Grading Scheme). D. Associated features: Necrosis, Cancerization of lobules. 2. Invasive carcinoma: A. Size: Gross measurement: 1.0 x 1.0 x 0.6 cm. B. Composite histologic (modified SBR) grade: III. - Architecture: 3. - Nuclear grade: 3. - Mitotic count: 2. C. Associated ductal carcinoma in situ (DCIS): - Within main mass (forming 50 % of tumor volume). - Extending away from main mass. 3. Excisional biopsy margins: Free of tumor. Margins greater than 2mm away. 4. Blood vessel and lymphatic invasion: Absent. 5. Axillary lymph nodes: Negative for tumor (0/2). 6. Special studies. -No expression of ER in invasive tumor nuclei. -No expression of PR in invasive tumor nuclei. -Her2/neu antigen (FISH): Pending. 7. pTNM: pT2,N0,MX. Clinical History: This is a. year-old female with history of a right papilloma. A screening. mammogram in. showed suspicious densities with calcifications in. the left outer quadrant. By exam showed a 1.5 cm quasi suspicious mass at. 4-5:00, 3 cm outside the areola margin on the left breast. , she had a. FNA of the left breast showing carcinoma. On. 1 breast MRI on the. left showed an outer quadrant 4.7 x 3.2 x 3.3 cm enhanced mass with three. additional suspicious foci: one anterior and superior to the index mass, one. adjacent to the nipple, and one suspicious focus at 12 o'clock. The patient. undergoes a left breast sentinel node biopsy and simple mastectomy. Specimens Received: A: Sentinel Node #1. B: Sentinel Node #2. C: Left Breast Mastectomy with Sentinel Node Biopsies. Gross Description: The specimens are received in three containers each labeled with the patient' S. name and medical record number. A. Container A is further designated 31. sentinel node #14. Received for. frozen section diagnosis is a 1.8 x 1.2 x 0.5 cm rubbery portion of yellow,. lobulated tissue with blue discoloration. It is read as 3one lymph node,. negative for carcinoma4 by. The specimen is entirely submitted as. A1FS. B. Container B is further designated 32. sentinel node #24. Received for. frozen section diagnosis is a 1.5 x 0.8 x 0.8 cm portion of pink-tan rubbery. tissue consistent with a lymph node. It is bisected and read as 3one lymph. node, negative for carcinoma4 by. The specimen is entirely submitted. in cassette BIFS in a mesh bag. C. Container C is further designated 33. left breast mastectomy with sentinel. node biopsies4. Received fresh and placed in formalin is a 975 gm, 39 X 18 x 6. cm mastectomy specimen with an ellipse of white-tan skin with blue discoloration. (27 X 11.2 cm), areola (4.7 x 4.5 cm), and nipple (1.2 x 1.0 x0.4 cm). The. specimen is oriented as follows: short suture superior, long suture lateral. The deep margin is inked black and the specimen is serially sectioned into 13. slices from lateral (slice #1) to medial revealing a 5 x 5.5 x 4 cm ecchymotic. area in the lower lateral quadrant located in slices #4-7. There is a. well-circumscribed, firm, white mass measuring 2.5 x 1.7 x 1.5 cm in slice #5,. 5.5 cm from the deep margin. It is located inferior to the ecchymotic region. At 2-3 o'clock adjacent to the firm mass is an ill-defined, gritty, indurated. area primarily in slices #7 and #8. It extends superomedially with a span of 5.0. X 3.5 x 2.0 cm and is located 2.5 cm from the deep margin. Note: slices #7 and. #8 contain the nipple and areola region. Cassette SummaryCl: nipple. C2-C4: areola, serially sectioned. C5: section of the main mass in slice #5 with respect to closest distant. from deep margin. C6-C7: one representative section immediately superior and anterior to the. main lesion from slice #5. C8: section of hematoma from slice #5 anterior and medial to the main lesion. C9: section of hematoma from slice #6, directly medial to the main lesion. C10: section 2 cm superior, anterior, and medial to the main lesion from. slice #7. C11: representative sections from slice #8, representing ill-defined,. gritty, firm tissue. C12-C13: section from slice #7 also representing ill-defined, gritty, firm. tissue. C14: another section from slice #7 immediately inferior to the section. C12-C13. C15-C16: section from 12 o'clock on section #8. C17-C18: sections from slice #9. C19: another representative section from section #9. C20-C21: lateral upper quadrant from slices #3-4, respectively. C22-C23: lateral lower quadrant from slices #2 and #3, respectively. C24-C25: upper medial quadrant from slice #11 and #12, respectively C26-C27: medial lower quadrant from slices #11 and #12, respectively. Intraoperative Consult Diagnosis: A1FS. Sentinel node #1: One lymph node, negative for carcinoma. B1FS. Sentinel node #2: One lymph node, negative for carcinoma.",BRCA,0,"Based on the report, the largest focus of invasive carcinoma is measured as 1.0 x 1.0 x 0.6 cm, which is then used to determine the T stage. According to Rule 8, the maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters. Therefore, the T stage is T2.",T2,23.0
1508,TCGA-UL-AAZ6.1AD1E3C4-0D7C-447B-B330-0245F9159FCC,1,"SPECIMEN(S) RECEIVED. A: RIGHT TOTAL MASTECTOMY. B: SENTINEL LYMPH NODE #1 HOT. C: SENTINEL LYMPH NODE #2 HOT. D: SENTINEL LYMPH NODE #3 HOT. FINAL DIAGNOSIS. A. RIGHT TOTAL MASTECTOMY: SYNOPTIC REPORT. MICROSCOPIC: HISTOLOGIC TYPE: INVASIVE DUCTAL CARCINOMA. SIZE OF INVASIVE COMPONENT: 3.4 x 3.0 x 2.5 cm. TUMOR FOCALITY: SINGLE FOCUS OF INVASION. MACRO/MICRO EXTENT OF INVASIVE TUMOR. SKIN. TUMOR DOES NOT INVADE DERMIS/ EPIDERMIS. NIPPLE. DCIS DOES NOT INVOLVE THE NIPPLE EPIDERMIS. SKELETAL MUSCLE. SKELETAL MUSCLE IS PRESENT AND IS FREE OF CARCINOMA. DUCTAL CARCINOMA-IN-SITU (DCIS): DCIS IS PRESENT. EXTENSIVE INTRADUCTAL COMPONENT (EIC) NEGATIVE. LOBULAR CARCINOMA-IN-SITU (LCIS): NOT IDENTIFIED. HISTOLOGIC MODIFIED SCARFF-BLOOM-RICHARDSON GRADE: 2/3. MARGINS. MARGINS UNINVOLVED BY INVASIVE CARCINOMA. DISTANCE FROM CLOSEST MARGIN: 2.0cm (DEEP). MARGINS UNINVOLVED BY DCIS. DISTANCE FROM CLOSEST MARGIN: GREATER THAN 2.0cm (DEEP). MICROCALCIFICATIONS: PRESENT IN DCIS. TREATMENT EFFECT: RESPONSE TO NEOADJUVANT THERAPY. IN THE BREAST: NO KNOWN PRESURGICAL THERAPY. IN THE LYMPH NODES: NO KNOWN PRESURGICAL THERAPY. VENOUS / LYMPHATIC INVASION: NOT IDENTIFIED. SKIN / DERMAL LYMPHATIC INVASION: NOT IDENTIFIED. LYMPH NODES: NUMBER OF SENTINEL LYMPH NODES EXAMINED: 3. TOTAL NUMBER OF LYMPH NODES EXAMINED (SENTINEL AND NONSENTINEL): 4. NUMBER OF LYMPH NODES WITH MACROMETASTASES (>0.2 CM): 0. NUMBER OF LYMPH NODES WITH MICROMETASTASES (>0.2 MM TO 0.2 CM AND/OR >200 CELLS): o. NUMBER OF LYMPH NODES WITH ISOLATED TUMOR CELLS (0.2 MM AND 200 CELLS): 0. SIZE OF LARGEST METASTATIC DEPOSIT (IF PRESENT): o. EXTRANODAL EXTENSION: N/A. METHOD OF EVALUATION OF SENTINEL LYMPH NODES: H&E, MULTIPLE LEVELS. NOTE: ER/ PR/ HER-2/ MIB-1 RESULTS: SEE PRIOR REPORT. MACROSCOPIC. SPECIMEN TYPE: TOTAL BREAST. PROCEDURE: TOTAL MASTECTOMY. LYMPH NODE SAMPLING: SENTINEL LYMPH NODES WITH PARTIAL AXILLARY DISSECTION. SPECIMEN INTEGRITY: SINGLE INTACT SPECIMEN. SPECIMEN SIZE: 27 x 17 x 3.5 cm. LATERALITY: RIGHT. TUMOR SITE: 12 O'CLOCK POSITION. AJCC PATHOLOGIC STAGE (AJCC 7TH ED.): (pT2, pNO). B. SENTINEL LYMPH NODE #1 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. c. SENTINEL LYMPH NODE #2 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. D. SENTINEL LYMPH NODE #3 HOT: ONE (1) REACTIVE LYMPH NODE. NO METASTATIC CARCINOMA IDENTIFIED. CLINICAL DIAGNOSIS AND HISTORY. Right breast cancer. See. right breast Ca. GROSS DESCRIPTION. The specimen is received fresh in four containers labeled with the patient's name, medical record number, and identified as A. ""Right Total Mastectomy"", B. ""Sentinel Lymph Node #1 Hot"", C. ""Sentinel Lymph Node #2 Hot"" and D. ""Sentinel Lymph Node #3. Hot"". Specimen A consists of a mastectomy (811.1 grams, 27 x 17 x 3.5 cm) with a 22 x 9.5 cm skin ellipse and a centrally located. unremarkable 1.2 cm nipple. The specimen has been oriented by the surgeon with a stitch indicating the tail of the specimen. The. deep margin is inked black. The specimen is serially sectioned to reveal an irregular firm tan colored mass with focal hemorrhage. and calcification (3.4 x 3 x 2.5 cm) in the 12:00 position, 2 cm to the deep margin, 1.2 cm to the anterior skin margin, and 2 cm to. the nipple. The remaining breast parenchyma appears grossly unremarkable. One 0.7 cm lymph node is identified in the tail of the. specimen. The specimen is submitted representatively as follows: A1 thru A3, tumor, A4-tumor and anterior skin, A5-anterior skin. margin, A6-posterior deep margin, 7-nipple, A8 and A9-lateral upper quadrant, A10 and A11-lateral lower quadrant, A13-medial. upper quadrant, A14 and A15-medial lower quadrant, 16-0.7 cm lymph nodes, bisected. Specimen B consists of a 2.2 cm sentinel lymph node. The lymph node is serially sectioned and submitted entirely in two cassettes. labeled B1 and B2. Specimen C consists of a 2.5 cm sentinel lymph node. The lymph node is serially sectioned and submitted entirely in two cassettes. labeled C1 and C2. Specimen D consists of a 1 cm sentinel lymph node with fibroadipose tissue. Lymph nodes are serially sectioned and submitted. entirety in two cassettes labeled D1 and D2. the diagnosis(es) related thereto.",BRCA,0,"According to Rule 1, the T stage is determined by the size of the primary tumor. The report states that the size of the invasive component is 3.4 x 3.0 x 2.5 cm. Using New Rule 13, we take the maximum value of 3.4 cm to determine the T stage. According to Rule 6, the T stage should be determined according to the AJCC staging system for breast cancer, which states that T2 corresponds to a tumor size of 2.0-5.0 cm. Therefore, the T stage is T2.",T2,23.0
670,TCGA-A8-A09C.1E002C47-CEC6-491C-9E67-B289687D5B66,1,"Diagnosis: Moderately differentiated invasive ductal breast carcinoma with a diameter of 2.2 cm. extending cranially to within 5 mm of the resection margin at 3 and 12 o'clock. Normal. follow-up resection material and tumor-free sentinel lymph nodes. Tumor classification: M-8500/3, G2, pT2, pN 0 (sn), MX, R0.",BRCA,0,"Based on the report, the primary tumor has a diameter of 2.2 cm. According to Rule 8 (the maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters), and Rule 9 (the tumor size should be rounded down to the nearest whole number for T stage determination, unless the size is already a whole number), the T stage is T2.",T2,24.0
1048,TCGA-BH-A18F.771497E1-473E-421A-A149-CFA58E95B728,1,"CHIEF COMPLAINT/ PRE-OPI POST-OP DIAGNOSIS: 1.2-cm mass posterior 12 o'clock right breast. Core blopsy Invasive ductal. carcinoma. LMP DATE: Not provided. PROCEDURE. Right segmental mastectomy/sentinel lymph node biopsies. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY No. CHEMORADIATION THERAPY: No. OTHER DISEASES No. ADDENDA: Addendum. There a few satellite nodules ranging in size from 0.5-2 mm, which measure 0.5-1.2 cm from the main dominant nodule. These. satellite nodules are the nodules that are seen closest to the margins, as reported. FINAL DIAGNOSIS: PART 1: BREASTRIGHT/SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA (see comment). B. NOTTINGHAM GRADE 3 (TUBULE FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 3;. TOTAL SCORE 9/9). C. THE INVASIVE TUMOR MEASURES 1.1 CM IN GREATEST DIMENSION (ON SLIDE IK). D. NO DUCTAL CARCINOMA IN-SITU (DCIS) IS IDENTIFIED. E. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. F. RESECTION MARGINS ARE NEGATIVE FOR INVASIVE CARCINOMA; INVASIVE CARCINOMA MEASURES. LESS THAN 1 MM FROM THE ANTERIOR AND INFERIOR MARGINS, 1 MM FROM THE MEDIAL MARGIN, AND. 1.5 MM FROM THE POSTERIOR MARGIN. G. SKIN, NEGATIVE FOR TUMOR. H. ATYPICAL DUCTAL HYPERPLASIA. I. CALCIFICATIONS ASSOCIATED WITH INVASIVE CARCINOMA. J. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA ANO COLUMNAR CELL ALTERATIONS. K. CHANGES CONSISTENT WITH PRIOR BIOPSY SITE. THE INVASIVE TUMOR CELLS ARE NEGATIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND. ALSO NGATIVE FOR HER-2/NEU (SCORE 0). AS PER PREVIOUS REPORT. PART 2: AXILLA, RIGHT, CYST EXCISION -. EPIDERMAL INCLUSION CYST. PART 3: LYMPH NODE, RIGHT AXILLARY, SENTINEL #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 4: LYMPH NODE, RIGHT AXILLARY, SENTINEL #2, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 5: LYMPH NODE, RIGHT AXILLARY, SENTINEL #3, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). COMMENT: The triple negative invasive tumor was reported to be positive for basal markers, as per previous report (I. Although the mass grossly measured 1.4 cm by gross examination, the tumor is best estimated to be 1.1 cm. based on the microscopic measurement from slide 1K. CASE SYNOPSIS: SYNOPTIC . PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Clock position:12 oclock. SIZE OF TUMOR: Maximum dimension invasive component: 11 mm. MULTICENTRICITY/MULTIFOCALTY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS, Other Type(s): Basal-like phenotype confirmed by IHC. on biopsy. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation 3. Mitotic activity score. 3. Total Nottingham score: 9. Nottingham grade (1, 2, 3): 3. ANGIOL YMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 0.5 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH, FCD, Other: ductal epithelial hyperplasia, columnar cell alterations. T STAGE, PATHOLOGIC: pTic. N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: negative. PROGESTERONE RECEPTORS: negative. HER2/NEU: 0.",BRCA,0,"Based on the report, the maximum dimension of the invasive component of the tumor is 11 mm. According to the rules provided, we should use the maximum size of the tumor to determine the T stage, even if it is given in centimeters (Modified Rule 8). Therefore, the tumor size is 11 mm, which falls under the T1 category (Tumor size  20 mm) of the AJCC staging system for breast cancer (Rule 6).",T1,25.0
1322,TCGA-E9-A3Q9.FE3E1376-1527-42C0-8F5F-8849D0F2743B,2,Laterality:Right. Path Report BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 5.2 x 5.2x5.2 cm. Grossly evident lesion: Yes. Histologic type: Lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 22/22 positive for metastasis (Axillares 22/22). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,BRCA,3,"The tumor size is given in the format of X x Y x Z (5.2 x 5.2 x 5.2 cm). According to New Rule 13, we use the maximum value to determine the T stage, which is 5.2 cm. This value is then converted from millimeters to centimeters (New Rule 19), resulting in a tumor size of 5.2 cm. Using Modified Rule 8 and New Rule 18, we determine the T stage based on the exact value of the tumor size. As the tumor size is greater than 5 cm, the T stage is T3.",T3,26.0
904,TCGA-AR-A5QQ.511282C5-02AC-4105-8B52-5BBEC8B45D22,2,"A. Breast, right, simple mastectomy: Moderately differentiated squamous carcinoma. (metaplastic carcinoma) involving the mammary parenchyma forming a 5.2 x 5.0 x 4.7 cm mass. located in the central aspect of the breast with skin ulceration. Angiolymphatic invasion is. present. The surrounding breast parenchyma shows nonproliferative fibrocystic changes. A single. (of 3) intramammary lymph node is positive for metastatic carcinoma forming a solid and cystic. mass (6.5 x 5.0 x 4.7 cm) located in the lateral aspect of the breast. Extranodal extension is. present. The skin and nipple areolar region is involved by tumor. All surgical resection margins,. including skin and deep margins, are negative for tumor (minimum tumor free margin, 1.7 cm,. deep margin). Estrogen receptor, progesterone receptor, and HER2 will be performed and reported in an. addendum. B. Lymph nodes, right axillary, excision: Multiple (21) lymph nodes are negative for metastatic. carcinoma. With available surgical materials, [AJCC pT3N1] (7th edition, 2010).",BRCA,1,"The maximum size of the primary tumor is 5.2 cm, which falls under T3 category (T3: > 5 cm) according to the AJCC staging system for breast cancer. This is in line with the new rule 19, which states that if the tumor size is given in centimeters, the T stage can be determined directly from the measurement.",T3,27.0
754,TCGA-AN-A0AT.3E8F2012-A457-4358-9C8B-23292374A743,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,"The report states that the tumor size for the primary infiltrative ductal carcinoma in the right breast is not explicitly given in centimeters or millimeters. However, it does mention that the tumor grade is 3 and the sample was obtained through a radical mastectomy procedure. Given the information in the rules, we can infer that the T stage is T2, as the size of the tumor is between 2 cm and 5 cm, which is typical for a grade 3 tumor removed through a radical mastectomy. This is in line with Rule 6, which states that the T stage should be determined according to the AJCC staging system for breast cancer.",T2,28.0
1043,TCGA-BH-A0W3.801A4E2F-E26E-424F-BF42-CD0D9CD62BCE,0,"PATIENT HISTORY: CHIEF COMPLAINT/PRE-OP/POST-OP DIAGNOSIS: 1.2-cm mass upper inner quadrant left breast, core blopsy Invasive ductal. carcinoma. LMP DATE: Not provided. PROCEDURE: Left segmental mastectomy, sentinel lymph node biopsy. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. ADDENDA: Addendum. Immunostains for HER-2/neu were performed on block 1B. HER2 IMNUNOHISTOCHEMISTRY: Using appropriate formalin fixed (8 - 96 hours), controls and tissue. test block, 4B5 antibody clone is used as part of FDA approved Pathway on the. and interpreted as follows: 2+. A weak to moderate complete membrane staining is. (Equivocal). observed in more than 10% of the tumor cells). NOTE: Her-2/Neu FISH was ordered and will be subsequently reported. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 15 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: TUMOR TYPE, IN SITU: Cribriform. Micropapillary. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: LYMPH NODES EXAMINED: 4. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 300. PROGESTERONE RECEPTORS: positive, H-score: 225. HER2/NEU: 2+. INTERPRETATION. nuc ish(D17Z1,ERBB2)x2-6[80]. No amplification of the HER-2/NEU gene was seen by interphase FISH analysis. Fluorescence in situ hybridization (FISH) analysis was performed on a formalin-fixed Block 1B (Left segmental mastectomy 10:00). using the DNA probe for the HER-2/NEU gene. An adequate number of invasive tumor cells were. present and evaluated by four independent observers. The ratio of HER-Z/NEU signals (ERBB2) to chromosome 17 centromere. signals (. was determined to be 1.69. A ratio of greater than 2.2 is considered to be amplified with ratios of 1.80 to 2.20 in. the equivocal range; therefore, this specimen is not amplified. The average number of HER-2/NEU signals per cell was 4.10. The average number of signals for the chromosome 17 centromere was 2.43. Many of the cells exhibited 3 or more signals for. both the HER-2/NEU gene and for the chromosome 17 centromere. This may be indicative of either polyploidy or aneuploidy. for chromosome 17. Concurrent positive and negative control specimens showed the expected results. This FISH test is performed using a modification of the Vysis FDA approved PathVysion HER-2 DNA Probe Kit (1:2 LSI HER-2/neu. / CEP17 probe : T-denhyb-2 buffer). This FISH test was developed and Its performance determined by the. Pursuant to the requirements of CLIA '88, this laboratory has established and vermed the test's. accuracy and precision. FINAL DIAGNOSIS: PART 1: BREAST, LEFT, SEGMENTAL MASTECTOMY AT 10:00-. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION 3, NUCLEAR GRADE 2,. MITOTIC ACTIVITY 1; TOTAL SCORE 6/9). B. THE INVASIVE TUMOR MEASURES 1.5 CM IN LARGEST DIMENSION (GROSS MEASUREMENT). C. DUCTAL CARCINOMA IN SITU (DCIS), MICROPAPILLARY AND CRIBRIFORM PATTERNS, NUCLEAR GRADE. 2. D. DCIS ACCOUNTS FOR 6% OF TOTAL TUMOR VOLUME, ADMIXED WITH OR CLOSE TO INVASIVE. COMPONENT. E. INVASIVE TUMOR IS 2.5 MM FROM ANTERIOR MARGIN AND 4 MM FROM POSTERIOR MARGIN; DCIS IS. LESS THAN 0.2 MM FROM THE ANTERIOR MARGIN. F. NO LYMPHOVASCULAR INVASION IDENTIFIED. G. ATYPICAL DUCTAL HYPERPLASIA. H. NON-NEOPLASTIC BREAST TISSUE SHOWING PAPILLOMA, FIBROCYSTIC CHANGE AND DUCTAL. EPITHELIAL HYPERPLASIA. I. BIOPSY SITE CHANGES. J. TUMOR IS POSITIVE FOR ER AND PR, HER-2/NEU SCORE 2+ (. PART 2: ADDITIONAL ANTERIOR MARGIN, NEW ANTERIOR MARGIN, EXCISION -. BENIGN BREAST FIBROADIPOSE TISSUE. PART 3: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. A. ONE OF TWO (1/2) LYMPH NODES, POSITIVE FOR METASTATIC CARCINOMA (SEE COMMENT). B. THE TUMOR MEASURES 1 CM. PART 4: LEFT SENTINEL LYMPH NODE #2, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 5: LEFT SENTINEL LYMPH NODE #3, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1).",BRCA,1,"According to the report, the maximum dimension of the invasive component of the tumor is 15 mm (1.5 cm). Using Rule 1, the T stage is determined by the size of the primary tumor. Modified Rule 8 states that the maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters. Rule 9 states that the tumor size should be rounded down to the nearest whole number for T stage determination, unless the size is already a whole number. In this case, the tumor size is already a whole number, so we use the exact value. Therefore, the T stage is T1 (T1a for  0.5 cm, T1b for > 0.5 cm but  1 cm, T1c for > 1 cm but  2 cm).",T1c,28.0
676,TCGA-A8-A09M.EBBF2A70-2773-40FA-823A-E608ABFEF591,1,"Diagnosis: Right-sided breast excision material with a poorly differentiated invasive ductal breast. carcinoma measuring about 4.3 cm with invasion of the lymph vessels and a minimum margin. of 3 mm at 6 o 'clock and 10 mm at 12 o 'clock and 1.5 cm or more at 3 and 9 ""clock. No. intraductal tumor component. Tumor classification: M-8500/3, G3, pT 2, pN 3a (14/28), pMx, stage III c. R 0.",BRCA,3,"The report states that the size of the primary tumor is approximately 4.3 cm. According to the modified Rule 8 and New Rule 19, the maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters and converted from millimeters. The tumor size is already a whole number, so there is no need to round down or up (Rule 9, New Rule 18, and Rule 12). Therefore, the T stage is T2.",T2,29.0
615,TCGA-A8-A06U.A314FB55-F20A-4485-965D-D7894D070A16,1,"Diagnosis: 1. Right-sided ablated breast tissue multicentric, poorly differentiated, invasive ductal breast. carcinoma with at least four foci measuring a maximum diameter of 2 cm, 3 cm, 0.7cm and. 2.5 cm, partly with inclusion of a high-grade intraductal carcinoma with comedo necroses in. the tumor periphery and surrounded by a mastopathy with partially sclerotic, intraductal,. papillomatous scleradenosis with microcalcifications and also cystic mastopathy and. cylindrical epithelial metaplasia. The overlying skin and nipple are tumor-free, no pagetoid. pattern of spread. the outer resection margins are tumor-free. Tumor classification: M-8500/3, G 3, pT2 (m), pN1a (2/25), pMX, stage II B. R0.",BRCA,1,"The report mentions 'at least four foci measuring a maximum diameter of 2 cm, 3 cm, 0.7cm and 2.5 cm'. According to New Rule 13, we use the maximum value to determine the T stage, which is 3 cm. This is rounded down to the nearest whole number, as per Rule 9, resulting in a T2 stage.",T2,30.0
1050,TCGA-BH-A18H.DF536409-601F-489B-9F8A-A2B372BF9999,0,"PATIENT HISTORY: Site Code : breast, NOS C50.9. CHIEF COMPLAINT/ PRE-OP/ POST-OP DIAGNOSIS: Left breast cancer 1.3 cm, positive nodes. Right invasive ductal. carcinoma 9 d'clock. LMP DATE: Not provided. PROCEDURE: Bilateral segmental mastectomies, right sentinel lymph node biopsy. left axillary lymph node dissection. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. FINAL DIAGNOSIS: PART 1: BREAST, RIGHTAT 9 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NO SPECIAL TYPE (See comment). B. NOTTINGHAM GRADE 2 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 1;. TOTAL SCORE: 6/9). C. THE INVASIVE TUMOR MEASURES 0.8 CM IN LARGEST DIMENSION. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM, MICROPAPILLARY AND FOCAL. PAPILLARY TYPE WITH CALCIFICATIONS. E. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. F. THE DCIS CONSTITUTES 60% OF THE TOTAL TUMOR VOLUME AND is PRESENT ADMIXED AND. ADJACENT TO THE INVASIVE COMPONENT. G. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. H. RESECTION MARGINS ARE NEGATIVE FOR TUMOR. I. BOTH INVASIVE CARCINOMA AND IN SITU CARCINOMA ARE MORE THAN 0.5 CM FROM ALL MARGINS. J. FOCAL ATYPICAL DUCTAL HYPERPLASIA. K. PREVIOUS BIOPSY SITE CHANGES. L. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES. M. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN (H-score 230), POSITIVE FOR. PROGESTERONE RECEPTORS (H-score 180), AND NEGATIVE FOR HER-2/NEU (IHC 2+, FISH not amplified). AS PER THE PREVIOUS PATHOLOGY REPORT. PART 2: RIGHT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC TUMOR (0/1). PART 3: BREAST, LEFT. AT 12 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA NO SPECIAL TYPE. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 2;. TOTAL SCORE: 8/9). C. THE INVASIVE TUMOR MEASURES 1.3 CM IN LARGEST DIMENSION. D. ADDITIONAL SATELLITE NODULE OF INVASIVE CARCINOMA MEASURING 0.2 CM IS IDENTIFIED. E. THE SATELLITE NODULE IS 0.5 CM FROM THE DOMINANT TUMOR NODUI E. F. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID TYPE. G. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. H. THE DCIS CONSTITUTES 15% OF THE TOTAL TUMOR VOLUME AND IS PRESENT ADJACENT TO THE. INVASIVE COMPONENT. I. FOCAL LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. J. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. K. INVASIVE CARCINOMA IS 0.4 CM FROM THE NEAREST (POSTERIOR) MARGIN. L. DUCTAL CARCINOMA IN SITU IS MORE THAN 0.5 CM FROM ALL MARGINS. M. SKIN IS NEGATIVE FOR TUMOR. N. PREVIOUS BIOPSY SITE CHANGES. O. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES. P. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN RECEPTOR (H-ccore 300), POSITIVE FOR. PROGESTERONE RECEPTOR (H-score 235), AND NEGATIVE FOR HER-2/NEU, AS PER PREVIOUS. PART 4: LEFT AXILLARY CONTENTS, EXCISION -. A. METASTATIC CARCINOMA INVOLVES TWO OF TWENTY-FOUR LYMPH NODES (2/24). B. THE LARGEST METASTATIC FOCUS MEASURES 4.0 CM. C. NO EXTRACAPSULAR EXTENSION IDENTIFIED. COMMENT: Part 1: The gross examination demonstrated an III-defined firm nodule with surrounding fibrous tissue measuring 2.0 x. 1.1 x 0.7 cm. This area was entirely submitted for histologic evaluation and shows Invasive carcinoma in only two. sections of 0.4 cm thickness and therefore, the invasive tumor size is estimated to be 0.8 cm in largest dimension. The. majority of this gross lesion is composed of ductal carcinoma in situ (DCIS). Part 3: The invasive tumor demonstrates scattered cells with intra-cytoplasmic lumina or signet ring cell morphology. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Clook position:9.00. SIZE OF TUMOR: Maximum dimension invasive component: 8 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (Invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Cribriform. Micropapillary. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of Invasive tumor to closest margin: 6 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 6 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC 1 BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: pT1b. N STAGE MODIFIER: (sn). N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 230. PROGESTERONE RECEPTORS: positive, H-score: 180. HER2/NEU: 2+. HER2/NEU (FISH): Not amplified. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: ( Left. PROCEDURE: Segmental. Clock position: 12.00. SIZE OF TUMOR: Maximum dimension invasive component: 13 mm. MULIICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI;. TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 15 mm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Solid. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 4 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 24. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 40 mm. LYMPH NODE METASTASIS(-ES WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 300. PROGESTERONE RECEPTORS: positive, H-score: 235. HER2/NEU: 1+.",BRCA,0,"Based on the report, the largest invasive tumor size in the left breast is 1.3 cm, which falls under the T1 category. The right breast tumor is 0.8 cm, also falling under T1. The AJCC staging system for breast cancer was used, taking into account the largest tumor size and the fact that it is an invasive ductal carcinoma.",T1,31.0
462,TCGA-A1-A0SN.D0269758-EFAE-4EBA-8CCF-4A6CF4D4B35A,0,"Final Pathologic Diagnosis: A. Lymph node, left axillary sentinel node #1, excision: No metastatic carcinoma in. one lymph node (0/1). B. Lymph node, left axillary sentinel node # +2, excision: Metastatic carcinoma in one. lymph node with extension into peri-nodal fat (1/1). C. Lymph node, left axillary sentinel node # 3, excision: Metastatic carcinoma in one. lymph node (1/1). D. Lymph node, left axillary non-sentinel node # 1, excision: Metastatic carcinoma in. one lymph node (1/1). Working Draft. E. Lymph node, left axillary non-sentinel node #2, excision: Metastatic carcinoma in. one lymph node (1/1). F. Breast, left, partial mastectomy: 1. Infiltrative ductal carcinoma, SBR grade 2, 1.1 cm in maximum dimension,. margins negative; see comment. 2. Ductal carcinoma in situ, high-grade, solid and comedo types, 1.1 cm in maximum. dimension, intermixed with invasive ductal carcinoma, margins negative. G. Breast, left lateral anterior, excision: Benign breast tissue, no carcinoma. identified. H. Breast, medial superior anterior, excision: Benign breast tissue, no carcinoma. identified. I. Lymph node, left axillary contents, excision: No metastatic carcinoma in eight. lymph nodes (0/8). Note: Breast Tumor Synoptic Comment. - Laterality: Left. - Invasive tumor type: Invasive ductal carcinoma. - Invasive tumor size: 1.1 cm maximum diameter. - Invasive tumor grade (modified Bloom-Richardson): 2. Nuclear grade: 3, 3 points. Mitotic count: <10 mitotic figures/10 HPF, 1 point. Tubule/papilla formation: <10%, 3 points. Total points and overall grade = 7 points = grade 2. - Lymphatic-vascula invasion: Extensive lymphatic-vascular invasion is noted with intra-lymphatic. metastasis noted in lymphatics at least 1 cm from the main tumor. - Perineural Invasion: Not present. - Resection margins for invasive tumor: - Deep margin: Negative; (tumor is 0.2 cm away, on slide F6). - Medial margin: Negative; (tumor is greater than 1 cm). - Lateral margin: Negative; (tumor is greater than 1 cm). - Anterior/superior margin: Negative; (tumor is 0.2 cm away, on slide F6). - Anterior/inferior margin: Negative; (tumor is 0.3 cm away, on slide F4). - Ductal carcinoma in situ (DCIS) type: Comedo and solid. - Ductal carcinoma in situ size: 1.1 cm, intermixed with invasive ductal carcinoma. - Ductal carcinoma in situ nuclear grade: High-grade. - Necrosis in DCIS: Comedonecrosis. - Microcalcifications: Not identified. - Resection margins for ductal carcinoma in situ: - Deep margin: Negative; (tumor is 0.6 cm away, on slide F6). - Medial margin: Negative; (tumor is greater than 1 cm). - Lateral margin: Negative; (tumor is greater than 1 cm). - Anterior/superior margin: Negative; (tumor is 0.25 cm away, on slide F6). - Anterior/inferior margin: Negative; (tumor is 0.25 cm away, on slide F6). - Lobular carcinoma in situ (LCIS): None. - Lymph node status: Positive. - Number of positive lymph nodes: 4. - Total number sampled: 13. - Diameter of largest metastasis: 0.8 cm. Working Draft. - Extranodal extension: Present. - AJCC/UICC stage: pT1cN1MX. An immunohistochemical test for estrogen and progesterone receptors was performed by manual. morphometry on block #. The test for estrogen receptors is positive. There isstrong nuclear staining in 90% of tumor cells. Internal positive control is positive. The test for progesterone receptors is positive. There is moderate nuclear staining in 60% of tumor. cells. Internal positive control is positive. Result of HER2/neu test: This carcinoma is positive for HER2/neu oncoprotein over-expression. An immunohistochemical assay was performed by manual morphometry on block F8 using the CB11. monocional antibody to HER2/neu oncoprotein. The staining Intensity of this carcinoma was 3 on a. scale of 0-3 (HER2 test interpreted by Dr. Carcinomas with staining intensity scores of 0 or 1 are considered negative for over-expression of HER2/neu oncoprotein. Those with a staining intensity score of 2 are considered indeterminate. We and others have observed that many carcinomas with. staining intensity scores of 2 do not show gene amplification. All carcinomas with staining intensity scores of 2 are therefore. submitted for FISH testing. The results of the FISH test are issued directly from the molecular cytogenetics laboratory. Carcinomas with staining intensity scores of 3 are considered positive for over-expression of HER2/neu oncoprotein. Tumors in. this category show an excellent correlation between the results of immunohistochemical and FISH testing, and almost always show. gene amplification. Intraoperative Consult Diagnosis. FS1 (A) Left axillary sentinel lymph node #1, biopsy: No tumor seen. (Tissue section and. cytopreparation) (Dr. FS2 (B) Left axillary sentinel lymph node #2, biopsy: Positive for metastatic carcinoma. (Tissue. section and cytopreparation) (Dr. FS3 (C) Left axillary sentinel lymph node #3, blopsy: Positive for metastatic carcinoma. (Tissue. section and cytopreparation) (Dr. 1. FS4 (D) Left axillary non-sentinel lymph node #1, biopsy: Positive for metastatic carcinoma. (Tissue. section and cytopreparation) (Dr. Clinical History. The patient is a. year-old woman with left breast invasive ductal carcinoma. She undergoes partial. mastectomy. Gross Description. The specimen is received fresh in nine parts, each labeled with the patient's name and medical record. number. Part A is additionally labeled. It consists of a single irregular piece of. soft-firm, pink-red tissue, measuring 0.5 x 0.3 X 0.2 cm. The specimen is bisected, and cytologic. touch and scrape preparations are prepared. The specimen is then entirely submitted for frozen. section diagnosis as FS1, with the frozen section remnant submitted in cassette A1. Part B is additionally labeled. It consists of a single oval piece of soft-to-firm,. red-pink tissue, measuring 0.9 x 0.6 x 0.6 cm. The specimen is bisected, and cytologic touch and. scrape preparations are made. The specimen is then entirely submitted for frozen section diagnosis as. FS2, with the frozen section remnant submitted in cassette B1. Part C is additionally labeled. It consists of a single ovoid piece of soft-to-firm,. Working Draft. pink-red tissue, measuring 0.8 x 0.5 x 0.4 cm. The specimen is bisected, and cytologic touch and. scrape preparations are prepared. I he specimen is then entirely submitted for frozen section. diagnosis as FS3, with the frozen section remnant submitted in cassette C1. Part D is additionally labeled. It consists of a single ovoid piece of. soft-to-firm, pink-red tissue, measuring 1.3 x U.I x 0.5 cm. The specimen is bisected, and cytologic. touch and scrape preparations are prepared. The specimen is then entirely submitted for frozen. section diagnosis as FS4, with the frozen section remnant submitted in cassette D1. Part E is additionally labeled. It consists of a single ovoid piece of firm,. off-white/tan tissue, measuring 1.5 x 0.7 x 0.4 cm. The specimen is bisected and entirely submitted. in cassette E1. Part F is additionally labeled. t consists of. an oriented portion of fat, measuring 10.3 (anterior- posterior) x 7.4 (medial-lateral) x 6.4. (superior-inferior) cm and weighing 13 gm. There is a 1.1 cm in diameter white-yellow hard mass. with a white homogeneous interior located within the specimen (slices 3-6). This mass abuts the. posterior margin, is 0.6 cm from the anterior-inferior and anterior-superior margins, 1 cm from the. lateral margin, and 7 cm from the medial margin. The specimen is inked so as the anterior-superior. surface is blue, the anterior- inferior surface is green, and the posterior surface is black. A. representative section is taken for tissue banking. The specimen is serially sectioned, from lateral to. medial into thirteen 0.5 cm slices. Representative sections are submitted as follows: Cassette F1: Lateral margin, slice 1, perpendicular. Cassettes F2-F3: Slice 2, two pieces. Cassettes F4-F5: Slice 3, two pieces, mass. Cassettes F6-F7: Slice 4, two pieces, mass. Cassette F8: Representative section of slice 5, mass. Cassette F9: Representative section of slice 6, mass. Cassette F10: Slice 12. Cassette F11: Medial margin, slice 13. perpendicular. Part G is additionally labeled. It consists of a. small fragment of fat, measuring 0.6 x 0.7 x 0.7 cm. A stitch marks a portion of the specimen. indicating the true margin. The specimen is inked so as this true margin is blue, and the rest of the. specimen is black. The specimen is entirely submitted in cassette G1. Part H is additionally labeled. It. consists of a fragment of yellow-white, soft fat, measuring 1 x 0.6 x 0.7 cm. A stitch marks the true. margin of the specimen. The specimen is inked so as this true margin is blue, and the remaining. portion of the specimen is black. The specimen is entirely submitted in cassette H1. Part I is additionally labeled. It consists of a portion of fat measuring 4.2 x 3.8. x 0.9 cm. Multiple pink-tan lymph nodes are noted within the specimen ranging in size from 0.6-1.3. cm in diameter. Many of these nodes are previously bisected or trisected. Representative sections. of. the specimen are taken and submitted as follows: Cassette 11: Six lymph nodes attached. Cassette 12: Two lymph nodes, one bisected and one trisected. 'Pathology Resident. Fee Codes: Working Draft. Other Specimens. Specimen Class: i. Accessioned: Specimen(s) Received: Skin, biopsy, punch bx, right posterior calf. Final Diagnosis. {Final Report Not Signed Out}. (Not Entered}. Specimen Class: Accessioned: Specimen(s) Received: SP Consult. Final Diagnosis. Review. from. Breast, left, 1 o'clock, core needle biopsy: 1. Invasive carcinoma; see comment. 2. Microscopic focus of ductal carcinoma in situ, high nuclear grade; see comment.",BRCA,1,"The report states that the largest diameter of the tumor is 1.1 cm, which falls within the T1 category (T1:  2 cm) according to the AJCC staging system for breast cancer. The specific subcategory (T1a, T1b, T1c) cannot be determined without additional information about the tumor size relative to the invasive component.",T1,32.0
680,TCGA-A8-A09T.C616E97C-8352-4FED-9E83-558318216FB6,0,"Diagnosis: 3. Left-sided breast resection material with a 1.8 cm moderately differentiated tubulolobular. breast carcinoma with an equally sized component of intraductal tumor propagation of the. lobular tumor component and a minimum margin of 5 mm at 12 o'clock and over 10 mm at. 3 o'clock and about 1 mm at 6 o'clock (well over 10 mm at 9 o'clock) without any evidence. of invasion of the lymph vessels. Tumor classification: M-8500/3, G2, pTlc, pLO, pSNO (0/2), pMx, stage I. R 0.",BRCA,0,"Based on the report, the size of the primary tumor is 1.8 cm. According to the modified Rule 8, we use the maximum size of the tumor to determine the T stage, even if it is given in centimeters or millimeters. Next, according to Rule 9, we round down to the nearest whole number for T stage determination, unless the size is already a whole number. However, in this case, we have to consider Rule 12, which states that if the tumor size is given in decimal form and is closer to the next whole number, round up to the next whole number for T stage determination. Therefore, the T stage is T1.",T1,33.0
556,TCGA-A2-A3XX.770EEADF-19CD-4AB9-A7FA-1A05EE17984C,1,"Specimen #: (Age. Race. SPECIMEN: A: SENTINEL NODE #1 B: LEFT BREAST TISSUE. FINAL DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, BIOPSY: - ONE (1) LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA BY H&E AND. IMMUNOSTAINS. B. BREAST, LEFT, MASTECTOMY: - TUMOR TYPE: INFILTRATING DUCTAL CARCINOMA. - NOTTINGHAM GRADE: 3 OUT OF 3. - NOTTINGHAM SCORE: 8 OUT OF 9 (Tubules= 3, Nuclei= 2, Mitoses= 3. mitotic count 22 per 10 HPF at 40x power). TUMOR SIZE (GREATEST DIMENSION) : 2.2 CM (MEASURED GROSSLY). - TUMOR NECROSIS: PRESENT IN BOTH THE INVASIVE AND IN SITU COMPONENTS. - MICROCALCIFICATIONS: ABSENT. - VENOUS / LYMPHATIC INVASION: ABSENT. - MARGINS NEGATIVE. DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0.1 CM, FROM THE. SUPERFICIAL (GREEN INKED) MARGIN. (MEASURED MICROSCOPICALLY) (SLIDE. B6). - INTRADUCTAL COMPONENT: PRESENT. DUCTAL CARCINOMA; HIGH NUCLEAR GRADE. (GRADE III) SOLID SUBTYPE WITH CENTRAL NECROSIS. - LYMPH NODES: ONE (1) NEGATIVE FOR TUMOR. (SEE PART A). - NIPPLE INVOLVEMENT: ABSENT. - SKIN INVOLVEMENT: ABSENT. - MULTICENTRICITY: ABSENT. - ESTROGEN RECEPTORS: NEGATIVE (SEE CASE. - PROGESTERONE RECEPTORS : NEGATIVE (SEE CASE. - HER 2 NEU by IHC: NEGATIVE (SEE CASE. - PATHOLOGIC STAGE: pT2 NO (i-) MX. - ADDITIONAL PATHOLOGIC CHANGES. INTRADUCTAL PAPILLOMA. FIBROADENOMATOUS CHANGES. FIBROCYSTIC CHANGES. COMMENT: Cytokeratin staining of part A supports the above diagnosis. This case received prospective intradepartmental peer review. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL US ONLY - PERSONAL DATA - PRIVACY ACT or. Specimen #. FINAL DIAGNOSIS (continued). CLINICAL DIAGNOSIS AND HISTORY: yr old. with left breast cancer. PRE-OPERATIVE DIAGNOSIS: none provided. POST-OPERATIVE DIAGNOSIS: none provided. GROSS DESCRIPTION: A: Received fresh, labeled with the patient's name,. Id. designated ""Sentinel Node #1 with markings; suture marks hottest point at. 1152 hours"" is a 2.5 x 2.5 x 0.7 cm irregular portion of soft tissue. Sectioning reveals a 2.5 x 1.5 x 0,5 cm pink-tan lymph node with attached. adipose tissue. The specimen is entirely submitted as follows: Cassette Summary: A1- sentinel lymph node; A2- adipose tissue. At the time of submission the specimen will have been in formalin for. approximately 23 hours Matched sections of cassette A1 are. submitted in OCT for. Protocol. B: Received fresh, labeled with the patient's name,. and. designated ""Left Breast Tissue, long-lateral, short-superior 1 pm' is. a. 468 gm left mastectomy specimen oriented with a short stitch at the. superior aspect and long stitch at the lateral aspect. The specimen. measures 20.0 cm from superior to inferior by 18.0 cm from medial to. lateral by 3.0 cm from anterior to posterior. The darkly pigmented skin. ellipse measures 9.5 x 3.5 cm and displays a 1.5 cm centrally located,. everted nipple free of discharge. The deep margin is inked in black, and. the left outer quadrant superficial margin is inked in green. Serial. sectioning reveals a 11-circumscribed 2.2 x 2. x 1.8 cm mass in the. lower outer quadrant located 0.3 cm from the superficial margin and 0. cm. from the deep margin. The cut surface is firm gritty pink-red and focally. congested. The remainder of the specimen is composed of evenly. distributed pink-tan fibrous tissue admixed adipose tissue. No additional. lesions are identified. No lymph nodes are identified within the specimen. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT or. specimen #: GROSS DESCRIPTION (continued) : Representative sections are submitted. At the time of submission the. specimen has fixed in formalin for approximately 21 hours. Cassette Summary: B1- - skin; B2-B3 - lower outer quadrant deep margin;. B4-B6- mass with superficial margin; B7 - representative section of grossly. normal breast parenchyma from the upper outer quadrant; B8- representative. section of grossly normal breast parenchyma from the upper inner quadrant;. B9 representative section of grossly normal breast parenchyma from the. lower inner quadrant; B10- representative section of grossly normal breast. parenchyma from the lower outer quadrant; B11- - representative section of. grossly normal breast parenchyma from the central area; B12-. representative section of nipple with associated subcutaneous tissue. Matched sections of cassette B1, B4-B5, B7-B11 are submitted in OCT for. ) Protocol. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY.",BRCA,0,"Based on the report, the size of the primary tumor is 2.2 cm, which is greater than 2 cm but less than or equal to 5 cm. According to the AJCC staging system for breast cancer and the rules provided, a tumor size of 2.2 cm corresponds to a T2 stage. The report specifies that the tumor size is measured in centimeters, and the maximum size is used to determine the T stage. The tumor size is already a whole number, so there is no need to round up or down.",T2,33.0
1504,TCGA-S3-AA12.9F96B0B1-2B88-49AE-8D3C-9FED70F1D950,2,"Surgica Pathology Final Report. Temporary Copy. los. Diagnosis. A. LEFT BREAST AND AXILLARY LYMPH NODES, MASTECTOMY AND. LYMPHADENECTOMY: - INVASIVE DUCTAL CARCINOMA, GRADE 2, 9.0 CM IN GREATEST DIMENSION. - METASTATIC CARCINOMA ION TWO OF EIGHTEEN LYMPH NODES. - MARGINS OF RESECTION ARE NOT INVOLVED. - SEE SYNOPTIC REPORT AND NOTE. NOTE: biomarkers studies have been ordered and will be reported-in an addendum. B. SKIN OF LEFT BREAST, ADDITIONAL INFERIOR, EXCISION: - SEGMENT OF UNREMARKABLE SKIN. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 27 cm. Additional dimensions: 19 x 11 cm. SPECIMEN LATERALITY: Left. TUMOR SITE: INVASIVE CARCINOMA: Upper inner quadrant. Lower inner quadrant. Central. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 9.0 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma directly invades into the dermis or epidermis without skin ulceration. Nipple: DCIS does not involve the nipple epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative (small foci, less than 5% of the entire tumor). ARCHITECTURAL PATTERNS: Cribriform. Temporary Copy. NUCLEAR GRADE: Grade II (intermediate). NECROSIS: Not identified. LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTLATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in. both size and shape. MITOTIC COUNT: Score 1. OVERALL GRADE: Grade 2: scores of 6 or 7. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: 15 mm (deep fascial margin). Margins uninvolved by DCIS (if present). Distance from closest margin: 15 mm (deep fascial margin). LYMPH-VASCULARI INVASION: Present. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Total number of lymph nodes examined (sentinel and nonsentinel): 16. Number of lymph nodes with macrometastases (>0.2 cm): 2. Size of largest metastatic deposit: 3.5 cm. EXTRANODAL EXTENSION: Not identified. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT3: Tumor >50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. DISTANT METASTASIS (M): Not applicable. MICROCALCIFICATIONS: Present in non-neoplastic tissue. CLINICAL HISTORY: Palpable mass. Specimen Source. A. LT Breast and Axillary Nodes. B. Additional Inferior Skin. Clinical Information. Temporary Copy. Patient with large mass upper Central breast, core biopsy positive. PRE-OP DIAGNOSIS: Left breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Left mass and axillary node dissection. Gross Description. The specimen is labeled ""LEFT BREAST AND AXILLARY NODES "" and is received in formalin. It consist. of mastectomy specimen with lymph nodes weighing 1330 grams and measuring 27 x 19 x 11 cm with brown. skin ellipse measuring 24 x 13 cm, containing grossly unremarkable 1.8 cm in diameter nipple. The posterior. margin is composed of smooth fascia which is inked black. Superior non-deep margin is inked with red ink and. the inferior non-deep margin is inked with blue ink. The breast is slices in sagittal planes revealing a large well. defined pink-tan lobulated mass measuring 9 x 7 x 6 cm and is located central portion of the breast and. extending upper inner and lower inner quadrant. This mass is 1.5 cm away from the deep fascial margin of. resection, 1.5 cm from the superior non-deep fascial margin and 2 cm from the inferior non-deep fascia margin. of resection. The remaining portions reveal unremarkable yellow mammary fat with streaks of white-gray. mammary parenchyma. The axillary fat pad measuring 10 x 10 x 5 cm. On sectioning multiple lymph nodes are. identified. The largest lymph node is consists of a 2 matted lymph nodes measuring 4 x 3 x 3 cm and is pink tan. and firm in consistency for 3.5 cm. Representative sections are submitted as follows: Al = nipple. A2-A5 = mass. A 6 = mass closest deep fascial margin of resection. A7 = representative sections upper outer quadrant. A8 = representative sections lower outer quadrant. A 9 = mass with closest skin surface. A 10 = six lymph nodes. A 11 = bisection of a single lymph node. A 12 = bisection of a single lymph node. A 13 = bisection of a single lymph node. A 14 = bisection of a single lymph node. A 15 = bisection of a single lymph node. A 16 = bisection of a single lymph node. A 17 = bisection of a single lymph node. A 18 = bisection of a single lymph node. A 19-A 20 = representative sections of 2 matted lymph nodes. Specimen is in formalin more than 6 hours and less than 48 hours. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 45 minutes. Special Stains / Slides. 23 H&E. Temporary Copy. Tissue Code. Addendum Report. Temporary Copy. Addendum Report. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA. ESTROGEN RECEPTORS: 99 %, positive, moderate staining intensity. PROGESTERONE RECEPTORS: <1 %, negative, moderate staining intensity. HER-2NEU: SCORE 1+, negative. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Block A4) using the. following monocional antibodies: Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2) and. Her-2neu (. Clone 4B5); control sections for HER-2Neu are provided within a kit (score 0 MCF-7, score. 1+. T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection system used: polymer. Primary antibodies,. reagents and control sections for HER-2neu are all provided by. All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively. stained nuclei of tumor cells. Reference values (CAP accreditation program checklist 2010 and guidelines on. webpage): Positive: nuclear staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist. 2010 and guidelines on webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a. portion of the membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or >10% of tumor cells but only a portion of the. membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in > 10% of tumor cells or. circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform. membrane staining. A homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food. and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical. purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. (Electronic signature). Verified:",BRCA,1,"The maximum size of the primary tumor is given as 9.0 cm, which falls in the T3 category (T3: tumor size > 5 cm) according to the AJCC staging system for breast cancer. This is consistent with Rule 1, Rule 6, and the modified Rule 8.",T3,33.0
1138,TCGA-D8-A1X9.E69CF3E3-4799-4892-87E9-4291B14A1B9C,1,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Total organ resection - left breast with axillary tissues. Material collected on: : Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell. nuclei. HER2 protein stained with HercepTest by DAKO. Score = 2+, FISH verification recommended. Macroscopic description: Left breast sized 22 x 15 x 5 cm removed along with axillary tissues sized 13 x 7.5 x 1.5 cm and a skin flap of 19 x 11 cm. Retracted nipple. Tumour sized 2.5 x 2 x 2.8 cm found on the boundary of lower quadrants, located 3.5 cm from the lower. boundary, 0.4 cm from the base and 3 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG2 (2+2+3/21 mitoses/10 HPF - visual area 0.57mm). Glandular tissue showing. lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis simplex (UDH 1. AXILLARY LYMPH NODES: Metastases carcinomatosae in lymphonodis (No III/XXIII). Infiltratio capsulae lymphonodorum. Histopathological diagnosis: Carcinoma ductale invasivum mammae sinistrae. Invasive ductal carcinoma of the left breast. Metastases carcinomatosae in lymphonodosi axillae (No III/XXIII) (NHG2, pT2, pNIa). Cancer metasta  of axillary lymph nodes (No III/XXIII) (NHG2, pT2, pNIa). S. Examination: Histopathological examination. page 2 / 2. Gender: F. Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND.",BRCA,1,"Based on the report, the size of the primary tumor is 2.5 x 2 x 2.8 cm. According to the modified Rule 8 and New Rule 13, the maximum value should be used to determine the T stage. Therefore, the T stage is T2 (> 2 cm but  5 cm).",T2,34.0
968,TCGA-BH-A0B4.00C75246-4343-490D-9782-E6C0068C77B2,1,"FINAL DIAGNOSIS: PART. 1: BREAST AND NODES, LEET, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 3 (TUBULE FORMATION 3, NUCLEAR. PLEOMORPAISM 3, MITOTIC ACTIVITY 3, TOTAL SCORE 9/9). B. INVASIVE CARCINOMA MEASURES 2.2 CM (MICROSCOPIC MEASUREMENT). C. INVASIVE CARCINOMA EXTENSIVELY INVOLVES NIPPLE PAPILLARY DERMIS UNDER THE BASAL LAYER. OF THE EPIDERMIS. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, SOLID TYPE, CONSTITUTES 2% OF TOTAL. TUMOR MASS, ADMIXED WITH INVASIVE CARCINOMA. E. ALL RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA; INVASIVE CARCINOMA IS 1.1 CM TO THE. CLOSEST MARGIN. F. SIX OUT OF TEN AXILLARY LYMPH NODES ARE POSITIVE FOR METASTATIC CARCINOMA, WITH. MULTIPLE AREAS OF EXTRACAPSULAR EXTENSION. H. NO DEFINITIVE LYMPHVASCULAR INVASION NOTED. G. METASTATIC TUMOR MEASURES 2.5 CM IN GREATEST DIMENSION (RANGING FROM 0.7 CM TO 2.5 CM). I. FIBROCYSTIC CHANGES ARE PRESENT. PART 2: LYMPH NODE, LEFT, BIOPSY -. A. FIBROADIPOSE TISSUE. B. NO LYMPHATIC TISSUE IS IDENTIFIED. C. ENTIRE SPECIMEN SUBMITTED FOR MICROSCOPIC EXAMINATION. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Modified radical mastectomy. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 2.2 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 3. Total Nottingham score: 9. Nottingham grade (1,2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: TUMOR TYPE, IN SITU: Solid. Percent of tumor occupied by in situ component: 2 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 6. LYMPH NODES EXAMINED: 10. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 25 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN2a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",BRCA,2,"The maximum dimension of the invasive component of the tumor is given as 2.2 cm, which falls under the T2 category of the AJCC staging system for breast cancer, as it is greater than 2 cm but less than or equal to 5 cm.",T2,35.0
563,TCGA-A2-A4S0.0118D9AE-B923-4EEF-BBBC-82D559763FF9,1,"Status: DIS-IN. M.D. Specimen: Sp type: SURGICAL P. M.D. PREOPERATIVE DIAGNOSIS. BREAST CA. OPERATION PERFORMED. DOCTOR (S) : PROCEDURE : TOTAL MASTECTOMY; EXCISION OF AXILLARY SENTINEL NODE. TISSUE REMOVED. A. RIGHT BREAST STITCH AT 12 O'CLOCK. B. RIGHT SENTINEL NODE #1. GROSS DESCRIPTION. RECEIVED IN 2 PARTS. A RECEIVED LABELED. RIGHT BREAST STITCH AT 12 O'CLOCK IS. A 2041 SIMPLE MASTECTOMY MEASURING 33.5 CM FROM MEDIAL TO LATERAL, 28 CM. FROM SUPERIOR TO INFERIOR, AND UP TO 5.5 CM FROM ANTERIOR TO POSTERIOR. THE NIPPLE IS INVERTED WITHIN A 31 X 17 CM SKIN ELLIPSE. A SUTURE. DENOTES 12 O'CLOCK. 4 CM LATERAL TO THE NIPPLE AT 9 O'CLOCK IS A. LOBULATED RED-TAN GLISTENING MASS MEASURING 2.2 CM FROM SUPERIOR TO. INFERIOR, 2 CM FROM ANTERIOR TO POSTERIOR, AND 4.5 CM FROM MEDIAL TO. LATERAL. THIS LESION IS 2.5 CM FROM THE DEEP MARGIN. TOWARDS THE. LATERAL EDGE THERE IS A 2ND NODULE ADJACENT BY LESS THAN 1 CM MEASURING. 1 x 1 X 1 CM. THERE IS A RIBBON CLIP ASSOCIATED WITH THIS AREA. THE. REMAINING BREAST TISSUE CONSISTS OF BLAND YELLOW FATTY TISSUE WITH FINE. FIBROUS BANDS. A WING CLIP IS IDENTIFIED IN THE LARGER LESION. REPRESENTATIVE SECTIONS ARE SUBMITTED AS FOLLOWS: A1--NIPPLE, A2--DEEP. MARGIN TO LARGER LESION, A3--THE MOST LATERAL PORTION OF THE LARGER. LESION, A4--THE MOST MEDIAL PORTION OF THE LARGER LESION 4.5 CM FROM A3,. A5 THROUGH A7--ADDITIONAL SECTIONS OF LARGER LESION, A8 AND --SMALLER. SUPERIOR RIBBON CLIP LESION, A10--UPPER INNER QUADRANT 10 CM FROM THE. LESION, All--UPPER OUTER QUADRANT 4 CM FROM LESION, A12--LOWER OUTER. QUADRANT 4 CM FROM LESION, A13--LOWER INNER QUADRANT 10 CM FROM LESION. TISSUE IS TAKEN PER CLINICAL BREAST CARE PROJECT RESEARCH PROTOCOL OF. THE LARGER LESION LABELED P1-p5 WITH FROZEN OCT SAMPLES AS MIRROR IMAGES. TO P1 AND P2. IN ADDITION A MIRROR IMAGE SECTION OF THE NIPPLE (A1) IS. SUBMITTED FROZEN IN OCT ALONG WITH THE 4 RANDOM QUADRANT SECTIONS. Specimen: Sp type: SURGICAL P. D. GROSS DESCRIPTION. A10-A13. B RECEIVED LABELED. RIGHT SENTINEL NODE #1 HOT AND BLUE. COUNT 39252 IS A PORTION OF PINK-TAN TISSUE WITH BLUE COLORATION. MEASURING 1.3 X 0.8 X 0. . 4 CM. THE SPECIMEN IS BISECTED AND SUBMITTED. LABELED B. COMMENT: THIS CASE EXCEEDS THE MAXIMUM CAP/ASCO. GUIDELINE OF 48 HOURS FORMALIN FIXATION. PATH PROCEDURES. PROCEDURES: 88307/2, IMMUNOPEROXIDAS, A BLK/13, BBX X6. FINAL DIAGNOSIS. PART A RIGHT BREAST, SIMPLE MASTECTOMY: 1. Macinous CA 1/1/1. INVASIVE MUCINOUS CARCINOMAS (2) GRADE I WITH NUCLEAR GRADE 1 AND. LOW MITOTIC INDEX. 2. THE TUMORS MEASURE 4.5 AND 1.0 CM IN GREATEST DIMENSION. THE NIPPLE. AND DEEP MARGIN ARE FREE OF NEOPLASM. 3. LYMPHATIC INVASION IS NOT IDENTIFIED. 4. BIOPSY SITE CHANGES WITH CLIPS PRESENT. 5. PROLIFERATIVE FIBROCYSTIC DISEASE WITH CALCIFICATIONS PRESENT. PART B RIGHT SENTINEL NODE 1: LYMPH NODE (1), NEGATIVE FOR TUMOR BY. STEP SECTION AND CYTOKERATIN STAIN. , M.D.",BRCA,0,"Based on the report, the largest tumor nodule measures 4.5 cm in greatest dimension (Rule 7, Modified Rule 8, New Rule 13). According to the AJCC staging system for breast cancer, T2 corresponds to a primary tumor size of > 2 cm but  5 cm (New Rule 19). Therefore, the T stage is T2.",T2,35.0
467,TCGA-A2-A04P.0E4B0EA9-14D1-4A82-814D-51CC2B9BA2B5,1,"Specimen #: Race: Physician (s) : SPECIMEN: A: LEFT BREAST LUMPECTOMY B: AXILLARY CONTENTS. C: LEFT SUPRACLAVICULAR LYMPH NODE. FINAL DIAGNOSIS: A. LEFT BREAST, LUMPECTOMY: RESIDUAL INFILTRATING DUCTAL CARCINOMA, POORLY DIFFERENTIATED. RESIDUAL TUMOR SIZE: 2.5 X 2.0 X 1.5 CM. DEEP SURIGIAL MARGIN INVOLVED BY MAIN TUMOR. MEDIAL, SUPERIOR, AND INFERIOR MARGINS FOCALLY INVOLVED BY. DISCONTINUOUS TUMOR FOCI (LOCAL MICROMETASTASES). EXTENSIVE LYMPHATIC INVOLVEMENT. B. LEFT AXILLARY CONTENTS, DISSECTION: METASTATIC CARCINOMA INVOLVING 18 OF 20 EXAMINED LYMPH NODES. EXTENSIVE EXTRANODAL EXTENSION AND NON-NODAL METASTASES. C. LEFT SUPRACLAVICULAR LYMPH NODE, EXCISON: METASTATIC CARCINOMA INVOLVING 1 EXAMINED LYMPH NODE. COMMENT: The findings were discussed with. by phone. The deep surgical margin is involved by residual gross tumor (Block A24) . The medial, superior, and inferior margins are involved K< 0.6mm) by. microscopic foci, separate from the tumor. (Blocks A5, A10, A11, A23, A39) . Of the 18 involved axillary lymph nodes, 1 has a micrometastasis (B3) . An. additional lymph node (B22) has isolated tumor cells. These were. identified by routine light microscopy and hematoxylin-eosin stain. ==. Specimen #: CLINICAL DIAGNOSIS AND HISTORY: A. year old. female with left breast cancer with a positive margin. Palpable lymph node. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. POST-OPERATIVE DIAGNOSIS: Left breast cancer. GROSS DESCRIPTION: A. LEFT BREAST LUMPECTOMY Received fresh, labeled with the patient's. name, and designated ""LEFT BREAST TISSUE, SKIN INTERIOR, ONE STITCH. MEDIAL, TWO STITCHES SUPERIOR"" is a specimen which consists of a piece of. fibrofatty tissue, 6.5 x 6.5 x 5.3cm with an overlying ellipse of skin,. 5.0 x 2.0cm. There is a 3. 5cm scar on the skin surface. Posteriorly a. small patch of skeletal muscle is noted. The specimen is oriented with. sutures (one - medial; two - superior) . Inked as follows: blue -. superior; green - inferior; yellow - medial, red - lateral, and black -. posterior. Sectioning reveals a 3. 0cm biopsy cavity with hemorrhagic. walls and surrounding fat necrosis in the medial half of the specimen. Medially. adjacent to the cavity and involving the deep margin is a firm,. tan tumor measuring 2.5 x 2.0 x 1.5cm. The remaining tissue is fat and. fibrous tissue. Sections of skin, tumor, and grossly normal fibrous. tissue are harvested for the CBCP protocol with matching paraffin sections. as follows: A1, skin, lateral tip; A2, tumor, medial portion; A3, tumor,. lateral aspect; A4, grossly normal fibrous, mid medial - superior, 2.5cm. from the tum; A5-A6, medial margin; A7-A8, adjacent representative. section; A9-A12, biopsy cavity; A13-A17, representative biopsy cavity; A18. A19, biopsy cavity; A20-A22, biopsy cavity; A23-A25, biopsy cavity;. A26-A28, biopsy cavity; A29-A30, biopsy cavity; A31-A33, adjacent left mid. section; A34, representative section; A35, representative section;. A36-A39, lateral margin. 39CF. B. AXILLARY CONTENTS Received fresh, labeled with the patient's name,. anddesignated ""AXILLARY CONTENTS, LEFT TAG AT HIGHEST AXILLARY NODE"" is. a. specimen which consists of a piece of soft yellow tissue, 14.5 x 6.5 x. 3 5cm, containing numerous and large lymph nodes. There are several. cyst-like structures found on serial sectioning ranging in size from 2.5. x 2.0 x 1.0cm to 1.5 x 1.5 x 1. Ocm. The cyst are filled with a red. viscous fluid. Further sectioning reveals a 3.5 x 3.0 x 2.0cm hemorrhagic. cyst-like structure that has a tan-red surface and is poorly defined. Its. mass trails to the lateral edge biopsy tail. Multiple possible lymph nodes. are identified ranging in size from 2.0 x 2.0 x 1.5cm to 0.4 x 0.3 x. 0.2cm. Two grossly positive lymh nodes and one grossly benign lymph node. Specimen # : GROSS DESCRIPTION (continued) : are harvested for the CBCP protocol with matching paraffin sections as. follow: Cassette B1, lymph node with tumor, 2.0 x 2.0 x 1.2cm, lower. axillary tale; B2, lymph node with tumor, 1.6cm, lower axillary tail; B3,. grossly benign lymph node, 0. 7cm, upper axillary tail; B4, grossly. positive single lymph node; B5, single lymph node in multiple pieces;. B6-B7, multiple possible lymph nodes; B8, bisected possible lymph node;. B9, single positive possible lymph node; B10, single possible bisected. lymph node; B11, fragments of possible lymph node; B12, fragments of. possible lymph node; B13-B14, bisected possible lymph node; B15, possible. lymph node; B16, single possible lymph node; B17-B18, skeletal muscle with. cyst wall; B19-B22, representative sections of axillary mass; B23-B25,. area of possible lymph nodes. 25CF. C. LEFT SUPRACLAVICULAR LYMPH NODE Received in formalin, labeled with the. patient's name, and designated ""LEFT SUPRACLAVICULAR LYMPH NODE"" is a. specimen which consists of a 1.3 x 0.7cm lymph node containing a 0. .8cm. tumor. A portion of the lymph node is submitted for the CBCP protocol. 1CF.",BRCA,3,"Based on the report, the residual tumor size is given as 2.5 x 2.0 x 1.5 cm. Using the maximum value of the tumor size, we have a diameter of 2.5 cm. According to the AJCC staging system for breast cancer, T2 corresponds to a tumor size of more than 2 cm and up to 5 cm. Therefore, the T stage for this report is T2.",T2,35.0
766,TCGA-AN-A0FY.6C520037-2A9B-41CB-8362-97FFCA2AA6E2,0,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 3. T Stage: 1c N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube. ICD-0- - 3.,BRCA,0,"Based on the pathology report, the tumor size is not explicitly stated in the T stage description. However, there is a mention of 'T Stage: 1c'. According to the AJCC staging system for breast cancer, T1c refers to a tumor size of 1.1 to 2.0 cm. As per the new rule 23, if the tumor size is given in decimal form, we round to the nearest whole number for T stage determination, unless the size is already a whole number, in which case we use the exact size. Therefore, the T stage is T1.",T1,35.0
1309,TCGA-E9-A22G.E34F4BF0-A0C3-4C72-8E3A-F319D4CDDD5D,1,Laterality:Left upper outer quadrant. Path Report:BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3.5x3x3cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Poorly differentiated. Tumor extent: Not specified. Lymph nodes: 0/6 positive for metastasis (Regional 0/6). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,BRCA,0,"Using the modified and new rules provided, the T stage is determined by the size of the primary tumor. The tumor size is given as 3.5x3x3 cm. According to New Rule 13, we use the maximum value to determine the T stage, which is 3.5 cm. According to New Rule 19, we convert millimeters to centimeters, resulting in a tumor size of 3.5 cm. According to Rule 9, we round down to the nearest whole number for T stage determination, unless the size is already a whole number. In this case, the size is already a whole number, so we use the exact size. Therefore, the T stage is T2.",T2,35.0
594,TCGA-A7-A426.B644AEB6-7D46-4D4D-BA00-D42BCDDCB164,2,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Lymph nodes, right axillary sentinel nodes, resection: 2 of 3 lymph nodes contain metastatic lobular carcinoma (2/3). B. Lymph node, left axillary sentinel node, resection: Single lymph node negative for metastatic carcinoma (0/1). C. Breast, right, simple mastectomy: Invasive lobular carcinoma. The nipple, overlying skin and deep margin of the mastectomy are free. of carcinoma. Fibrocystic changes with ductal hyperplasia and lobular carcinoma in. situ. Post-biopsy changes are present. D. Breast, left, simple mastectomy: Invasive lobular carcinoma. The nipple, overlying skin and deep margin of the mastectomy are free. of carcinoma. Fibrocystic changes with ductal hyperplasia microcalcifications. Post-biopsy changes are present. E. Lymph nodes, right axillary, resection: 11 of 17 additional lymph nodes contain metastatic lobular carcinoma. (11/17). (See template for total lymph node count). A portion of breast tissue is also present which contains a. microscopic focus. of invasive lobular carcinoma. The margins of resection of that tissue portion are. free of carcinoma. Microscopic Description: A.,C. and E.: Right Breast -. Invasive carcinoma: Histologic type: Invasive lobular carcinoma. Histologic grade: 1. Overall grade: Architectural score: 3. Nuclear score: 1. Mitotic score: 1. Greatest dimension (pT) : Tumor measures grossly a span of. approximately 6 cm (pT3). Specimen margins: Deep margin of the mastectomy is negative for. malignancy. Vessel invasion: Negative. Nipple: Negative. Invasion of skin or chest wall: Negative. Description of non-tumorous breast: Fibrocystic changes with ductal. hyperplasia and lobular carcinoma in situ. Lymph nodes: Number of positive nodes of total: 13 of 20 (including 2 of 3. positive sentinel lymph nodes). Size of largest metastasis: 1.1 cm. Extracapsular extension (present/absent) : Present. pN: pN3a. Distant metastasis (pM) : pMx. Prognostic markers: See prior core biopsy. The invasive. tumor was estrogen receptor positive, progesterone receptor positive. and showed normal expression for HER-2/neu. B. and D.: Left breast-. Invasive carcinoma: Histologic type: Invasive lobular carcinoma. Histologic grade: 1. Overall grade: Architectural score: 3. Nuclear score: 1. Mitotic score: 1. Greatest dimension: Residual tumor measures maximally 5 x 5 x 3 mm. as measured from the glass slide. Specimen margins: Deep margin mastectomy is negative for. malignancy. Vessel invasion: Negative. Nipple: Negative. Invasion of skin or chest wall: Negative. Description of non-tumorous breast: Fibrocystic changes with ductal. hyperplasia and microcalcifications. Lymph nodes: Number of positive nodes of total: 0 of 1 (sentinel lymph node). pN: pNO. Distant metastasis (pM) : pMx. Prognostic markers: See prior core biopsy (. The invasive. carcinoma was estrogen receptor positive, progesterone receptor. positive showed normal expression for HER-2/neu. Specimen. A. Right axillary sentinel node. B. Left axillary sentinel node. C. Right breast. D. Left breast. E. Right axillary contents. Clinical Information. year-old white. Bilateral invasive lobular carcinoma. Intraoperative Consultation. FSA) Right axillary sentinel nodes - Three lymph nodes present. Two of. three nodes positive for metastatic lobular carcinoma. FSB) Left axillarv sentinel node - Negative for metastatic carcinoma. Gross Description. A. Submitted fresh for frozen section labeled ""right axillary sentinel. node' or 3 nodules of partially cauterized tan yellow soft tissue. Bisecting the nodules reveal them to range from 0.7-1.8 cm in greatest. dimension. They're grossly involved by tumor. Half of each is. submitted for frozen section the remainder is kept for permanents. B. Submitted fresh for frozen section labeled ""left axillary sentinel. node is enlarged 3 x 2 x 1.5 cm mass of fatty tissue. Bisecting the. mass shows it to be possibly a large lymph node replaced with fat. Lymph node is bisected and submitted entirely for frozen section in 2. blndve. The remainder of the fat is submitted for permanent sections. C. Received fresh and subsequently fixed in formalin labeled ""right. breast ""is a 22.0 x 20.0 x 5.8 cm mastectomy which is partially covered. with a 13.0 x 7.5 cm pink-tan wrinkled skin ellipse having a 2.0 cm. everted nipple. The specimen is inked black the deep margin and. sectioned to show predominantly fibrous cut surface which is diffusely. nodular. Specimen shows an ill circumscribed fibrous mass which is. approximately 6 cm in greatest dimension. The shows a 0.8 cm previous. biopsy site, partially filled with white rice-like pellets. This comes. within 0.5 cm of the deep margin is located toward the lateral aspect. of the specimen. The specimen is diffusely nodular firm and rubbery no. additional biopsy sites are grossly identified. No lymph nodes are. grossly identified in the apex of the specimen. The specimen is. collected at. received in pathology at. and fixed in. formalin at. Representative sections of the specimen are submitted. as follows: 1 - 2 - entire nipple with representative skin, 3 - 6 -. representative sections of tumor, biopsy site and deep margin, 7 -. representative upper outer quadrant, 8 - representative lower outer. quadrant, 9 - representative lower inner quadrant, 10 - representative. upper inner quadrant. D. Received fresh and subsequently fixed in formalin labeled ""left. breast ""is a 23.0 x 20.0 x 6.5 cm mastectomy which is partially covered. with a 13 x 8 cm pink-tan wrinkled skin ellipse having a 2.0 cm everted. nipple. The specimen is inked at the deep margin to show a. predominantly white yellow nodular fibrous cut surface. There is a 1.5. x 1.2 x 0.5 cm hemorrhagic focus which is grossly consistent with a. previous biopsy. Located in the lower outer quadrant, coming within 1.2. cm of the deep margin. No other discrete biopsy sites are grossly. identified. The fibrous tissue is remarkably firm and nodular. diffusely. No lymph nodes gross identified in the apex of the specimen. The specimen is collected at. received in pathology at. and fixed in formalin at. Representative sections of the specimen. are submitted as follows: 1 - 2 - entire nipple with skin, 4 - 6. entire biopsy site representative deep margin and surrounding tissue,. 7. - representative inner upper quadrant, 8 - representative lower inner. quadrant, 9 - representative lower outer quadrant, 10 - representative. upper outer quadrant. RS 10. E. Received fresh and subsequently fixed in formalin labeled ""right. axillary content ""is a 9.5 x 8.5 x 4.5 cm aggregate of friable fatty. tissue. Less than has a suture is undesignated. This may designate the. highest node. Due to the fragment in nature, orientation of the. remainder of the tissue is indeterminate. Also received is a 6.5 cm. additional portion of possible breast tissue was which is fibrous and. nodular. Representative sections which include all the lymph nodes are. submitted as follows: 1 - representative section of breast tissue, 2. highest node, 3 - 3 possible lymph nodes, 4 - 4 possible lymph nodes, 5. - 2 possible lymph nodes, 6 - 5 possible lymph nodes, 7 - 2 possible. lymph node.",BRCA,3,"The maximum size of the tumor in the right breast is approximately 6 cm, which falls under the T3 category (T3: tumor size > 5 cm) according to the AJCC staging system for breast cancer. This is confirmed by the report stating 'Greatest dimension (pT) : Tumor measures grossly a span of approximately 6 cm (pT3)'",T3,35.0
1347,TCGA-EW-A1P1.AE0C51EF-017E-4F53-968C-804110F9A7E6,1,"F. Pathologic Interpretation: A. Sentinel node #1 (. right FS: - Metastatic carcinoma into one lymph node (1/1). B. Sentinel node #2 I. ) FS: - Metastatic carcinoma into theree out of four lymph nodes (3/4). C. Sentinel node #3 (. FS: - One benign lymph node (0/1). D. Right breast lumpectomy, long - lateral, short - superior: - In situ and invasive carcinoma. - The entire tumor mass measures 2.3 cm in greatest dimensions. - The invasive component represents the majority of the tumor mass and is of Nottingham grade of 3 +3 +3=9/9. - Foci of vascular invasion are noted. - The in-situ component is of ductal type, high nuclear grade with central necrosis and calcifications (comedocarcindma). - All margins of resection appear free of invasive and intraductal carcinoma. - The closest margins of resection are the medial and anterior at 4 mm from the tumor. - The non-neoplastic breast tissue shows fibroproliferative disease, radial scar, atypical ductal hyperplasia and changes consistent. with previous biopsy site. D. Right axillary content: - Metastatic carcinoma into six out of twenty-thre lymph nodes (6/23). E. Level 3 (right) permanent: - Metastatic carcinoma into one out of three lymph nodes (1/3). Tumor Summary: Specimen Type Lumpectomy. Lymph Node Sampling: Axillary dissection. Specimen Size (for excisions less than total mastectomy): 6 cm in greatest dimensions. Laterality: Right. Tumor Site: Not specified. Size of Invasive Component: 2.3 cm in greatest dimensions. Histologic Type: Ductal. Histologic Grade (any grading system may be used; mitotic count is also required independent of the grading system): 3 +3 +3=9/9. Total Nottingham Score:9/9. Margins: Free. Pathologic Staging (pTNM). pT 2, N3, MX. SURGICAL PATHOL Report. NOTE: IDS-ER. Some PgR immunokissochemical 636-PR, A4RS-HER2. antibodies H-II=EGFR. are analyte All immunohistochemical specific reagents (ASRs) stains validated are used by with our formalin laborasory. or molecular These ASRs fixed. are paraffis clinically embedded useful indicators tissue. Derection that do not is by require Envision FDA Method. approval. the These results ciones are read are used: by a. pathologist as positive or negative. As the attending pathologist, / attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). Intraoperative Consultation. A. Sentinel node #1 (. right FS: Metastatic adenocarcinoma to one lymph node (1/1). B. Sentinel node #2 (. ) FS: Metastatic adenocarcinoma to three of four lymph nodes (3/4). C. Sentinel node #3 (. 1 FS: One lymph node, no tumor seen (0/1). 1 MD. Clinical History: None provided. Operation Performed. Right breast lumpectomy with sentinei node blopsy, possible axiliary node dissection; possible left breast reduction. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Sentinel node #1. 1) right FS. B: Sentinel node #2 (. ) FS. C: Sentinel node #3 (. FS. D: Right breast lumpectomy, long - lateral, short - superior. E: Right axillary content. F: Level 3 (right) permanent. Gross Description: A. Received fresh is an irregular fragment of fibroadipose tissue, measuring 2.3 x 1.2 x 0.7 cm. One lymph node is ill-. defined. The lymph node is submitted in toto in one cassette for frozen section. B. Received fresh is an irregular fragment of fibroadipose tissue, measuring 3.2 x 1.7 x 0.9 cm. Four lymph nodes are. grossly identified. The lymph nodes are submitted in toto as follows: 1. One lymph node for frozen. 2. Lymph node for frozen section. C. Received fresh is an irregular fragment of fibroadipose tissue, measuring 1.9 x 1.1 x 0.7 cm. One lymph node is grossly. identified. The lymph node is submitted in toto in one cassette for frozen section. D. Received in formalin is a lumpectomy specimen measuring 6 cm from medial to lateral, 5.4 cm from superior to inferior. and 4.4 cm from anterior to posterior. The specimen has an ellipse of skin in the anterior surface measuring 3.8 x 0.9 cm. The specimen is labelled as follows: long stitch lateral; short stitch superior. The margin is inked as follows: Anterior. yellow, posterior black, superior blue, inferior green, medial red, lateral orange. Upon sectioning ill-defined fiem white and. SURGICAL PATHOL Report. tan mass is identified measuring 2.3 x 2 x 1.5 cm. The mass is 1 cm from the lateral margin up to 1.6 cm from. the. superior margin, 0.5 cm from the inferior margin, 0.5 cm from the posterior margin, 0.4 cm from the medial. margin and 0.4. cm from the anterior margin from the skin. Other areas of the mastectomy specimen show unremarkable ibroadipose. tissue. Representative sections are submitted as follows: 1. Lateral margin. 2. Superior margin. 3. Anterior margin and skin in relation with the tumor. 4. Medial margin in relation with the tumor. 5. Posterior margin in relation with the tumor. 6. Inferior margin in relation with the tumor. 7-8. Other areas of the mass. E. Received in formalin are multiple irregular fragments of fibroadipose tissue measuring 9 x 7.5 x 2.2 cm in aggregate. Five-. possible lymph nodes are identified. The lymph nodes are submitted in toto-. as follows: 1-2. One lymph node bisected per cassette. 3-4. Lymph node bisected per cassette. 5-6. Three lymph nodes bisected per c assette. 7-8. Four lymph nodes per cassette. F. Received in formalin are four irregular fragments of soft tan brown and yellow tissue measuring 1 x 0.5 x 0.4 cm in. aggregate. Submitted in toto in one cassette.",BRCA,3,"Based on the report, the size of the primary tumor is 2.3 cm, which is greater than 2 cm but less than or equal to 5 cm. According to the AJCC staging system for breast cancer and the rules provided, this corresponds to a T2 stage. The maximum size of the tumor is used to determine the T stage, even if it is given in centimeters or millimeters. If the tumor size is given in decimal form, it should be rounded down to the nearest whole number for T stage determination, unless the size is already a whole number. However, in this case, the tumor size is closer to the next whole number, so it is rounded up to the next whole number for T stage determination.",T2,35.0
1474,TCGA-OL-A5RV.0CA74400-1596-4C14-AF02-4F5169D61942,1,"FINAL PATHOLOGIC DIAGNOSIS. A. Right breast; modified radical mastectomy: - Invasive ductal (tubulo-lobular) carcinoma, SBR grade II, focally associated. with microcalcification, see parameters. - Ductal carcinoma in situ, low and intermediate nuclear grade, cribriform,. micropapillary and solid type, associated with necrosis and microcalcifications. - Ductal carcinoma in situ is < 2 mm from posterior margin. - Biopsy site changes. - Columnar cell changes. - Two small fibroadenomas. - Twenty of twenty-nine lymph nodes, positive for metastatic carcinoma (20/29). - Extranodal extension present. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Gross measurement: 4.5 cm (main lesion) and 1 cm (satellite in upper. outer quadrant). B. Composite histologic (modified SBR) grade: II. - Architecture: 2. - Nuclear grade: 2. - Mitotic count: 2. C. Associated intraductal carcinoma in situ (DCIS): - Within main mass (forming 40% of tumor volume). 2. Intraductal carcinoma: A. Gross measurement: 4.5 cm, admixed with invasive carcinoma. B. Type: Cribriform / Solid / Micropapillary. C. Nuclear grade: Low / Intermediate. D. Associated features: Necrosis / Microcalcifications / Cancerization of. lobules. 3. Excisional biopsy margins: - DCIS < 2 mm from posterior (closest) margin. - Invasive carcinoma > 4 mm from posterior (closest) margin. 4. Blood vessel and lymphatic invasion: Present. - Present in breast parenchyma. - Present in axillary tissue. 5. Nipple: DCIS extending into lactiferous duct. 6. Skin: uninvolved. 7. Skeletal muscle: absent. 8. Axillary lymph nodes: Positive (20/29). - Size of largest metastatic deposit: 12 mm. - Extranodal extension: present (7 mm; largest focus). - Tumor deposits in axillary tissue (up to 5 mm). 9. Special studies (see. - ER: Strong expression in >90 % of invasive tumor nuclei. - PR: Strong expression in >90 % of invasive tumor nuclei. - Her2/neu antigen (FISH): Non-amplified (ratio:1.00). 10. pTNM (AJCC, 7th edition, 2010): pT2(m), N3, MX. Clinical History: The patient is a year old female, with a right breast mass (MRI: 1.3 x 0.9 x. 0.8 cm) and biopsy diagnosis of invasive ductal carcinoma undergoing right. modified radical mastectomy. Specimens Received: A: Right breast; mastectomy. Gross Description: A. The specimen is received in a single container labeled with the patient's. name, medical record number, and additionally identified as, 'right breast'. Received fresh and placed in formalin is a 653 gm modified radical mastectomy. specimen. The specimen is oriented with a short suture designating the superior. margin and a long suture designating lateral margin. The specimen measures 18.5. cm from superior to inferior, 22.5 cm from medial to lateral, and 3.9 cm from. anterior to posterior. There is an attached 9.6 X 7.9 X 1.5 cm axillary tail. On the anterior surface is a 18.0 X 8.0 cm tannish brown ellipse of skin with a. 4.0 X 4.5 cm areola and a 1.5 X 1.4 X 0.5 cm raised nipple. The nipple-areolar. complex reveals no evidence of ulceration or retraction. The specimen is inked as follows: superior edge - blue;. inferior edge - green;. posterior - black. The specimen is serially sectioned from medial to lateral into 11 slices to. reveal a rubbery, irregularly shaped, white-tan, 4.5 X 3.5 x 2.5 cm mass with. a. granular cut surface in slices 3 through 5. A clip is identified in slice 3. The. mass is 0.5 cm from the posterior margin and widely free (>2 cm) from the. anterior superior and anterior inferiormargins. The remainder of the specimen. consists of approximately 30% dense gray-white fibrous breast parenchyma and 70%. lobulated yellow adipose tissue. No additional masses or nodules are grossly. identified. Sectioning through the axillary tail reveals multiple tan-brown,. rubbery lymph nodes ranging from 0.3-2.5 cm in greatest dimension. Block summary: A1: mass surrounding clip and closest approach to posterior margin and. surrounding clip, slice 3. A2: mass, slice 4. A3: mass, slice 4. A4: mass, slice 5. A5: mass and biopsy site, slice 5. A6: upper outer quadrant, slice 7. A7: lower outer quadrant, slice 6. A8: upper inter quadrant, slice 2. A9: lower-inner quadrant, slice 5. A10: skin adjacent to mass. A11: nipple. A12: tissue directly beneath nipple. A13: one lymph node, sectioned. A14: one lymph node, bisected. A15: one lymph node, sectioned. A16: one lymph node, bisected. A17: one lymph node, bisected. A18: one lymph node, bisected. A19: two lymph nodes. A20: two lymph nodes. A21: three lymph nodes. A22: three lymph nodes. A23: one lymph node, sectioned. A24: three lymph nodes. A25: four lymph nodes. A26: three lymph nodes.",BRCA,3,"Based on the report, the size of the primary tumor is 4.5 cm, which is larger than 2 cm but less than or equal to 5 cm. This falls under the T2 category according to the AJCC staging system for breast cancer. The maximum size of the tumor is used to determine the T stage, regardless of whether it is given in centimeters or millimeters. If the tumor size is given in decimal form, it should be rounded to the nearest whole number for T stage determination, unless the size is already a whole number.",T2,36.0
750,TCGA-AN-A0AL.20F4DBD9-02FA-4FFD-AEF5-234910D31263,3,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. 1 Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 4 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,"The report does not provide a specific size for the primary tumor, but it does mention that it is an infiltrative ductal carcinoma in the left breast. Based on the rules provided, we can assume that the size of the tumor was not provided in whole centimeters, otherwise it would have been specified. Therefore, we must interpret the rules to handle decimal or millimeter values.\n\nModified Rule 8: The maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters or millimeters, converted to centimeters.\nNew Rule 20: If the tumor size is given in millimeters, convert it to centimeters for T stage determination (T1:  2 cm, T2: > 2 cm but  5 cm, T3: > 5 cm). In this case, we don't have an exact size, so we cannot convert it to centimeters. However, since the report does not mention a size of 2 cm or less, we can assume it is larger than 2 cm.\n\nGiven that the tumor size is larger than 2 cm but we don't have an exact size, we can predict that the T stage is T2.",T2,37.0
861,TCGA-AR-A1AR.747FB91B-F523-4FA0-91DD-6014EF55643D,0,"Final Diagnosis. Breast, left, lumpectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III), [tubules. 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a 1.8 x 1.5 x 1.5 cm mass [AJCC. pT1c]. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Changes consistent with prior core biopsy site. All surgical. resection margins, after re-excision of the superior margin, are negative for tumor (minimum. tumor free margin, 0.5 cm, deep margin). Lymph nodes, left axilla, axillary dissection: Multiple 5 (of 14) left axillary lymph nodes are. positive for metastatic carcinoma with extranodal extension (AJCC pN2).",BRCA,2,"The report states that the size of the primary tumor is 1.8 x 1.5 x 1.5 cm. According to New Rule 13, we use the maximum value to determine the T stage, which is 1.8 cm. New Rule 19 states that if the tumor size is given in millimeters, we convert it to centimeters for T stage determination. However, in this case, the size is already given in centimeters. New Rule 24 states that if the tumor size is given in decimal form, we round to the nearest whole number for T stage determination, unless the size is already a whole number, in which case we use the exact size. In this case, the size is already a whole number, so we use the exact size of 1.8 cm. According to the AJCC staging system for breast cancer (Rule 6), T1 is defined as a tumor 2 cm or less in greatest dimension. Therefore, the T stage for this report is T1.",T1,37.0
882,TCGA-AR-A24W.0F2464F7-4108-4700-B2EC-17BC6C432D42,1,"Breast, right, total mastectomy: Infiltrating ductal carcinoma, Nottingham grade II (of III), [tubules 3/3, nuclei 2/3, mitoses 1/3;. Nottingham score 6/9], forming a 2.1 x 1.4 x 1.1 cm mass located in the central breast (AJCC pT2). Ductal carcinoma. in. situ,. intermediate nuclear grade, comprising approximately 5-25% of tumor volume. Angiolymphatic invasion is present. The non-. neoplastic breast parenchyma shows proliferative fibrocystic changes. Calcifications present in malignant ducts. Biopsy site. changes present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All surgical resection margins,. including deep margin, are negative for tumor (minimum tumor free margin, 2.1 cm, deep margin). Lymph nodes, right axillary sentinel Nos. 1A, 1B, 1C and 2, sentinel biopsy: Three (of 4) right axillary sentinel lymph nodes are. positive for metastatic carcinoma (>2.0 mm) [AJCC pN1(5n) ]. Extranodal extension is not present. Blue dye is identified in. lymph nodes Nos. 1A and 1B. Lymph node No. 1C does not contain blue dye. Lymph nodes, right axillary, dissection: Multiple (18) right axillary lymph nodes are negative for tumor. Breast, left, total mastectomy: Ductal carcinoma in situ, micropapillary and cribriform types, low nuclear grade without. intraluminal necrosis, involving an area over 5.7 x 2.3 x 1.4 cm [AJCC pTis]. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Calcifications are present in malignant ducts. Biopsy site changes are present. Nipple and. skin are without diagnostic abnormality. All surgical resection margins are negative for tumor (minimum tumor free margin, 1.5. cm, deep margin).",BRCA,1,"Based on the report, the size of the primary tumor in the right breast is given as 2.1 x 1.4 x 1.1 cm. According to the AJCC staging system for breast cancer and the rules provided, we need to use the maximum size of the tumor to determine the T stage. In this case, the maximum size is 2.1 cm. Therefore, the T stage is T2.",T2,38.0
623,TCGA-A8-A07C.DC5B662B-1ADD-4D6E-A6E3-3EF8B922BC71,1,"Diagnosis: 1. and 2. Bifocal poorly differentiated invasive ductal carcinoma (tumor diameters: 2.8 and. 0.8 cm). Concluding tumor classification: NOS, G III, pT2(mult)NOLOVORO.",BRCA,0,"Based on the report, there are two tumor foci with diameters of 2.8 cm and 0.8 cm. According to New Rule 13, we use the maximum value of 2.8 cm to determine the T stage. New Rule 19 states that if the tumor size is given in millimeters, it should be converted to centimeters. However, in this case, the sizes are already provided in centimeters. New Rule 24 states that if the tumor size is given in decimal form, it should be rounded to the nearest whole number for T stage determination. Since the maximum size is already a whole number, we use the exact size of 2.8 cm. According to the AJCC staging system for breast cancer, T1 is  2 cm, T2 is > 2 cm but  5 cm, T3 is > 5 cm. Therefore, the T stage is T2.",T2,39.0
1101,TCGA-BH-A6R9.1DB8FAFB-FC4A-4401-8316-30FB5352335D,1,"FINAL DIAGNOSIS: BREAST, LEFT, TOTAL MASTECTOMY (120.1 GRAMS) -. A. METAPLASTIC CARCINOMA OF THE BREAST, SPINDLE CELL TYPE, NOTTINGHAM GRADE II (TUBULE. FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 1; TOTAL SCORE 7/9). B. THE INVASIVE TUMOR MEASURES 3.8 CM IN GREATEST DIMENSION. C. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. D. INKED MARGINS ARE NEGATIVE FOR CARCINOMA; HOWEVER, A FOCUS OF INVASIVE CARCINOMA IS LESS. THAN 1.0 MM (LESS THAN 0.1 CM) FROM THE ANTERIOR INKED MARGIN. E. THE INVASIVE CARCINOMA IS LOCATED IN THE CENTRAL AREA. F. THE NIPPLE DERMIS AND ADJACENT SKIN DERMIS, BUT NOT THE EPIDERMIS, ARE INVOLVED BY INVASIVE. CARCINOMA. G. NIPPLE DUCTS WITH SQUAMOUS METAPLASIA. H. PREVIOUS BIOPSY SITE CHANGES. I. THE INVASIVE TUMOR CELLS ARE NEGATIVE FOR ESTROGEN RECEPTOR, WEAKLY POSITIVE FOR. PROGESTERONE RECEPTOR, AND NEGATIVE FOR HER-2, AS PER PREVIOUS PATHOLOGY REPORT. (see comment). J. NON-NEOPLASTIC BREAST WITH RADIAL SCARS. COMMENT: Due to the weakly positive PR result on the core biopsy based on stains performed at. hormone. receptor immunohistochemistry will be repeated and an addendum will follow. Addendum. BREAST TUMOR IMMUNOHISTOLOGY RESULTS. HORMONE RECEPTOR IMMUNOHISTOCHEMISTRY. H SCORE. RAW IMMUNOSTAINING SEMIQUANTITATION. ER: Weakly positive. 10. (0: 91%; 1+: 8%; 2+: 1%; 3+: 0%). PR: Negative. o. (0: 100%; 1+: 0%; 2+: 08; 3+:0%). ESTROGEN/PROGESTERONE RECEPTORS (ER/PR) TEST DETAILS: Using formalin fixed tissues (8-96 hours) and appropriate. positive and negative internal/external controls; the test for the presence of hormone receptor protein is performed by the. immunoperoxidase method according to the ASCO-CAP Guidelines. A positive Estrogen or Progesterane receptor tumor shows. nuclear immunostaining in greater than or equal to 1% of the tumor cells (i.e. and H-score of 1 or higher). The ER and PR. Histologic Score (H-Score, or HS) is calculated as the sum of intensity of staining times the proportion of cells staining and has a. dynamic range of 0 to 300. The semiquantitation immunostaining raw data used to calculate the H-score is also shown above in. the report. Generally, the H-score correlates to percentage of positive cells. According to. the correlation of mean H-score versus percent cells staining for ER is as follows: H-score of 251 (>75% cells staining); H-. score of 130 (51-75% cells staining); H-score of 42 (10-50% cells staining); H-score of 4 (<10% cells staining). Estrogen receptor antibody SP1, an IVD, is performed using the. Progesterone receptor antibody 1E2, an IVD, is performed using the. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Simple mastectomy. Central subareolar. SIZE OF TUMOR: Maximum dimension invasive component: 38 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Metaplastic carcinoma. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMALLYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: LYMPH NODES EXAMINED: 0. METHOD(S) OF LYMPH NODE EXAMINATION: Other: None. SKIN INVOLVED (ULCERATION): T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pNX. M STAGE: Not applicable. ESTROGEN RECEPTORS: negative. PROGESTERONE RECEPTORS: positive, H-score: 60. HER2/NEU: 0. MICROSCOPIC: Block 1B: Antibody/Antigen. Vimentin. Positive. S-100. Rare weakly positive cells. CK5. Positive. AE1/AE3. Weakly positive. CK17. Positive. P63. Positive. CK14. Positive. Block 1C: Antibody/Antigen. P63. Highlights tumor cells and myoepithelial cells. Smooth muscle myosin heavy chain Highlights myoepithelial cells. Utilizing formalin-fixed (8-96 hour range), paraffin embedded tissue, immunohistology is. performed with the following selected antibodies and designated antibody clone (s), directed. against the following antigenic target (s), with adequate positive and negative internal and. external controls. Antibodies are optimized appropriate for fixation times. ANTIBODY. CLONE. TARGET ANTIGEN. VENDOR. Vimentin. V9. Mesenchymal cells. S-100. Polyclonal Rabbit. Melanoma screen. CK 5. XM26. High molec wt keratin. AE1/AE3. AE1/AE3. carcinomas. CK 17. E3. High molec wt keratin. p63. 4A4. Myoepithelial cells. CK 14. LL002. High molec wt keratin. Myosin. SMMS-1. Myoepithelial cells.",BRCA,0,"The maximum size of the tumor is given as 3.8 cm, which falls within the T2 category (> 2 cm but <= 5 cm) according to the AJCC staging system for breast cancer.",T2,40.0
830,TCGA-AQ-A1H2.1B5FA34B-E3B4-4D4B-AF0A-1C90016CC532,1,"SURGICAL PATHOLOGY REVISED REPORT. Diagnosis: Breast, right, mastectomy. Tumor type: invasive ductal carcinoma with extensive fibrosis (see comment). Nottingham combined histologic grade: 2. Tubule formation score: 2. Nuclear Pleomorphism Score: 3. Mitotic count score: 2. Focality of tumor: single focus. Tumor size (greatest dimension): 3.5 cm (see comment). Lymphovascular invasion: present (A8). In Situ Component: present. In Situ Component type/Architecture pattern: solid and cribriform. In Situ Component nuclear grade: 3. In Situ Component necrosis: none identified. In Situ Component extent/size: DCIS is present with tumor and focally away from tumor. Size is approximately 6 mm. Extensive intraductal component: Absent. The DCIS comprises approximately 2% of total tumor. Nipple involvement: none identified. Skin involvement: none identified. Margin status: nvasive component: >5 mm. in Situ component: >5 mm. Axillary lymph nodes: Total number with metastasis: 7. Total number examined: 10 (1 from part A, 9 from part B below). Size of largest metastasis: 1.3 cm (A14, A15). Extracapsular extension: present and extends into fibrous septae of surrounding fibroadipose tissue. Microcalcifications: associated with invasive carcinoma, ductal carcinoma in situ, and sclerosing adenosis. Other findings: - Fibrocystic changes with ductal epithelial hyperplasia. - Sclerosing adenosis. - Benign skeletal muscle. AJCC PATHOLOGIC TNM STAGE: pT2 pN2a. Note: This pathologic stage assessment is based on information available at the time of this report, and is subject to. change pending clinical review and additional information. B: Soft tissue, axillary contents, removal. - Six of nine lymph nodes with metastatic carcinoma (6/9). - Largest metastatic focus 1.3 cm. - Extracapsular extension is present. Comment: Although two foci of carcinoma were previously identified radiologically (2.0 cm and 1.5 cm) and sampled by core. biopsy, only one large focus of tumor is identified grossly in this mastectomy specimen. Gross examination has. been repeated several times and additional sections submitted with no second tumor nodule identified. A second firm. nodule was identified 3 cm away from the first, but microscopically it appeared to be sclerosing adenosis and this was. confirmed with positive immunostaining with p63 and smooth muscle myosin heavy chain (A17). The current single. focus of tumor is extremely fibrotic and measures 3.5 cm (which is equal to the two previously identified foci combined). Of the two foci initially seen, one was described as superficial and the other deep, but they were very close to each. other (10:00 and 9:00 to 10:00). The current large focus is located at 9:00 to 10:00 and extends from superficial to. deep. Histologically, the tumor demonstrates morphologic features consistent with both of the previous core biopsies. (predominant morphology is that of the ""deep"" core with some areas resembling the ""superficial"" core). The. different-appearing areas merge into each other and are part of the same nodule of tumor. Immunostain for e-cadherin was performed on a couple of areas that have lobular features (similar to the superficial. core biopsy); it is positive, confirming the ductal phenotype of the tumor (A8, B3). Immunostain for AE1/AE3 was. performed on block B8 and confirms no metastatic tumor in that lymph node. Immunohistochemical stains for ER, PR and HER2/Neu were performed with the following results. These stains were. performed on tumor that resembles the deep core biopsy, and results are similar to those from the deep core biopsy. (except HER2 is 1+ instead of 0, but still considered negative). Material from an additional block (with areas resembling. the superficial core) has been submitted to see if it stains similarly to the superficial core; the original superficial. core showed HER2 at 2+ and amplification by FISH. These results will be reported in an addendum. Estrogen receptor (: , clone SP1): Interpretation: Positive. Computer-assisted quantitative score: 100%. Progesterone receptor (. clone 1E2): Interpretation: Positive. Computer-assisted quantitative score: 12%. HER2/neu (Ventana, clone 4B5, FDA-approved): Interpretation: Negative (not overexpressed). Computer-assisted quantitative score: 1+. Site: right breast. Performed on block: A7. Fixation: 10% neutral buffered formalin. Fixation time: 6-48 hours. Reference range: Estrogen receptor and progesterone receptor: <1%=NEGATIVE, 1-10% WEAK POSITIVE, >10% POSITIVE. HER2/neu: 0,1=NEGATIVE FOR OVEREXPRESSION, 2=INDETERMINATE, 3=POSITIVE FOR OVEREXPRESSION. Comment: The quantitative scores reported above were obtained using the FDA-approved. The control slides for this case show appropriate staining. Some of the immunohistochemical reagents used in this case may be classified as analyte specific reagents (ASR) or. research use only (RUO) reagents. These were developed and have performance characteristics determined by the. These reagents have not been cleared or. approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not. necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This. laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform. high complexity clinical laboratory testing. Intraoperative Consult Diagnosis: Clinical History: with right breast cancer. Gross Description: Received are two appropriately labeled containers. Container A: Specimen fixation: formalin. Time in fixative: 9 hours. Type of mastectomy: modified radical. Weight of specimen: 970 grams. Size of specimen: 25 cm medial to lateral, 24 cm superior to inferior, and 3.5 cm anterior to posterior. Orientation of specimen: Inking: lateral=yellow, anterior=blue, posterior=black. Skin ellipse dimensions: 21.5 x 16.3 cm. Nipple/areola: 0.6 cm/3.4 cm, respectively. Axillary tail: absent. Biopsy site: not identified. Discrete Mass(es): present; one large firm mass is identified. The cut surface is tan with small areas of hemorrhage and. fat necrosis. The mass is well demarcated and lobular in shape. Number of discrete masses: one. Size of mass (es)/biopsy site: 3.5 x 2.9 x 1.8 cm. Location of mass(es): upper outer quadrant. Distance of mass/biopsy site from surgical margin: 2.4 cm from the black inked posterior margin and 4.5 cm from the. closest blue inked anterior margin. Gross involvement of skin or fascia/muscle by tumor: absent. Description of remaining breast: The remainder of the breast tissue is predominantly yellow lobulated fat which is. interspersed with delicate strands of white fibroconnective tissue. Other remarkable features: There is an arterial graft in the subareolar breast tissue that runs from the superior to. inferior aspects of the specimen. This graft is 11.7 cm long and 1.4 cm in diameter. Tissue submitted for special investigations: tumor and normal tissue are submitted for. Addendum: On further gross examination, a second mass is identified. The second mass is approximately 3 cm medial to. the first mass. The second mass is a well circumscribed, white firm nodule measuring 1.5 x 1.0 x 1.0 cm. This mass is 7.5. cm from the nearest blue inked anterior margin, 3.0 cm from the nearest black inked deep margin, and 3.0 cm from the. skin. There is no evidence of hemorrhage or necrosis associated with this mass. (Histologically, this mass is sclerosing. adenosis.). Block Summary: Inking: lateral=yellow, anterior=blue, posterior=black). A1 - perpendicular sections of nipple. A2 - areola, en face. A3 - representative section of mass with closest black inked posterior margin. A4 - representative section of breast tissue from closest anterior margin. A5-A9 - representative sections of mass. A10 - representative section of breast tissue from upper inner quadrant. A11 - representative section of breast tissue from lower inner quadrant. A12 - representative section of breast tissue from lower outer quadrant. A13 - representative section of breast tissue from upper outer quadrant. A14,A15 - intraparenchymal lymph node, serially sectioned. A16-A18- second mass, submitted entirely from lateral to medial. Container B holds a 9.5 x 5.4 x 3.5 cm mass of yellow/tan lobulated fat with associated connective tissue. This specimen. is unoriented. The specimen is dissected to identified lymph node candidates and multiple lymph node candidates. are identified. The largest candidate measures 3.1 x 1.9 x 1.0 cm. Block summary: 1,B2 - largest lymph node candidates, serially sectioned. B3 - one lymph node candidate, serially sectioned. B4 - one lymph node candidate, serially sectioned. B5 - one lymph node candidate, serially sectioned. B6 - three lymph node candidates. B7 - one lymph node candidate, serially sectioned. B8 - one lymph node candidate, serially sectioned. B9 - two lymph node candidates. B10 - three lymph node candidates. B11 - one lymph node candidate, bisected. B12 - one lymph node candidate. Grossing Pathologist: Light Microscopy: Light microscopic examination is performed by Dr. For cases in which immunostains are performed, the following applies: Appropriate internal and/or external positive and. negative controls have been evaluated. Some of the immunohistochemical reagents used in this case may be classified. as analyte specific reagents (ASR). These were developed and have performance characteristics determined by the. Anatomic Pathology Department,. These reagents have not been cleared or. oproved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not. necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This. laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform. high complexity clinical laboratory testing. Resident Physician: Attending Pathologist: I have personally conducted the evaluation of the above specimens and have. rendered the above diagnosis(es). Procedures/Addenda: Addendum. Addendum. The following addendum is issued to report the results of estrogen receptor, progesterone receptor, and HER2/neu. immunohistochemical studies. Estrogen receptor (1. 1, clone SP1): Interpretation: Positive. Computer-assisted quantitative score: 94%. Progesterone receptor t. clone 1E2): Interpretation: Negative. Computer-assisted quantitative score: 0%. HER2/neu (. clone 4B5, FDA-approved): Interpretation: Positive (overexpressed). Computer-assisted quantitative score: 3+ (see note). NOTE: This block (A5) includes areas that show morphologies similar to both the superficial and deep cores. ER and PR are. relatively homogeneous throughout the tumor, regardless of morphology. Immunostain for HER2 is heterogeneous, but. staining does not correlate with any particular morphology. There is enough strong complete staining to interpret the. HER2 as 3+ (overexpressed); however, areas in this block range from no staining to strong and complete staining. Site: right breast. Performed on block: A5. Fixation: 10% neutral buffered formalin. Fixation time: 6-48 hours. Reference range: Estrogen receptor and progesterone receptor: <1%=NEGATIVE, 1-10% WEAK POSITIVE, >10% POSITIVE. HER2/neu: 0,1=NEGATIVE FOR OVEREXPRESSION, 2=INDETERMINATE, 3=POSITIVE FOR OVEREXPRESSION. Comment: The quantitative scores reported above were obtained using the FDA-approved. The control slides for this case show appropriate staining. Jome of the immunohistochemical reagents used in this case may be classified as analyte specific reagents (ASR) or. research use only (RUO) reagents. These were developed and have performance characteristics determined by the. These reagents have not. been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance. or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational. or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as. qualified to perform high complexity clinical laboratory testing.",BRCA,2,"Based on the report, the size of the tumor is given as 3.5 cm. According to the AJCC staging system for breast cancer, a T stage of T2 is assigned to tumors with a greatest dimension between 2.1 and 5 cm. Therefore, the T stage for this report is T2.",T2,41.0
479,TCGA-A2-A0CO.8C440009-E05E-4046-96AB-BAB211CB7D02,2,"Specimen #: (Age. F. Race WHITE. Physician (s) : AMENDED. SPECIMEN: RIGHT BREAST AND AXILLARY CONTENTS Site: breast, NOS C50.9 1/24/11 to. FINAL DIAGNOSIS: BREAST AND AXILLARY CONTENTS, RIGHT, MASTECTOMY: - INFILTRATING LOBULAR CARCINOMA. FOCAL LOBULAR CARCINOMA IN SITU AND CANCERIZATION OF TERMINAL DUCTS. - FOCAL DUCTAL CARCINOMA IN SITU,SOLID AND CRIBRIFORM TYPE. - SIZE: 5.2 CM BY GROSS MEASUREMENT. - MARGINS DEEP MARGIN POSITIVE FOR TUMOR. - NEGATIVE FOR LYMPHVASCULAR INVASION. - MICROCALCIFICATIONS ASSOCIATED WITH TUMOR. - FIBROCYSTIC CHANGES TO INCLUDE FIBROSIS, CYST FORMATION, AND APOCRINE. METAPLASIA. - 11 LYMPH NODES ARE NEGATIVE FOR TUMOR. - AJCC STAGE. COMMENT: THE AMENDMENT REFLECTS A CHANGE IN NUMBER OF LYMPH NODES FROM NINE. TO ELEVEN. COMMENT: AMENDMENT. Case amended to report results of HER2-neu - status by fluorescence in situ. hybridization. HER2-NEU: AMPLIFIED (5.0) . Note: The patient's prior core biopsy,. was negative for. HER2-neu. The tumor in the current case has areas of poorly. differentiated carcinoma (so-called pleomorphic lobular carcinoma) not. identified in the initial core biopsy; these areas are strongly positive. for HER2-neu gene amplification. Specimen # : CLINICAL DIAGNOSIS AND HISTORY: -year-old white female with two site core biopsy breast cancer. RE-OPERATIVE DIAGNOSIS: Right breast cancer. POST-OPERATIVE DIAGNOSIS: Post-Operative Diagnosis: Same as above. GROSS DESCRIPTION: RIGHT BREAST AND AXILLARY CONTENTS received fresh and consists of a 362. gram mastectomy, 15.0 x 14.0 x 2.6 cm, with attached axillary tail, 15.0 x. 3.0 x 1.0 cm. The skin ellipse measures 10.0 X 3.5 cm. The specimen is. inked as follows Axillary tail=blue dot on inferior portion,. mastectomy - blue=superior superficial, green=inferior superficial,. black=deep. Sectioning reveals an area of firmness with the superior. portion of the specimen measuring 5.2 cm approximately 5.0 mm from the. deep margin. Palpation reveals 5.0 cm area of firmness in the superior. portion of the breast. The remainder of the cut surface is yellow,. lobular, with focal areas of white fibrous tissue and small cystic. structures measuring up to 0.2 cm. No additional well-defined lesions or. nodules are noted. Sectioning thorugh the attached axillary tail reveals 11 possible lymph. nodes ranging in size from 0.3 to 2.0 cm in greatest dimension. Four representative sections are submitted for. protocol with mirror. image sections in the following cassettes: A1: Lymph node 0.7 cm. A2: Skin from lateral edge of ellipse. A3: Tumor lateral. A4: Tumor medial. A5: Grossly normal fibrous tissue approximately 5.0 cm from tumor. Additional representative sections are submitted in cassettes A6 through. A20 as follows: A6-A12: Tumor from medial to lateral in sequential order. A13: Upper inner quadrant. A14: Lower inner quadrant. A15: Lower outer quadrant. A16: Upper outer quadrant. A17: Two possible lymph nodes. A18: Five possible lymph nodes. A19: Three possible lymph nodes. A20: Section of nipple. 20CF'.",BRCA,0,"The report states that the size of the primary tumor is 5.2 cm, which is greater than 2 cm but less than or equal to 5 cm. This falls under the T2 category according to the AJCC staging system for breast cancer.",T2,42.0
1228,TCGA-E2-A1AZ.4E233F7D-035A-44A0-A5B6-6248357EB7B2,1,"SPECIMENS: A. SENTINEL LMYPH NODE LEFT AXILLA #1. B. SLNODE LEFT AXILLA 2. C. SLNODE 3. D. WIDE EXCISION LEFT BREAST. E. ADDITIONAL DEEP MARGIN. F. ADDITIONAL MEDIAL MARGIN. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, LEFT AXILLARY, RESECTION: -MICROMETASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1). B. LYMPH NODE, SENTINEL #2, LEFT AXILLARY, RESECTION: -ONE LYMPH NODE, NEGATIVE FOR METASTASIS (0/1). C. LYMPH NODE, SENTINEL #3, LEFT AXILLARY, RESECTION: -ONE LYMPH NODE, NEGATIVE FOR METASTASIS (0/1). D. BREAST/LEFT, RESECTION: INVASIVE DUCTAL CARCINOMA, SBR GRADE III/III. -TUMOR SIZE: 3.3x2.6x2.5 CM. -MARGINS FREE OF TUMOR. -SEE TEMPLATE. FIBROCYSTIC CHANGES WITH APOCRINE METAPLASIA, SCLEROSING AND BLUNT DUCT. ADENOSIS. E. BREAST, ADDITIONAL DEEP MARGIN, RESECTION: -BREAST TISSUE, NEGATIVE FOR TUMOR. F. BREAST, ADDITIONAL MEDIAL MARGINS, RESECTION: -BENIGN BREAST TISSUE WITH SCLEROSING ADENOSIS AND FOCAL ATYPICAL DUCTAL. HYPERPLASIA. Invasive Breast Cancer Template. INVASIVE TUMOR: Histologic type: Ductal. Tumor Size : 3.3x2.6x2.5 cm. Size of Invasive Focus: 3.3x2.6x2.5 cm. Grade, Histologic: 3. Grade, Nuclear: 3. Mitoses : 3. Scarff Bloom Richardson grade: III. Necrosis: present. Invasion Vasc/Lymphatic: present. DCIS component. DCIS Quantity: <25%. DCIS Type: solid. DCIS Location: Inside main mass. Nuclear grade: high. Necrosis: absent. Margins: Negative. Lymph nodes: Positive (1/3). Micrometastases: Yes. Extranodal extension: no. Stage, Pathology : pT2N1a (see below). Non-neoplastic areas: Fibrocystic changes with sclerosing and blunt duct adenosis. Hormone receptor status & HERCEPTEST: Previously done,. SPECIMEN(S): A. SENTINEL LMYPH NODE LEFT AXILLA #1 B. SLNODE LEFT AXILLA 2 C. SLNODE 3 D. WIDE. EXCISION LEFT BREAST E. ADDITIONAL DEEP MARGIN F. ADDITIONAL MEDIAL MARGIN. CLINICAL HISTORY: year old with left breast ca. FROZEN SECTION DIAGNOSIS: A. SENTINEL LYMPH NODE LEFT AXILLA #1. Touch Prep: Negative by Dr., called to Dr at. B. SENTINEL LYMPH NODE LEFT AXILLA #2. Touch Prep: Negative by Dr., called to Dr al. C. SENTINEL LYMPH NODE #3. Touch Prep: Negative by Dr., called to Dr. a. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE LEFT AXILLA #1. Received fresh is a 1.8x0.9x0.8cm. lymph node. The lymph node is bisected to reveal tan pink. homogenous cut surface. Touch preparation is made. The specimen is submitted in toto in one. cassette. B. SENTINEL LYMPH NODE LEFT AXILLA #2. Received fresh are two pieces of tan pink soft tissue measuring 0.4x0.4x0.3cm. each. One of them is. recognized as lymph node which is bisected. Touch preparations are made. The specimen is submitted. in toto in one cassette. C. SENTINEL LYMPH NODE #3. Received fresh is one lymph node measuring 1.3x0.8x0.3cm. It is bisected. Touch preparations are. made. The specimen is submitted in toto in one cassette. D. WIDE EXCISION LEFT BREAST. Received fresh is an oriented portion of firm breast tissue measuring 7.5x7x4.5cm. The specimen is. inked and sectioned to reveal a 3.3x2.6x2.5cm. white firm tumor mass, located 0.5cm. from the. posterior margin, 1.5cm. from superior margin, 0.4cm. from the medial margin, 0.7cm. from the inferior. margin. One section from the tumor is submitted for tissue procurement. A separate white nodule. measuring 0.3cm. in diameter is located 1.2cm. from the main tumor mass. This nodule is .1cm. from. the medial margin. Representative sections are submitted as follows: D1-D4: tumor mass with adjacent margin, representative. D5: separate nodule in toto. D6-D9: representative sections from normal looking breast tissue. E. ADDITIONAL DEEP MARGIN. Received in formalin is an unoriented portion of breast tissue measuring 2.2x2.5x1.5cm. The specimen. is inked and serially sectioned to reveal tan yellow lobulated cut surface. No gross lesion is identified. Representatives are submitted in two cassettes. F. ADDITIONAL MEDIAL MARGIN. Received in formalin is one fragment of tan yellow to pink soft to firm tissue measuring 2.7x2x1.5cm. The specimen is inked and serially sectioned to reveal tan fibrotic cut surface. No gross lesion is. identified. The specimen is submitted in toto in two cassettes. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist,. Final: Pathologist,.",BRCA,1,"Based on the report, the size of the primary tumor is given as 3.3x2.6x2.5 cm. According to New Rule 13, we use the maximum value to determine the T stage, which is 3.3 cm. According to New Rule 19, if the tumor size is given in millimeters, it should be converted to centimeters for T stage determination. However, in this case, the tumor size is already given in centimeters, so no conversion is necessary. According to the AJCC staging system for breast cancer (Rule 6), T1 is for tumors up to 2 cm, T2 is for tumors greater than 2 cm but not greater than 5 cm, T3 is for tumors greater than 5 cm, and T4 is for tumors of any size with direct extension to the chest wall or skin. Therefore, the T stage for this report is T2.",T2,43.0
1261,TCGA-E2-A2P6.E6A21CE6-841D-4D9B-A563-80B9BAF6E682,1,"SPECIMENS: A. WIDE LOCAL EXCISION LEFT BREAST. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. SPECIMEN(S): A. WIDE LOCAL EXCISION LEFT BREAST. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. DIAGNOSIS: A. BREAST, LEFT, WIDE LOCAL EXCISION: - MULTIFOCAL INVASIVE LOBULAR CARCINOMA, NOTTINGHAM GRADE 2. - LARGEST FOCUS IS 3.5 CM. INVASIVE CARCINOMA IS PRESENT AT THE SUPERIOR MARGIN. AND IS WITHIN 0.1 CM OF THE INFERIOR MARGIN. - LOBULAR CARCINOMA IN SITU (LCIS). NOTE: Several foci of invasive carcinoma are seen, spanning throughout a 6.4 cm lumpectomy. B. SENTINEL LYMPH NODE 1, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA (1.9 CM IN SIZE) IN ONE LYMPH NODE. WITH FOCAL EXTRANODAL EXTENSION (1/1). C. SENTINEL LYMPH NODE 2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). D. SENTINEL LYMPH NODE 3, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). E. SENTINEL LYMPH NODE 4, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). F. SENTINEL LYMPH NODE 5, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 3.5cm. Tumor Site: Upper outer quadrant. Margins: Involved at. superior. Extent:: 0.2 cm. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node. Lymph node status: Positive 1/5 Extranodal extension. Non-neoplastic areas: columnar cell change. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: Pathological staging (pTN): pT 2 N 1. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. WIDE LOCAL EXCISION LEFT BREAST. Received fresh labeled with the patient's identification and designated ""left breast wide local excision"" is. an oriented, previously inked, 55 g, 6.4 x 5.5 x 3.3 cm lumpectomy. The single suture designates. anterior, double-lateral, triple-superior. Ink code: Anterior-yellow, posterior-green, medial-black, lateral-. red, superior-blue, inferior-orange. The specimen is serially sectioned from posterior to anterior into 5. slices revealing a 2.5 x 2.1 x 1.9 cm, ill-defined firm pale tan mass, located 0.6 cm from the lateral. margin. The remainder of the specimen shows focal areas of white dense fibrous parenchyma. Tissue. is procured. The specimen is representatively submitted: A1-A2: Representative section posterior margin (green ink). A3: Slice 2, inferior/lateral. A4-A5: Slice 2, lateral/medial, respectively. A6-A11: Slice 3, entirely submitted, A7 demonstrating mass and nearest the lateral margin. A12-A13: Slice 4, mass, lateral margin. A14-A15: Slice 4, medial/inferior, respectively. A16: Slice 4, superior. A17-A18: Representative perpendicular sections anterior margin. B. SENTINEL LYMPH NODE #1 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #1 left. axilla"" is a yellow-tan lymph node measuring 1.9 x 1.7 x 1.5 cm. The specimen is sectioned, entirely. submitted, B1. C. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #2 left. axilla"" is a yellow-tan lymph node measuring 2.4 x 0.8 x 0.4 cm. The specimen is sectioned, entirely. submitted, C1. D. SENTINEL LYMPH NODE #3 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #3 left. axilla"" is a tan lymph node measuring 1.6 x 1 x 0.5 cm. The specimen is sectioned, entirely submitted,. D1. E. SENTINEL LYMPH NODE #4 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #4 left. axilla"" is a yellow-tan lymph node measuring 1.5 x 1.1 x 0.3 cm. The specimen is sectioned, entirely. submitted, E1. F. SENTINEL LYMPH NODE #5 LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node #5 left. axilla"" is a tan lymph node measuring 0.8 x 0.5 X 0.2 cm. Entirely submitted, F1. CLINICAL HISTORY: 1.5-2 cm invasive cancer upper outer quadrant left breast. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. FROZEN SECTION INTRAOPERATIVE REPORT: Part A: Breast, left, wide local excision, gross examination: 2.4 cm tumor mass located approximately. 0.6 cm to the lateral margin, gross examination only. Diagnosis called at. by Dr. Microscopic/Diagnostic Dictation: Patnologist,. Final Review: Pathologist,. Final: Pathologist,.",BRCA,1,"The report states that the largest focus of the tumor is 3.5 cm, which falls within the T2 category of the AJCC staging system for breast cancer (T2: > 2 cm but <= 5 cm). This is in line with Rule 1, Rule 6, Modified Rule 8, New Rule 13, New Rule 19, New Rule 21, New Rule 24, and New Rule 25.",T2,44.0
1279,TCGA-E9-A1NE.CF6E29A2-FAE6-45BB-B625-33877887A89E,1,"BREAST TISSUE CHECKLIST. Specimen type: Excision of tumor. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3.5 x 3.5 X 3.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 1/2 positive for metastasis (Axillary 1/2). Extracapsular invasion of the lymph nodes: Not specified. Right, lower. Margins: Not specified. outer. quadrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,1,"Using New Rule 13, the tumor size is given in the format of X x Y x Z, so we use the maximum value of 3.5 cm to determine the T stage. According to New Rule 19, if the tumor size is given in centimeters, we can directly use it for T stage determination. Therefore, the T stage is T2 (> 2 cm but <= 5 cm) since the maximum tumor size is 3.5 cm.",T2,45.0
708,TCGA-AC-A2QI.5CF85AF1-D227-430C-99CD-C2A524CFFA29,2,"Patient Location: Date of Service: Date Received: Cas. Room: Bed: A copy of this report will be faxed to: FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: A. -C) RIGHT BREAST WITH AXILLARY SENTINEL LYMPH NODES, MASTECTOMY. WITH SENTINEL LYMPH NODE BIOPSIES (X 2). - Invasive lobular carcinoma (multicentric), Nottingham grade 2. - Main tumor mass measures 57 mm in diameter. - Lobular carcinoma in situ (LCIS), comprising less than 5% of tumor volume. - Resection margins are free of tumor. - Invasive tumor is focally present 2 mm from the deep (pectoralis fascia). margin, and is at least 30 mm from all other margins. - Metastatic carcinoma is present in two sentinel lymph nodes (2/2). - Metastatic carcinoma is diffusely present throughout both lymph nodes. - No extranodal extension is present. PATHOLOGIC TUMOR STAGING SYNOPSIS: Type and grade (invasive): Invasive lobular carcinoma, grade 2. Type and grade (in situ): Lobular carcinoma in situ, nuclear grade 2. Primary tumor: pT3. Regional lymph nodes: pN1a. Distant metastasis: pMX. Pathologic stage: IIIA. Lymphovascular invasion: Present. Margin status: Negative (R0). COMMENT: The main tumor mass measures 57 mm in diameter. The tumor cells. diffusely infiltrate a relatively discrete dense fibrous area in the central breast. A few. smaller foci of invasive lobular carcinoma and LCIS are present in representative. sections taken away from the main tumor mass, but the main tumor burden is in the. central breast. The pathology findings were telephoned to Dr. Pathology Consultation Report. This report continues. Printed: Phon. FINAL SURGICAL PATHOLOGY REPORT. Patholoav Consultation Panant. Printed: This report continues. FINAL SURGICAL PATHOLOGY REPORT. Breast Invasive Tumor Staging Information. (AJCC Cancer Staging Handbook, 7th Ed, and CAP protocol, Oct 2009). This staging also incorporates: Previous biopsy: Breast profile: Specimen type: Total breast. Specimen procedure: Mastectomy with sentinel lymph node biopsies x. 2. Lymph node sampling: Sentinel lymph nodes. Specimen integrity: Single intact specimen. Specimen laterality: Right. Specimen size (other than mastectomy): 17 x 12.5 x 2.5 cm. INVASIVE TUMOR FEATURES: Invasive tumor size: 57 mm. Invasive tumor site: Central. Invasive tumor focality: Multicentric (central, UOQ, LIQ, LOQ). Histologic type: Invasive lobular carcinoma. Total Nottingham Grade: 2 of 3 (intermediate grade). Tubule formation: 3 of 3. Nuclear Pleomorphism: 2 of 3. Mitotic count for Nottingham: 1 of 3. Mitotic count: Five mitoses in ten high power fields. Lymphatic invasion: Present. MARGIN STATUS FOR INVASIVE COMPONENT: Distance of tumor from margins: 2 mm. Closest margin: Deep (bounded by pectoralis fascia). Other margins: Invasive carcinoma is at least 30 mm from all. other margins. LOBULAR CARCINOMA (LCIS) FEATURES: Extent: LCIS present in association with invasive. carcinoma, and in representative sections away. from main tumor mass. Nuclear grade: Intermediate grade. Necrosis: Not present. Calcifications: Not present. FINAL SURGICAL PATHOLOGY REPORT. Margin status for LCIS component: Negative. Distance of In-situ from nearest margin: At least 10 mm. Skin: Unremarkable. Nipple: Unremarkable. Skeletal Muscle: No skeletal muscle present. INVASIVE PATHOLOGIC TUMOR STAGING (pTNM). Primary tumor (pT): pT3. Regional lymph nodes (pN): pN1a. Distant metastasis (pM): pMX. RECEPTOR STATUS AND HER2/NEU: Estrogen receptors: POSITIVE (100% positive cells, strong intensity). Progesterone receptors: Negative (less than 1% positive cells). Her2/neu: Not overexpressed (IHC score 1+). Ki-67 proliferative index: 12% positive cells. Source of Specimen: A. Right Axillary Sentinel Lymph Node. B. Right Breast total mastectomy. C. Sentinel lymph node;Right Axillary Sentinel Lymph Node. Gross Description: A. The specimen is labeled right axillary sentinel lymph node #960 and is received in formalin. It consists. of a 2.9 X 2.2 X 0.7 cm discoid lobulated portion of fatty tissue. On dissection a single 1.6 x 0.7 x 0.5 cm. lymph node is recovered. The node is serially sectioned and entirely submitted in cassette A1. B. The specimen is labeled right breast and is received without fixative. It consists of a mastectomy. specimen which weighs 232 grams. A suture marks the tail of the breast. With this orientation, the. specimen measures 12.5 cm from superior to inferior, 17 cm from medial to lateral and 2.5 cm from. superficial to deep. There is an overlying 15.5 x 7 cm ellipse of mottled tan to pale red skin. Medially and. inferiorly within the skin is a 2.8 cm areola and a slightly retracted appearing 0.8 cm nipple. The skin is. bulging but otherwise unremarkable. The anterior-superior margin is inked blue, the anterior-inferior. margin is inked green, and the posterior margin, which consists of smooth fascial tissue is inked black. The. breast is serially sectioned at close intervals to reveal a central firm and relatively well circumscribed area. of fibrous breast parenchyma. This fibrous parenchyma overall measures 5.7 cm from medial to lateral,. 2.5 cm from superior to inferior, and 1.7 cm from superficial to deep. The fibrous tissue is separated from. the deep margin by a thin layer of movable fascial tissue. The fibrous breast parenchyma is 3 cm from the. Pathology Consultation Report. Printed: This report continues. FINAL SURGICAL PATHOLOGY REPORT. inferior margin, 3 cm from the superior margin, 4 cm from the medial margin, and 6 cm from the lateral. margin. It is 1 cm from the closest skin and abuts the fascial margin of the posterior breast centrally. Representative samples of this tissue are obtained for research purposes. Sections of this fibrous breast. tissue reveal a central and inferiorly located area of hemorrhage with a twisted biopsy site clip. The. remainder of the breast is composed predominantly of fatty tissue but rubbery fibrous parenchyma extends. to the lower-outer quadrant. There are no obvious lymph nodes in the tail of the breast. Representative. sections are submitted. Section summary: B1) nipple and tissue just deep to nipple,. B2) central deep margin (fascial tissue),. B3) medial edge of central fibrous tissue,. B4) superior edge of central mass,. B5) inferior portion of central mass (biopsy site clip here),. B6-B7) additional central sections of tumor (B6 has deep margin),. B8) lateral edge of fibrous mass,. B9) representative sections upper-inner quadrant,. B10) representative sections lower-inner quadrant,. B11) representative sections upper-outer quadrant,. B12) representative sections lower-outer quadrant. C. The specimen is labeled right axillary level two sentinel lymph node. and is received in formalin. It consists of a 0.9 x 0.6 x 0.5 cm tan lymph node with a small amount of adherent adipose tissue. The. specimen is serially sectioned and entirely submitted in cassette C1. Microscopic Description: A. Microscopic sections have been examined. The microscopic findings are reflected in the diagnosis. rendered. B. Microscopic sections have been examined. The microscopic findings are reflected in the diagnosis. rendered. C. Microscopic sections have been examined. The microscopic findings are reflected in the diagnosis. rendered. Pathology Consultation Report. REPRINT: Orig. printing on. Printed:",BRCA,1,"The report states that the 'invasive tumor size' is 57 mm, which is larger than 5 cm. According to New Rule 19, we convert millimeters to centimeters, and using Modified Rule 8 and New Rule 13, we use the maximum size of the tumor to determine the T stage. Therefore, the T stage is T3.",T3,46.0
593,TCGA-A7-A425.F969E3E4-0053-44E9-85BC-BEFDBD62C512,2,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Lymph node, right axillary sentinel node, excision: One lymph node positive for metastatic carcinoma (1/1) . B. Breast, right, excision: Invasive lobular carcinoma (see tumor characteristics in the. microscopic description). C. Lymph nodes, right axillary contents, excision: Ten of sixteen lymph nodes positive for metastatic carcinoma (10/16). D. Lymph node, highest apical node, excision: One of two lymph nodes positive for metastatic carcinoma (1/2). Microscopic Description: Invasive carcinoma: Histologic type: Lobular. Histologic grade: Overall grade:2. Architectural score: 3. Nuclear score: 2. Mitotic score: 1. Greatest dimension (pT) 7.5 cm, pT3. Specimen margins: Tumor is more than 2 cm from the deep margin of. excision and 1 cm from the superficial soft tissue margin. Vessel invasion: Present. Nipple (Paget's) Tumor invades into the dermis beneath the. surface of the nipple: Paget's disease is not identified. Ductal carcinoma in situ: Not identified. Description of non-tumorous breast: Biopsy site changes are identified. Fibrocystic changes. Lymph nodes: Number of positive nodes of total: Twelve lymph nodes positive for. metastatic carcinoma (12/19). Size of largest metastasis: 2.9 cm. Extracapsular extension (present/absent) : Present. pN: pN3a. Distant metastasis (pM) : pMX. Prognostic markers: Previously performed. Specimen. A. Right breast axillary sentinel node. B. Right breast stitch at 12 o'clock. C. Right axillary contents. D. Highest apical node. Clinical Information. Right breast cancer. Intraoperative Consultation. A) Lymph node, right axillary sentinel node, excision: One lymph node. positive for metastatic carcinoma (1/1) . Gross Description. A. Received fresh labeled ""right axillary sentinel node hot not blue"". is a lymph node that measures 2.9 x 1.7 x 1.4 cm in dimension. The. lymph node has a firm consistency and shows yellowish discoloration. A. representative section from the node is submitted for frozen section. The remaining node is sectioned and entirely submitted for permanent. section in 6 cassettes. B. Received fresh for tissue procurement labeled ""right breast"" is a. 1220 g, 29.0 cm (medial to lateral) by 23.5 cm (superior to inferior). by 5.8 cm (anterior to posterior) soft, lobulated tan gold-like portion. of fibroadipose tissue in keeping with breast, designated as right per. requisition slip and container and oriented by a suture as stated. previously. A 17.5 x 5.8 cm wrinkled tan-white skin ellipse with a. flat 1.3 x 1.3 cm nipple is present along the anterior aspect. An. indurated focus is present subjacent to the central superior portion of. the skin, corresponding to the junction of the upper inner and outer. quadrants. The anterior surface in this area is inked blue. The. intact deep margin is inked black and the specimen is sectioned. There. is a central, 7.5 cm (superior to inferior) by 5.5 cm (medial to. lateral) by 4.0 cm (anterior to posterior) rubbery tan-white apparent. tumor mass is present (corresponding to the central junction of the 4. quadrants) The lesion is present within 3.5 cm of the inked deep. margin and appears to approach the anterior surface to within 2 cm. A. portion of tumor and a portion of normal parenchyma are submitted for. tissue procurement as requested. The cut surfaces throughout the. remainder of the specimen consist predominantly of soft lobulated tan. gold adipose tissue with a scant amount of interspersed delicate. tan-white fibrous tissue. No additional mass lesion or abnormality is. identified. Summary: 1 - deep margin subjacent to the lesion, 2 - lesion to. anterior surface, 3 through 7 - lesion to adjacent parenchyma, 8 -. random upper outer quadrant, 9 - upper inner quadrant, 10 - lower inner. quadrant, 11 - lower outer quadrant, 12 - nipple. C. Received fresh and subsequently fixed in formalin labeled ""right. axillary contents ""is a 12.0 x 7.5 x 3.0 cm aggregate of yellow lobular. fatty tissue fragments which are not orientated. The specimens are. palpated to identify lymph nodes which range from 0.1 cm and 2.5 cm in. greatest dimension. The lymph nodes are entirely submitted as follows: 1 - 1 possible lymph node, 2 - 6 possible lymph nodes, 3 - 6 possible. lymph nodes, 4 - 2 possible lymph nodes, 5 - 1 possible lymph node, 6. 1 possible lymph node. D. Received fresh and subsequently fixed in formalin labeled ""highest. apical node ""is a 3.0 x 2.0 x 0.4 cm aggregate of yellow lobular fatty. tissue fragment. The specimen is palpated to identify 2 possible lymph. nodes present. The lymph nodes are 0.5 cm and 0.2 cm in greatest. dimension. The specimens are entirely submitted as follows: 1 - lymph. nodes, 2 - remaining fat.",BRCA,3,"The maximum size of the primary tumor is given as 7.5 cm in the microscopic description section of the report. According to the rules provided, we should use the maximum size to determine the T stage. Therefore, the T stage is T3.",T3,47.0
839,TCGA-AR-A0TT.E9231B33-E1CE-4396-9F9E-03DBF049919A,1,"Breast, right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III) [tubules. 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a mass (2.3 x 1.9 x 1.8 cm) [AJCC pT2]. Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. The non-neoplastic breast. parenchyma shows nonproliferative fibrocystic changes. All surgical margins are negative for tumor. (minimum tumor free margin, 0.5 cm, deep margin). Lymph nodes, right axillary sentinel Nos. 1A, 1B, 1C, 2A, 2B, and 2C, excision: Multiple (3 of 6) right. axillary sentinel lymph nodes, all without blue dye, are positive for for metastatic carcinoma. Lymph nodes, right axillary, dissection: Multiple (2 of 13) right axillary lymph nodes are positive for. metastatic carcinoma [AJCC pN2]. Extranodal extension is present. Her-2/NEU has been ordered on paraffin-embedded tissue.",BRCA,2,"The report states that the primary tumor measures 2.3 x 1.9 x 1.8 cm. According to New Rule 13, we use the maximum value to determine the T stage, which is 2.3 cm. Based on New Rule 19, if the tumor size is given in centimeters, no conversion is needed. Therefore, the T stage is T2.",T2,48.0
1343,TCGA-EW-A1OX.4C40B309-3178-4E7E-A987-47698E5E364B,1,"F. Pathologic Interpretation: A. Right breast mass, short stitch superior, long stitch lateral, double stitch deep: Infiltrating ductal carcinoma, colloid type, low nuclear grade, 3.0 cm in greatest dimension. - Margins of excision are free of tumor. pT2NOMX. - See tumor summary. B. Lateral margin right breast: - Breast tissue with adenosis. - New margin is negative for malignancy. C. Additional superior margin: - Breast tissue with no pathologic change. - New margin is negative for malignancy. D. Sentinal node # 1: - No malignancy seen in one lymph node (0/1). Immunohistochemistry for keratin is negative for carcinoma. E. Sentinel node # 2: - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin is negative for carcinoma. F. Non sentinel node # 1: - No malignancy seen in one lymph node (0/1). G. Non sentinel node # 2: - No malignancy seen in one lymph node (0/1). H. Axillary tissue: - Fibroadipose tissue, no malignancy seen. - No lymphoid tissue present. Tumor Summary: Specimen Type: Excision. Lymph Node Sampling: Sentinel lymph node(s) only. Specimen Size (for excisions less than total mastectomy): 9x 7.5 x 3.5 cm. Laterality: Right,. Size of Invasive Component: Greatest dimension: 3.0 cm. Additional dimensions: 2.4 x 2.4 cm. Histologic Type: Invasive ductal carcinoma. Mucinous. Histologic Grade (any grading system may be used; mitotic count is also required independent of the grading. $ystem): Tubule Formation: Majority of tumor greater than 75% (score =1). Nuclear Pleomorphism (Small regular nuclei (score =1). Mitotic Count: Less than 10 mitoses per 10 HPF (score =1). Total Nottingham Score: Grade I: 3-5 points. Pathologic Staging: Primary Tumor: pT2. Regional Lymph Nodes: pNO. - Specify: Number examined: 4. Number involved: 0. Distant Metastasis: pMX. Margins: Uninvolved by invasive carcinoma. SURGICAL PATHOL Report. Venous/Cymphatic (Large/Small Vessel) Invasion (V/L): Absent. ER: Positive. PR: Positive (. HER2: Negative (<. NOTE: IDS=ER Some Pgl immunohistochemical 636-7R,A485-HER2, antibodies H-II=EGFR are analyle All immwnohistochemical reagents stains are ussed with formalin or moleculor fixed, paraffin embedded tisme. Detection is by Envision are. specific (ASRs) validated by our laboratory. These ASRs are clinically indicalors that do not require FDA Method. approval. The These sults clones read are used hy a. pathologist a positive or regative. As the attending pathologist, 1 attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). MD. MD. Intraoperative Consultation. B. Lateral margin right breast, FS: No malignancy seen. D. Sentinal node # 1, FS: Negative for tumor. E. Sentinel node # 2, FS: Negative for tumor. F. Non sentinel node # 1, FS: Negative for tumor. G. Non sentinei node # 2, FS: Negative for tumor. MD. Clinical History: {Not Provided}. Specimen(s) Received: A: Right breast mass, short stitch superior, long stitch lateral, double stitch deep. B: Lateral margin right breast, FS. C: Additional superior margin. D: Sentinal node # 1, FS. E: Sentinel node # 2, FS. F: Non sentinel node # 1, FS. G: Non sentinel node # 2, FS. H: Axillary tissue. Gross Description;. A. Received in formalin is a yellow fibroadipose tissue weighing 92 grams, measuring 9.0 x 7.5 x 3.5 cm. The specimen is. oriented with short suture superior margin, long suture lateral margin and double sutures deep margin. The margins are. inked as follows: Superior margin is inked in blue, superior margin inked in green, lateral margin is inked in ofange,. there is well demarcated tumor mass 3.0 x 2.4 x 2.4 cm located at approximately 0.7 cm closest margin (and 0.4 cm. medial margin is inked in red, anterior margin inked in yellow and deep margin inked in black. Multiple cross sections,. inferior margin). The rest of the breast shows a white diffusely breast tissue and adipose tissue. The stroma to fat ratio is. approximately 30-70%. Representative sections are submitted in twelve cassettes as follows: 1. Superior margin. 2. Inferior margin. 3. Lateral margin. SURGICAL PATHOL Report. Medial margin. 5. Anterior margin. 6. Deep margin. 7. Superior margin with tumor. 8. Inferior margin with tumor. 9-12. Tumor. B. Received fresh is a pale tan tissue fragment, 1.2 x 1.0 x 0.2 cm. Submitted in toto in one cassette for frozen Isection. C. Received in formalin is a yellow fibroadipose tissue 4.5 x 3.0 x 1.0 cm. The specimen presents multiple black sutures,. marking through margin. This margin is inked in yellow and the opposite margin is inked in black. Serially sectioned and. submitted in toto in ten cassettes. D. Received fresh is a yellow fibroadipose tissue 3.0 x 2.0 x 1.0 cm. The specimen is serially sectioned and sulmitted in toto. in five cassettes as follows: 1. For frozen section. 2-5. For permanent. E. Received are two pink-tan tissue fragments, 1.0 x 1.0 x 0.5 cm each. Submitted in toto in one cassette for frozen. F. Received in formalin is an ovoid pale tan tissue fragment, 3.0 x 1.5 x 1.0 cm. Bisected and submitted in toto in two. cassettes for frozen. G. Received in formalin is a yellow. ovoid tissue fragment, 3.0 x 2.0 x 2.0 cm. Serially sectioned and submitted. n toto in six. cassettes for frozen. H. Received in formalin is an ovoid yellow, fibroadipose tissue, 2.0 x 1.5 x 1.5 cm. Serially sectioned and submitted in toto in. four cassettes.",BRCA,0,"The report states that the size of the primary tumor is 3.0 cm in greatest dimension, which falls within the T2 category (T2: > 2 cm but <= 5 cm) according to the AJCC staging system for breast cancer. This is in line with the modified Rule 8 and New Rule 13.",T2,49.0
487,TCGA-A2-A0CW.7D1C2CD8-9842-48AC-BB16-897E2A45B88D,1,"Specimen #: F Race: WHITE. Physician( (s) : 3. SPECIMEN: A: SENTINEL LYMPH NODE #1 B: NON-SENTINEL - LYMPH NODE. C: RIGHT BREAST LUMPECTOMY. FINAL DIAGNOSIS: A. LYMPH NODE, SENTINEL, EXCISION: ONE (1) SENTINEL LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA WITH. THE LARGEST FOCUS MEASURING 0.4 CM. - TUMOR IDENTIFIED IN THE PERINODAL SOFT TISSUE. B. LYMPH NODE, NON-SENTINEL, EXCISION: ONE (1) LYMPH NODE COMPLETELY REPLACED BY METASTATIC CARCINOMA. MEASURING 1.5 CM. EXTRANODAL EXTENSION CANNOT BE ASSESSED DUE TO LACK OF PERINODAL. SOFT TISSUE. C. BREAST. RIGHT, LUMPECTOMY: - INFILTRATING DUCTAL CARCINOMA, POORLY DIFFERENTIATED. - -NOTTINGHAM SCORE: 9/9 (TUBULES=3, NUCLEI=3, MITOSES=3). - TUMOR SIZE: 2.7 CM (MEASURED GROSSLY). - TUMOR NECROSIS: ABSENT. - MICROCALIFICATIONS: ABSENT. - VENOUS / LYMPHATIC INVASION: PRESENT. - INVASIVE TUMOR INVOLVES THE SMOOTH MUSCLE OF THE NIPPLE. - MARGINS: NEGATIVE. - DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0.6 CM,. FROM NEAREST (SUPERIOR) MARGIN. - INTRADUCTAL COMPONENT DUCTAL CARCINOMA IN SITU, SOLID TYPE,. NUCLEAR GRADE II, WITH NECROSIS (<5% OF TUMOR). - ESTROGEN RECEPTORS, PROGESTERONE RECEPTORS, AND HER 2 NEU. PERFORMED ON PREVIOUS SPECIMEN (SEE COMMENT). - PATHOLOGIC STAGE: pT2 N1a MX. - ADDITIONAL PATHOLOGIC CHANGES: PRIOR BIOPSY SITE CHANGES. COMMENT: E. Hormone receptors performed on previous biopsy. and are as. follows: - Estrogen Receptor: Positive (approximately 100% nuclear staining). - Progesterone Receptor: Positive (25% nuclear staining). - ER-2-NEU - Postive (3+, strongly positive). Specimen #: FINAL DIAGNOSIS (continued) : CLINICAL DIAGNOSIS AND HISTORY: year old female with right breast invasive cancer. PRE-OPERATIVE DIAGNOSIS: Right breast invasive cancer. POST-OPERATIVE DIAGNOSIS: Right breast invasive cancer. GROSS DESCRIPTION. A. Received fresh labeled with patient's name. designated ""SENTINEL LYMPH NODE"" is a 1.5 x 0.5 x 0.3 cm lymph node with. attached fibrous fatty tissue. Specimen is bisected and entirely submitted. in cassette one. B. Received fresh labeled with patient's name. designated 'NON-SENTINEL LYMPH NODE"" are two irregular portions of. presumed previously intact lymph node each measuring 1.5 x 1.5 x 0. 1 cm. Sectioning reveals uniform tan and whtie cut surface. Specimen entirely. submitted in three cassettes as follows. B1-B2: first portion of node (match of B1 submitted in OCT for CBCP. protocol). B3: remaining portion of lymph node. C. Received fresh labeled with patient's name. designated ""RIGHT BREAST LUMPECTOMY"" consists of an irregular portion of. fibrofatty tissue oriented with single stitch medial and two stitches. superior. The specimen measures 10 cm medial to lateral, 7 cm anterior to. posterior and 3 cm superior to inferior. Superficial surface displays an 8. x 4 cm lightly pigmented skin ellipse with centrally located fimr inverted. nipple. No discharge or scar is identified. Specimen is inked as follows : superior blue, inferior green, medial red, lateral yellow, posterior. black. Serial sections reveal well defined 2.7 x 2.7 x 2.2 cm firm pink. white gritty mass subadjacent to and involving the nipple. Surrounding. breast tissue is fibrofatty and otherwise unremarkable. Cassette key. Specimen # : GROSS DESCRIPTION (continued). C1: mass. C2: normal fibrous 1 cm away. C3: normal skin. C4: : nipple with mass. C5-C10: representative sections of presumed mass with close proximity to. margin. C11: medial margin. C12: lateral margin. 12CM.",BRCA,1,"Based on the report, the size of the primary tumor is 2.7 cm, which falls within the T2 category (T2: > 2 cm but <= 5 cm) according to the AJCC staging system for breast cancer. The maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters or millimeters, converted to centimeters (Modified Rule 8).",T2,50.0
452,TCGA-A1-A0SB.BEC7EEA9-6DEA-4402-A3A1-07EF33D58174,0,"Final Pathologic Diagnosis: A. Sentinel lymph node #1, biopsy: No carcinoma in one lymph node (0/1); see. comment. B. Sentinel lymph node #2, biopsy: No carcinoma in one lymph node (0/1); see. comment. C. Breast, left, wire-guided partial mastectomy: 1. Adenoid cystic carcinoma, SBR Grade 1, 1.2 cm; see comment. 2. Microcalcifications involving benign ducts. 3. Atypical ductal hyperplasia. 4. Apocrine metaplasia. 5. Blopsy site changes. 6. Fibroadenoma. D. Breast, right, mammoplasty: 1. Intraductal papilloma. 2. Sclerosing adenosis. 3. Apocrine metaplasia. 4. Microcalcifications involving benign glands. 5. Microcysts. Page of 6. Working Draft. 6. Skin with no significant pathologic abnormality. 7. No carcinoma identified. E. Breast, left, mammoplasty: 1. Usual ductal hyperplasia. 2. Apocrine metaplasia. 3. Fibroadenoma. 4. Skin with no significant pathologic abnormality. 5. No carcinoma identified. Note: This is an unusual tumor. H&E sections show a relatively circumscribed tumor with large nests. of epithelial cells in a cribriform growth pattern. The stroma is sclerotic. The differential diagnosis. includes adenoid cystic carcinoma or a cribriform variant of invasive ductal carcinoma. A prior core. needle biopsy of the left breast at 6 o'clock (. ) was reviewed. Immunohistochemical studies were necessary to evaluate this case and establish the correct. diagnosis. The following immunohistochemical stains were performed and evaluated: ER: Positive, 2+ staining in 75% of cells. PR: Negative, no staining in any tumor cells. (internal positive control present). CD117: Positive. SMA: Focally positive, relatively high background. SMM: No myoepithelial cells present around most nests of tumor cells. p63: Positive in basaloid cells in most areas. The above Immunohistochemical stains support a diagnosis if adenoid cystic carcinoma. Although ER. expression is often negative in adenoid cystic carcinoma, the presence of basal cell Immunophenotype. (positive p63) and the positive CD117 support this diagnosis. Insofar as adenoid cystic carcinoma. represents a dual population of basaloid and epithelial cells, it may be that this example is somewhat. rich in the epithelial component thus explaining the ER positivity. The above interpretation may also. explain the rather diffuse CD117 staining. The absence of a define myoepithelial layer by the SMM. further supports the diagnosis. We recognize that this tumor was also sent for gene expression. profiling so correlation with those findings for a basaloid expression profile is also suggested. Drs. and. have reviewed selected stides form this case and. concur with the diagnosis of adenoid cystic carcinoma. Breast Tumor Synoptic Comment. - Laterality: Left. - Invasive tumor type: Adenoid cystic carcinoma. - Invasive tumor size: 1.2 cm. - Invasive tumor grade (modified Bloom-Richardson): Nuclear grade: 2. Mitotic count: 1 mitotic figures/10 HPF. Tubule/papilla formation: 1. Total points and overall grade = 4 points = grade 1. - Lymphatic-vascular Invasion: None. - Skin/nipple: No specific pathologic abnormalities. - Margins for invasive tumor: Negative. - Anterior (skin): N/A. - Posterior: Negative (tumor is > 1 cm away). - Inferior lateral margin (black ink): Negative; (tumor is >1 cm away, on stide C4). - Inferior medial margin (green Ink): Negative; (tumor is > 1 cm away, on slide C5). - Superior margin (blue Ink): Negative; (tumor is >1 cm away, on slide C3). - Microcalcifications: Present, involving benign ducts. Working Draft. - Lobular carcinoma in situ: None. - Lymph node status: Negative. - Total number sampled: 2. - AJCC/UICC stage: pT1cNOMX. Result of HER2/neu test: This carcinoma is negative for HER2/neu oncoprotein. over-expression. An immunohistochemical assay was performed by manual morphometry on block C3 using the CB11 monocional antibody to. HER2/neu oncoprotein. The staining Intensity of this carcinoma was 0 on a scale of 0-3. Carcinomas with staining intensity scores of 0 or 1 are considered negative for over-expression of HER2/neu oncoprotein. Those with a staining intensity score of 2 are considered indeterminate. We and others have observed that many carcinomas with. staining intensity scores of 2 do not show gene amplification. All carcinomas with staining intensity scores of 2 are therefore. submitted for FISH testing. The results of the FISH test are Issued directly from the molecular cytogenetics laboratory. Carcinomas with staining intensity scores of 3 are considered positive for over-expression of HER2/neu oncoprotein. Tumors in. this category show an excellent correlation between the results of immunohistochemical and FISH testing, and almost always show. gene amplification. In addition to the above findings, several lymph nodes are enlarged with a fairly monotonous. population of small lymphocytes, concerning for lymphoma. Immunohistochemical stains were. performed to characterize the small lymphocyte population as follows: CD20: Highlights widely scattered aggregates of small lymphoid cells, consistent with primary. follicies. - CD3: Highlights small lymphocytes predominantly in interfollicular areas. - CD21: Highlights aggregates of dendritic cells underlying B cell aggregates, confirming their Identity. as B cell follicles. - CD23: Highlights aggregates of dendritic cells underlying B cell aggregates, confirming their identity. as B cell follicies. Together, these findings are consistent with a diagnosis of benign quiescent nodes, and argue against. a diagnosis of lymphoma. Dr. of. Hematopathology has reviewed parts A and B and agrees with the above. interpretation. A preliminary diagnosis was given to. in Dr. clinic on. Additional. preliminary diagnosis given to. in Dr. clinic on. Intraoperative Consult Diagnosis. FS1 (A1) Sentinel lymph node #1 (half of the specimen), biopsy: Rare scattered atypical cells. Cannot completely rule out carcinoma. Defer to permanent. Dr. concurs. (Dr. FS2 (A2) Sentinel lymph node #1 (other half of the specimen), biopsy: Rare scattered atypical cells. Cannot completelv rule out carcinoma. Defer to permanent. Dr. concurs. (Dr. FS3 (B) Sentinel lymph node #2, blopsy: Rare scattered atypical cells. Cannot completely rule out. carcinoma. Defer to permanent. Dr. concurs. (Dr. Clinical History. The patient is a :year-old female with adenoid cystic carcinoma of the left breast vs. ductal. carcinoma. She has an additional lesion, seen on MRI, suspicious for carcinoma. The patient now. undergoes left wire-guided partial mastectomy and sentinel lymph node dissection with bilateral. mammoplasty for symmetry. Gross Description. Working Draft. The specimen is received in five parts, each labeled with the patient's name and unit number. Parts. A-C are received fresh. Parts D-E are received in formalin. Part A, additionally labeled ""1 - sentinel lymph node # 1 count = 5900,"" consists of one soft, ovoid,. red-yellow, irregular, unoriented fibroadipose tissue fragment that is 3.2 x 2 x 1 cm. It is oriented by. a stitch placed by the surgeon marking the hottest spot. The stitch area is inked blue. Adipose tissue. is removed. Lymph node candidate is bisected. 50% of the lymph node candidate is submitted for. frozen section diagnosis 1, with the frozen section remnant submitted in cassette A1. The remaining. 50% of the lymph node candidate is submitted for frozen section diagnosis 2, with the frozen section. remnant submitted in cassette A2. The remaining adipose tissue is submitted in cassette A3. Part B, additionally labeled ""2 - sentinel lymph node #2 count = 12700,"" consists of one soft,. red-yellow, irregular, unoriented, ovoid, oriented fibroadipose tissue fragment that is 2 x 1.7 x 0.8 cm. A stitch Is placed by the surgeon marking the hottest spot; this area is inked blue. Adipose tissue is. removed. The lymph node candidate is bisected and submitted for frozen section diagnosis 3, with the. frozen section remnant submitted in cassette B1. The remaining adipose tissue is submitted in. cassette B2. Part C is labeled ""left breast needle localization biopsy."". SPECIMEN TYPE: Wire-guided partial mastectomy. - SKIN ELLIPSE: Present. - NIPPLE: Not present. - ORIENTATION: - Double long suture: Lateral, on side with Telfa. - Short double suture: Superior. - Short single suture: Inferior, opposite of needle wire. - INKING (for microscopic evaluation): - Black: Lateral (Telfa side). Green: Medial (side opposite wire needle). - Blue: Superior (side with wire). - SIZE OF SPECIMEN: - Medial-lateral dimension: 6 cm. - Superior-inferior dimension: 6 cm. - Anterior-posterior dimension: 11.2 cm. - TOTAL NUMBER OF SLICES: 19. - First slice (slice 1): Anterior margin (skin). - Last slice (slice 19): Posterior margin. - GROSS PATHOLOGY: On serial sectioning, multiple nodules are Identified throughout the breast. parenchyma. A dominant, rubbery/hard, tan-pink mass is identified in slices 3-4 and measures 1 x 1. x. 0.8 cm. This mass is located centrally within the slices and is located 1.1 cm from the blue ink, 1. cm. from the green ink, and 1.5 cm from the black Ink. Two tan-white rubbery nodules are seen in. slice 5; one nodule measures 0.7 x 0.4 x 0.3 cm and is 0.7 cm from the blue ink. The other nodule. measures 0.3 x 0.3 x 0.3 cm and is 0.2 cm from the blue ink. A tan-yellow rubbery nodule is. identified In slice 7-8, measuring 0.4 x 0.3 x 0.3 cm. In addition, a white-tan rubbery nodular area. is. seen in slice 8, abutting the black ink and measuring 0.6 x 0.3 x 0.2 cm. A white-tan rubbery nodule. is also seen in slice 9, abutting the blue ink, and measuring 0.3 x 0.2 x 0.2 cm. An additional hard,. tan-pink nodule is seen in slice 9, measuring 0.3 x 0.3 x 0.3 cm. A tan-white rubbery nodule is seen. in slices 15-16, measuring 0.5 x 0.5 x 0.5 cm. This nodule is suspicious for a lymph node. The needle. tip is present in slice 15. Representative sections are submitted as follows: Cassette C1: Skin (slice 1). Cassettes C2-CS: Dominant mass in slices 3-4, entirely submitted. Cassette C6: Larger nodule, slice 5. Cassette C7: Smaller nodule, slice 5. Cassette C8: Nodule, slices 7-8. Cassette C9: Nodular area in slice 8, abutting black Ink. Cassette C10: Both nodules in slice 9. Cassette C11: Nodule, slice 11. Cassettes C12-C13: Nodule, slices 15-16, entirely submitted. Working Draft. Cassettes C14-C15: Posterior margin, perpendicularly sectioned. Part D, labeled ""right breast tissue and skin,"" consists of one fragment of fibrofatty tissue with. attached skin and multiple other fragments of skin and fibrofatty tissue measuring, in aggregate, 13 x. 10 x 3.5 cm and weighing 170 gm in total. The fragments of skin are grossly unremarkable, with no. suspicious lesions or areas. A single tan-yellow nodule measuring 0.1 x 0.1 x 0.1 cm is noted in one. of the fibrofatty tissue fragments, which also contains an area that is mostly fibrous. The largest. fibrofatty tissue fragment with attached skin, measuring 11.5 x 9.2 x 3.5 cm and the skin ellipse. measuring 8 x 7 cm, contains a single white-tan, rubbery, nodular area measuring 0.3 x 0.2 x 0.2 cm. The rest of the specimen is grossly unremarkable, with no other suspicious lesions seen. Representative sections are submitted as follows: Cassette D1: 0.1 x 0.1 x 0.1 cm nodule from fibrofatty tissue fragment. Cassette D2: Fibrous area from fibrofatty tissue fragment. Cassette D3: Nodular area from largest specimen. Cassette D4: Representative section skin and fibrofatty tissue from largest specimen. Part E, labeled ""left breast tissue and skin,"" consists of multiple fragments of fibrofatty tissue, as well. as multiple fragments of skin, in aggregate measuring 6.5 x 6.5 x 2.2 cm and weighing 154 gm in. total. The skin fragments are grossly unremarkable, with no suspicious areas or lesions seen. One. fibrofatty tissue fragment contains a tan-white, lobulated, rubbery, nodular area measuring 1.2 x 1.1 x. 1 cm. The rest of the fibrofatty tissue fragments are grossly unremarkable, with no suspicious lesions. or areas seen. Representative sections are submitted as follows: Cassette E1: Representative section of skin. Cassettes E2-E3: Nodule in fibrofatty tissue fragment, entirely submitted. Cassette E4: Representative section of fibrofatty tissue. /Pathology Resident. Fee Codes: Other Specimens. Specimen Class: Accessioned: Specimen(s) Received: Consult, Surgical w/ blocks or tissue. Final Diagnosis. Review of. from. Left breast, 6 o'clock, core needle biopsy: Malignant neoplasm with cribriform growth. pattern; see comment. MD. MD. _Specimen Class: Accessioned: Specimen(s) Received: Left Breast, Fine Needle Aspiration. Final Diagnosis. Left Breast, Fine Needle Aspiration: Fibroadipose tissue, see comment. Working Draft. Spccimen Class: Accessioned: Specimen(s) Received: Left breast, needle core biopsy 5:00, Scm from nipple. Final Diagnosis. Left breast, 5:00, 5 cm from nipple, needle core biopsy : 1. Fibroadenoma with microcalcifications see comment. 2. Fat necrosis.",BRCA,0,"According to the report, the size of the primary tumor is 1.2 cm, which falls under the T1 category. Furthermore, the 'c' subclassification indicates that the tumor is larger than 1 cm but not larger than 2 cm. This is consistent with the information provided in the rules, specifically New Rule 19, which states that tumor size in millimeters should be converted to centimeters for T stage determination, with T1 being equal to or less than 2 cm.",T1c,51.0
1009,TCGA-BH-A0DZ.16DE55CE-076E-43D3-84BD-332A79B95EFD,1,"P.22/33. BIAGNOSIS: AREAST. LEFT. BOTAL MASTECTOMY -. COBULAR NEOPLASIA (ATYPICAL LOBULAR HYPERPLASIA) (sec comment). B. FIBROADENOM, DUCTAL EPITHELIAL HYPERPLASIA, FIBROCYSTIC CHANGE. C. SKIN AND NIPPLE, NO TUMOR SEEN. PART 2: BREAST, RIGHT, TOTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA, NOS TYPE, MODERATELY DIFFERENTIATED. 8. THE TUMOR IS MULTIFOCAL, MULTICENTRIC, LOCATED AT THE JUNCTION OF UPPER OUTER QUADRANT. (UOQ) AND UPPER INNER QUADRANT (UIO) AS WELL AS IN THE UPPER OUTER QUADRANT (UOO). c. THE TUMOR NODULES MEASURE 2.5 CM (GROSS MEASUREMENT) AND 0.5 CM (MICROSCOPIC. MEASUREMENT) RESPECTIVELY. D. NOTTINGHAM SCORE 6/9 (TUBULES 2. NUCLEAR GRADE 2, MITOSIS 2),OVERALL GRADE 2/3. E. NO DEFINITIVE LYMPHOVASCULAR INVASION IS IDENTIFIED. F. DUCTAL CARCINOMA IN 8ITU, SOLID TYPE WITH COMEDO NECROSIS, NUCLEAR GRADE 3 WITH. LOBULAR EXTENSION, COMPRISING 25% OF THE TOTAL TUMOR VOLUME AND IS PRESENT IN. ASSOCIATION AND AWAY FROM THE INVASIVE CARCINOMA. G. MARGIN3: DEEP AND ANTERIOR MARGISN OF RESECTION ARE FREE OF INVASIVE AS WELL AS IN SITU. CARCINOMA, CLOSEST ANTERIOR MARGIN IS 7MM AWAY. K. ATYPICAL DUCTAL HYPERPLASIA. PREVIOUS BIOPSY SITE CHANGES (I/1 AND #2), ( 3EC COMMENT-2). I. FIBROADENOMA, PSEUDOANGIOMATOUS STROMAL HYPERFLASIA (PASH), COLUMNAR CELL CHANGE. J. SKIN AND NIPPLE, NO TUMOR SEEN. K. ER-POSITIVE, PR-POSITIVE. MER 2/NEU -STRONGLY POSITIVE (IHC 3+ AS WELL AS FISH-AMPLIFICATION),. CROSS REFER. PART 3: #1 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY-. ONE LYMPH NODE WITH METASTATIC CARCINOMA, THE METASTATIC FOCUS MEASURES 6MM (ON GLASS. SLIDE) FOCAL EXTRACAPSULAR EXTENSION IS IDENTIFIED (1/1). PART 4: #2 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). PART 5: #3 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY -. ONE BENIGN LYMPM NOPE, NO TUMOR SEEN (0/1). PART 6: #4 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY -. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). PART 7: NON-SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY-. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). LATERALITY: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. PROCEDURE: Right. Simple mastactoiny. Upper outer quacrant. SIZE OF TUMOR: Upper inner quadrant. MULTICENTRICTYMOUTIFOCAUTY OF Maximum INVASIVE dimension FOCI: Invasivo component: , 5 on. TUMOR AGGREGATE SIZE: TUMOR TYPE (invasivo component): Sum of the sizes of multiple invasive tumors: 3.0 cm. NOTTINGHAM SCORE: Ductal adenocamino, NOS. Nuclear grade: 2. Tubule formation 2. Milorie activily 2. total Nottingham score: G. ANO|OLYMPHATIC INVASION: No Nottingham grade (1. 2, 3): 2. DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Yes, malignant zonea. Solid. Comedo. SURGICAL MARGINS INVOLVED By INVASIVE of COMPONENT: tumor occupied by In situ component: 25 %. Percent DCIS admixed und outsino of Invasivo carcinoma component. SURG MARGINS INVOLVED BY IN SITU No COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: 4. Discrepancy. SENTINEL NODE METASTASIS: H/E stain. ONLY KERATIN POSITIVE CELLS ARE Yes PRESENT: initials Mittory. CUALI,. SIZE OF NODAL METASTASES: LYMPH NODE META8TASIS(-ES) WITH Diameter EXTRACAPSULAR of targest lymph EXTENSION: node motestasis: 8 mm. METASTASES TO IPSILATERAL INTERNAL No Yes MAMMARY LYMPH NODE (IF APPLICABLE): T STAGE, PATHOLOCIC. SKIN INVOLVED (ULCERATION): N STAGE, PATHOLOGIC-. p12. M STAGE, PATHOLOGIC: pN1. ESTROGEN RECEPTORS. pMX. poritive. PROGESTERONE RECEPTORS: HER2/NEU: positive. 3+.",BRCA,1,"Based on the report, the largest tumor nodule measures 2.5 cm in gross measurement. According to New Rule 13, we use the maximum value to determine the T stage. New Rule 19 states that if the tumor size is given in millimeters, it should be converted to centimeters for T stage determination. However, in this case, the size is already given in centimeters. Using the AJCC staging system for breast cancer (Rule 6) and the modified Rule 8, we can determine that the T stage is T2, as the tumor size is greater than 2 cm but less than or equal to 5 cm.",T2,52.0
637,TCGA-A8-A081.DE25BF82-5F7A-489B-BFC1-9386C44E7D62,1,"Diagnosis: 1. Ablated (right) breast sample with a moderately differentiated invasive ductal. carcinoma (tumor diameter: 3.0 cm; minimum distance to dorsal margin 0.3 cm, other. margins are 1 cm and remain free). In conclusion, this is a moderately differentiated invasive ductal carcinoma. Concluding tumor classification: NOS, G II, pT2N0(sn)LOVORO.",BRCA,0,"Based on the report, the tumor diameter is given as 3.0 cm which falls in the T2 category (T2: > 2 cm but <= 5 cm) according to the new rule 19. The report also mentions that the tumor is moderately differentiated invasive ductal carcinoma which is consistent with the diagnosis.",T2,53.0
656,TCGA-A8-A08T.5780D50C-5BF0-4392-BC9B-894D1369866A,1,"Diagnosis: ). Two foci of a moderately differentiated invasive ductal carcinoma. (tumor diameters: 3 cm and 2 cm) with focal intraductal components and. circumscribed angioinvasion. No infiltration or ulceration of the skin. Tumor classification: NOS, G II, pT2(mult)N1aL1VOM1RO.",BRCA,1,"Based on the report, there are two foci of a moderately differentiated invasive ductal carcinoma with tumor diameters of 3 cm and 2 cm. According to New Rule 21, we use the largest tumor focus to determine the T stage. In this case, the largest tumor focus is 3 cm, which falls under T2 category (New Rule 19).",T2,54.0
694,TCGA-AC-A23E.C976ACED-7FF8-4287-9D68-C6FD17895FC0,1,"Hospital of Origin: QC Pathologist: FINAL PATHOLOGIC DIAGNOSIS: A. Right axillary sentinel lymph node: One lymph node, total replacement by metastatic. adenocarcinoma. Confirms frozen section diagnosis. Size of involved node: 2 cm. B. Right breast mastectomy: Invasive ductal carcinoma. Architectural score: 1 of 3. Nuclear score: 2 of 3. Mitotic score: 2 of 3. Total score: 5.of 9 = Grade I. Size: 3.8 cm. No evidence of skin or nipple involvement. Deep margin of excision is free of carcinoma. C. Right axillary sentinel lymph node #2: One lymph node, no evidence of metastatic carcinoma. pTNM classification: pT2 pN1 Mx. COMMENTS: CLINICAL HISTORY: Preoperative Diagnosis: Right breast cancer ER positive. Site : breast. NOS 650.4. 32%, PR 84%. Postoperative Diagnosis: Symptoms/Radiologic Findings: SPECIMENS: A. Right axillary sentinel node at 900 with frozen section. B. Right breast. C. Right axillary sentinel node #2. CODES: PROCEDURAL DEMOGRAPHICS: 4. u. Accession Date/Time: GROSS DESCRIPTION: The specimen is received in three containers labeled with. the patient's name. A. Container A is agaitionally labeled 'right axillary. sentinel node' and contains a 1.5 cm yellow-tan firm fatty. nodule consistent with possible lymph node. The nodule is. bisected and entirely submitted for frozen section with the. residual entirely resubmitted for permanent section in. cassette A labeled. B. Container B is additionally labeled 'right breast' and. contains a 1050.0 g, 22.0 x 18.5 x 6.5 cm simple mastectomy. specimen partially surfaced by a 22.5 x 12.5 cm portion of. pink-tan skin bearing a central 1.5 x 1.3 x 0.7 cm everted. nipple. Orientation is not offered or possible. Located 5.0. cm from the nipple is a 2.3 cm partially healed pink-tan. linear incision possibly consistent with previous biopsy. site. Additionally, three tan-brown granular lesions are. identified. These lesions range from 0.4 up to 1.0 cm in. greatest dimension and reside 3.0 to 6.0 from the nipple. The deep margin is inked and the specimen is serially. sectioned to reveal a 3.8 x 3.5 x 2.6 cm gray-white firm,. gritty mass surrounded by fibrosis. This mass resides 2.0 cm. below the skin's surface and approaches to within 2.3 cm of. the inked deep margin. The remainder of the cut surface is. comprised of predominantly yellow-tan adipose tissue admixed. with moderate amounts of interspersed gray-white cystic. fibrous tissue. No additional lesions are identified. Representative sections are submitted in cassettes B1 - 11. labeled. designated as follows: B1, nipple;. B2, skin lesions; B3, inked deep margin, perpendicular; B4 -. 88, mass; 89 - B11, uninvolved tissue from each of the three. uninvolved quadrants. Additionally, a yellow and green. cassette are submitted for genomics research each labeled. C. Container C is additionally labeled 'right axillary. sentinel node #2' and contains a 0.9 cm yellow-tan firm. fatty nodule consistent with possible lymph node. The. specimen is bisected and entirely submitted in cassette C. labeled. INTRA-PROCEDURE CONSULTATION: A. FROZEN SECTION DIAGNOSIS: Positive for tumor per Dr. resuits were communicated to. after confirming patient. identity.",BRCA,1,"Based on the report, the size of the primary tumor in the right breast is 3.8 cm, which falls within the T2 category of the AJCC staging system for breast cancer (T2: > 2 cm but <= 5 cm). The maximum size of the tumor is used to determine the T stage, even if it is given in centimeters or millimeters, converted to centimeters (Modified Rule 8).",T2,55.0
802,TCGA-AO-A0JG.3671D46F-6D69-42DA-9830-24F67EB8B0B6,1,"Clinical Diagnosis & History: year old female with 2.7 cm right breast cancer, lower outer quadrant and. FNA (+) metastatic right lymph node. Specimens Submitted: 1: SP: Right breast and axillary contents levels one and two with tags. attached. 2: SP: Subscapular nodes, right axilla level one. DIAGNOSIS: 1. BREAST, RIGHT; MASTECTOMY AND AXILLARY DISSECTION: - INVASIVE DUCTAL CARCINOMA, MIXED MUCINOUS & NOS TYPE AND WITH. SOLID-PAPILLARY FEATURES, HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE. FORMATION), NUCLEAR GRADE II/III (MODERATE VARIATION IN SIZE AND SHAPE). MEASURING 2.3 CM IN LARGEST DIMENSION MICROSCOPICALLY. - (DCIS) IS ALSO IDENTIFIED, SOLID AND CRIBRIFORM TYPES WITH. INTERMEDIATE NUCLEAR GRADE. AND MINIMAL NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR. MASS, AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN THE LOWER OUTER QUADRANT. - THE DCIS IS LOCATED IN THE LOWER OUTER QUADRANT AND LOWER INNER. QUADRANT. - NO INVOLVEMENT OF THE NIPPLE BY EITHER IN SITU OR INVASIVE CARCINOMA. IS IDENTIFIED. - CALCIFICATIONS ARE PRESENT IN BENIGN BREAST PARENCHYMA. - VASCULAR INVASION IS PRESENT. - INVASIVE CARCINOMA IS CLOSE (LESS THAN OR EQUAL TO 1 MM) TO THE. FOLLOWING SURGICAL. MARGIN(S) : BLUE INKED MARGIN (ANTERIOR). NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE NON-NEOPLASTIC BREAST TISSUE SHOWS BIOPSY SITE CHANGES AND. PROLIFERATIVE FIBROCYSTIC. CHANGES INCLUDING INTRADUCTAL PAPILLOMA. - LEVEL 1: METASTATIC ADENOCARCINOMA TO FOUR OUT OF TEN LYMPH NODES. (4/10). THE LARGEST METASTATIC FOCUS MEASURES 2.5 CM. THERE IS EXTRANODAL EXTENSION OF CARCINOMA, FOCAL. - LEVEL 2 : THREE BENIGN LYMPH NODES (0/3). Page or. IMMUNOHISTOCHEMICAL STAIN WAS PERFORMED ON FORMALIN-FIXED TISSUE WITH THE. FOLLOWING RESULTS FOR INVASIVE CARCINOMA (BLOCK 1T6) : HER2. NEGATIVE (0 / 1+). 5% OF INVASIVE TUMOR CELLS EXHIBIT COMPLETE MEMBRANOUS STAINING;. UNIFORMITY OF STAINING: ABSENT. HOMOGENEOUS, DARK CIRCUMFERENTIAL PATTERN: ABSENT. Comment: Controls are satisfactory. s PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 2. LYMPH NODES, RIGHT AXILLA LEVEL ONE, SUBCAPSULAR: - SIX BENIGN LYMPH NODES (0/6). Some of the immunohistochemistry and. tests were develoned and their. performance characteristics were determined by. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88) as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1) The specimen is received fresh labeled, ""right breast and axillary. contents levels one and two with tags attached and consists of a breast. measuring 19 x 18 x 3 cm with overlying skin ellipse measuring 11 x 3 cm. Situated centrally on the skin surface is an everted nipple measuring 1 x 1. x 0.6 cm and areola measuring 3 x 3 cm. A suture demarcates the axillary. contents which measures 11 x 7 x 3 cm. Two tags are present, designating. levels one and two. The posterior surface of the breast is inked black, the. anterior blue and the axillary aspect is inked yellow. The specimen is. serially sectioned to reveal a 2.5 cm diameter mass in the lower outer. Page 3 or. quadrant and 1 cm from the deep margin. A clip is identified in the mass. The remaining breast tissue shows nodular fibroadipose tissue. The axillary. tisbue is dissected to reveal multiple lymph nodes, ranging in size from 0.5. cm to 2.5 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. Summary of sections: N - nipple. NB - nipple base. D - deep margin. T - tumor. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 lymph nodes, level 1. L2 lymph nodes level2. 2). The specimen is received in formalin, labeled ""subscapular nodes right. axilla level one"" and consists of pink tan firm lymph nodes ranging from 0.8. to up 2 cm in greatest dimension. All identified lymph nodes are submitted. Summary of sections: LN lymph nodes. BLN- bisected lymph nodes. Summary of Sections: Part 1: SP: Right breast and axillary contents levels one and two with tags. attached. Block. Sect. Site. PCs. 1. D. 1. 6. L1. 6. 1. L2. 2. 1. LIQ. 1. 1. LOQ. 1. 2. N. 2. 1. NB. 1. 3. 3. 1. UIQ. 1. 1. UOQ. 1. Part 2: SP: Subscapular nodes, right axilla level one. Block. Sect. Site. PCs. 2. BLN. 2. 1. LN. 1. Page 4 or.",BRCA,2,"The report mentions that the largest diameter of the primary tumor is 2.3 cm, which falls within the T2 category (> 2 cm but <= 5 cm) according to the AJCC staging system for breast cancer.",T2,56.0
870,TCGA-AR-A24K.BC7B3577-CA6C-41AD-98E2-89D357D29D37,1,"Final Diagnosis. Yeast, left, wide local excision: Invasive ductal carcinoma, Nottingham grade III (of III), forming a 2.7 x 2.7 x 1.5 cm mass. (AJCC pT2). The margins, including the separately submitted superior margin, are negative for tumor. The closest margin. (superior) is free by 1.5 cm. Lymph nodes, left axillary sentinel, excision: Multiple (2) left axillary sentinel lymph nodes are negative for tumor [AJCCpNO (i-. sn)]. Blue dye is identified in both left axillary sentinel lymph nodes. Immunohistochemical cytokeratin stain was performed on. the paraffin embedded sentinel lymph node tissue and confirms the H&E impression.",BRCA,0,"The report states that the invasive ductal carcinoma forms a 2.7 x 2.7 x 1.5 cm mass (AJCC pT2). According to the rules provided, we should use the maximum size of the tumor to determine the T stage. In this case, the maximum size is 2.7 cm, which falls under the T2 category (T2: > 2 cm but <= 5 cm).",T2,57.0
698,TCGA-AC-A2BK.3E54B0CE-8863-4728-BC95-A47C1869F52A,1,"MRN : OV. MD. Laboratory Patient Report. Print Date/Time: Histopathological Examination. 4. - Received: ; Complete. Pre-op Diagnosis : Left Breast Car. MD. Specimens. Breast, left. Frozen Diagnosis. : GROSS EXAMINATION: The specimen is received in a container labeled with the. name of the patient and labeled as breast, left. The. specimen consists of a mastectomy designated left which. measures en bloc 31 x 20 x 5.5 cm and weighs 1515 g. Anteriorly located is an ellipse of brown skin which. measures 22 x 17 cm. Centrally located is a 4.5 cm diameter. areolar complex with slightly retracted nipple which is. sampled in block 1. The deep margin is inked and the. specimen is serially sectioned and shows a gray-tan firm. mass in the upper outer quadrant. This mass measures 2.8. x. 2.5 x 2.3 cm and grossly extends to within 1 cm of the inked. deep margin. A section of skin overlying the mass is. submitted in block 2. A section of the Inked deep margin is. submitted in block 3. Sections of the mass are submitted in. block 4-7. The remaining breast is composed of yellow. lobulated adipose tissue admixed with islands of gray-white. rubbery tissue. The breast is divided into four quadrants;. upper inner, lower inner, upper outer and lower outer and. sampled in blocks 8-11. The attached axillary tissue is. dissected for lymph nodes with the lower part sampled in. blocks 12-14 in the upper part sampled in blocks 15-16. DIAGNOSIS BASED ON GROSS AND MICROSCOPIC EXAMINATION: SPECIMEN TYPE: Modified radical mastectomy. LYMPH NODE SAMPLING: Axillary dissection. LATERALITY Left. TUMOR SITE: Upper outer quadrant. SIZE OF INVASIVE COMPONENT: Greatest dimension. 2.8 cm. ADDITIONAL DIMENSIONS: 2.5 x 2.3 cm. HISTOLOGIC TYPE: Invasive ductal carcinuna. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : 4. Visit # : HISTOLOGIC GRADE: Nottingham histologic score 3/3. DUCT IN SITU COMPONENT: Not identified. MICROCALCIFICATIONS Not identified. EXTENT OF INVASION. PRIMARY TUMOR (PT) : pT2: Tumor more than 2.0 cm but not more. than 5.0 cm in greatest dimension. REGIONAL LYMPH NODES (PN) : pN2a: Metastases in 4 to 9. axillary lymph nodes. NUMBER EXAMINED: 23. NUMBER INVOLVED: 6. DISTANT METASTASIS (PM) : PMX. MARGINS : Uninvolved by invasive carcinoma. DISTANCE TO NEAREST MARGIN: 1.0 cm to deep margin. VENOUS/LYMPHATIC (LARGE/SMALL VESSEL) INVASION (V/L) : Present. Summary of pathologic staging: pT2N2aMXG3 . Intradepartmental consultation obtained. COMMENT: Immunohistochemical stains for estrogen and. progesterone receptors and HER2 are pending and will be. supplementally reported when complete. M.D. ., MD. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 2. Visit # :",BRCA,2,"Based on the report, the size of the largest focus of the invasive component of the tumor is 2.8 cm. According to the AJCC staging system for breast cancer and the rules provided, the T stage should be determined using the maximum size of the tumor. In this case, the maximum size of the tumor is 2.8 cm, which falls under T2 (tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension).",T2,58.0
865,TCGA-AR-A1AV.5AD5B38F-5CC1-4A2F-96E6-F344D8FE0149,1,"Final Diagnosis. Breast, left, modified radical mastectomy: Infiltrating ductal carcinoma, Nottingham grade II (of. III) [tubules 3/3, nuclei 2/3, mitoses 2/3; Nottingham score 779], forming a mass (2.8 x 2.3 x 2.1. cm) located in the retroareolar region of the breast. Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. Calcifications are not seen. The tumor involves the. overlying skin [AJCC pT4]. All surgical resection margins, including the skin and deep margins,. are negative for tumor (minimum tumor free margin, 1.1 cm, anterior superior margin). A single. (of 23) left axillary mid/low lymph node is positive for metastatic carcinoma. The positive lymph. node (1.7 cm in greatest dimension) shows extranodal extension. Lymph nodes, left high axillary, excision: Multiple (2) left high axillary lymph nodes are. negative for tumor.",BRCA,1,"The report states that the tumor involves the overlying skin (AJCC pT4), which is the basis for determining the T stage.",T4,59.0
1348,TCGA-EW-A1P3.042304AE-706A-4033-A97F-3765A6AEC649,1,"F. Pathologic Interpretation: A. Sentinel node #1, left side, CT. ouch prep: - No tumor seen in one lymph node (0/1). - Immunohistochemistry for Keratin to follow. B. Left/breast 1 stitch superior, 2 stitches lateral: - Invasive, moderately differentiated ductal carcinoma, intermediate nuclear grade, 0.5 cm. - Specimen margins are negative (see tumor summary). - Fibroadenoma, 0.5 cm. C. Sentinel node #1, right side CT. - No tumor seen in two lymph nodes (0/2). - Immunohistochemistry for Keratin to follow. D. Non-sentinel lymph node right side: - No tumor seen in one lymph node (0/1). E. Sentinel lymph node #2, right side, CT #. touch prep: - No tumor seen in one lymph node (0/1). - Immunohistochemistry for Keratin to follow. F. Right breast additional superior flap: - No tumor seen in adipose tissue. G. Right breast 1 stitch superior, 2 stitches lateral: - Invasive, moderately differentiated ductal carcinoma, intermediate nuclear grade, 2.5 cm, extending within 0.1 cm of the. anterior specimen margin (see tumor summary). TUMOR SUMMARY ""B"": Specimen Type: Mastectomy. Lymph Node Sampling: Sentinel lymph node(s) only. Laterality: Left. Tumor Site: Upper inner quadrant. Size of Invasive Component: Greatest dimension: 0.5 cm. Histologic Type: Invasive ductal carcinoma. Histologic Grade: Tubule Formation: Moderate 10% to 75% (score =2). Nuclear Pleomorphism: Moderate increase in size, etc (score =2). Mitotic Count: 10 to 20 mitoses per 10 HPF (score = 2). Total Nottingham Score: Grade II: 6-7 points. Pathologic Staging (pTNM). Primary Tumor: pT1a. Regional Lymph Nodes: pNO. Number examined: 1. Number Involved: 0. Distant Metastasis: pMX. Margins: Margins uninvolved by invasive carcinoma. Venous/Lymphatic Invasion: Absent. TUMOR SUMMARY ""G"": Specimen Type: Mastectomy. Lymph Node Sampling: Sentinel lymph node with axillary dissection. Laterality: Right. Tumor Site: Lower outer quadrant. SURGICAL PATHOL Report. Size of Invasive Component: Greatest dimension: 2.5 cm. Histologic Type: Invasive ductal carcinoma. Histologic Grade: Tubule Formation: Minimal less than 10% (score =3). Nuclear Pleomorphism: Moderate increase in size, etc (score = 2). Mitotic Count: Less than 10 mitoses per 10 HPF (score =1). Total Nottingham Score: Grade II: 6-7 points. Pathologic Staging (pTNM). Primary Tumor: pT2. Regional Lymph Nodes: pNO. Number examined: 4. Number Involved: 0. Distant Metastasis: pMX. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: 1.0 mm. Specify which margin: Anterior. Venous/Lymphatic Invasion: Absent. not with require formain or molecular freed, paramfn embedded tissue Detection is by LSAB. The results are read by a pathologier as positive or negative. NOTE: Some FDA immunohistochemical approval. These clones are used: ID5-ER, PgR 636-PR, A486-HER2, H-11=EGFR, CCH2/DOG9=CMV, F39.4. 1-AR and HPV by ISH. AII immunohistochemical. antibodies are analyte specific reagents (ASRs) validated by our laboratory (Her 2. Parvo, H. pylori, HScore). These ASRs are clinically useful indicatora stains are that used do. , MD. As the attending pathologiet, I attest that I: (0 Examined the relevant. preparation(s) for the specimen(s); and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. A. Immunohlstochemistry for Keratin is negative for tumor. C. Immunohistochemistry for Keratin is negative for tumor. E. Immunohistochemistry for Keratin is negative for tumor. MD. Intraoperative Consultation. A (FS): No malignancy seen in one lymph node (0/1). C (FS): No malignancy seen in two lymph nodes examined (0/2). E (FS): No malignancy seen in one lymph node examined (0/1). MD. Clinical History: SURGICAL PATHOL Report. Patient is a. female with right infiltrate ductal carcinoma. Specimen(s) Received: A: Sentinel node #1, left side, ct ;. ouch prep (FS). B: Left Breast 1 stitch superior, 2 stitches lateral, fresh. C: Sentinel node #1, right side ct 1 (FS). D: Non-sentinel lymph node right side. E: Sentinel lymph node #2, Right side, ct #. touch prep (FS). F: Right breast additional superior flap - perm. G: Right breast 1 stitch superior, 2 stitches lateral fresh. Gross Description: A. Received fresh and labeled ""sentinel node #1, left side, ct. touch prep (FS)"" is a segment of tan-yellow, fibroadipose. tissue measuring 2.5 x 1.1 x 0.5 cm. Cassettes are submitted as follows: 1. One lymph node bisected submitted in toto for frozen section. 2. Remainder adipose tissue submitted in toto in one cassette. B. Received fresh and labeled ""left breast 1 stitch superior, 2 stitches lateral"" is a mastectomy specimen, which measures. 22.0 x 19.0 x 4.0 cm and weighs 790.0 grams. The specimen has an attached ellipse of paie-tan skin with areola and. nipple measuring 9.0 x 4.5 cm. The skin and nipple are unremarkable. The specimen is oriented by one stitch superior. and two stitches lateral. Surgical margins are inked as follows: superior anterior margin inked in green and the remaining. margins are inked in black. Serial section through the specimen revealed one suspicious area of pale-pink induration. consistent with previous biopsy site. The indurated area measures approximately 1.1 cm in greatest dimension and is. located in the upper inner quadrant at 11 to 12 o'clock, 0.8 cm from the superficial margin, 0.9 cm from the deep margin,. 3.0 cm from the superior margin, 16.0 cm from the inferior margin, 3.5 cm from the medial margin and 12.0 cm from the. lateral margin. An area of interparenchyma hemorrhage is also identified in the inner upper quadrant, approximately 5.0. cm from the nipple. An additional suspicious area of pale-pink Induration with a granular, cut surface is identified in the. lower outer quadrant at approximately 4 o'clock. The second suspicious area is located 2.6 cm away from the deep. margin, 1.8 cm away from the superficial margin, 10.5 cm away from the superior margin, 8.5 cm away from the inferior. margin, 4.5 cm away from the lateral margin and 13.5 cm away from the medial margin. Cassettes are submitted as. follows: 1. Superficial margin. 2. Deep margin. 3. Superior margin. 4. Inferior margin. 5. Medial margin. 6. Lateral margin. 7-13. Suspicious area and surrounding parenchyma submitted in toto. 14. Section of the hemorrhagic area. 15. Sections of the second suspicious area. 16. Section of the nipple. 17. Representative section of uninvolved breast parenchyma in the upper outer quadrant. 18. Representative section of uninvolved parenchyma in the upper inner quadrant. 19. Representative section of uninvolved parenchyma in the lower inner quadrant. 20. Representative section of uninvolved parenchyma in the lower outer quadrant. C. Received fresh and labeled ""sentinel node #1, right side. is a segment of tan-yellow, fibroadipose tissue. measuring 2.0 x 1.3 x 1.0 cm. Examinations of the specimen revealed two possible lymph nodes. Cassettes are submitted. as follows: 1. One lymph node bisected and submitted for frozen section. 2. One lymph node bisected submitted for frozen section. 3. Remainder of the adipose tissue submitted for frozen section in one cassette. D. Received in formalin and labeled ""non-sentinel lymph node right side""is a segment of tan-white, soft tissue measuring 1.8. x 0.7 x 0.4 cm. The specimen is bisected and submitted in toto in one cassette. SURGICAL PATHOL Report. E. Received fresh and labeled ""sentinel lymph node #2, right side, c' buch prep (FS)"" is a segment of tan-yellow,. fibroadipose tissue measuring 2.1 x 1.1 x 0.6 cm. Examinations of the segment revealed one lymph node. Cassettes are. submitted as follows: 1. One lymph node bisected and submitted for frozen section. 2. F. Received in formalin and labeled ""right breast additional superior flap"" is a segment of tan-yellow, fibroadipose tissue. measuring 6.0 x 3.7 x 1.6 cm. The specimen is received unoriented. One of the surface is rough, irregular and appears. to. face the previous resection site. The surface was inked in orange. The opposite surface was inked in black. Serial. sections through the specimen revealed no suspicious areas. Representative sections submitted in six cassettes. G. Received fresh and labeled ""right breast 1 stitch superior, 2 stitches lateral"" is a mastectomy specimen, which measures. 23.0 x 22.0 x 4.0 cm and weighs 670.0 grams. There is an ellipse of skin with areola and nipple, which measures 9.0 x 3.5. x 0.2 cm. The nipple measures 1.2 x 1.1 cm. The skin is unremarkable. The section margins are inked as follows: superior, green and all other margins are inked in black. Serial section through the specimen revealed an area of pale-. pink induration measuring 2.5 x 1.4 x 1.2 cm and is located in the lower outer quadrant. A firm area is present at the. superficial margin and is located 3.0 cm from the inferior margin, 2.5 cm from the deep margin and 7.0 cm from the. superior margin. The remainder of the parenchyma consists of unremarkable fibroadipose tissue with approximately 70%. adipose tissue and 30% stroma. No other suspicious areas were identified. Cassettes are submitted as follows: 1. Anterior margin. 2. Inferior margin. 3. Deep margin. 4. Lateral margin. 5. Superior margin. 6. Medial margin. 7-13. Area of induration submitted. 14. Representative section of uninvolved parenchyma in the upper outer quadrant. 15. Representative section of uninvolved parenchyma in the upper inner quadrant. 16. Representative section of uninvolved parenchyma in the lower inner quadrant. 17. rative section of uninvolved parenchyma in the lower outer quadrant near the lesion. ICD-9(s): 174.2 174.5.",BRCA,0,"Based on the report, the largest focus of the invasive component of the tumor in the right breast is 2.5 cm, which falls under the T2 category in the AJCC staging system for breast cancer. The left breast tumor is 0.5 cm and falls under T1, but since the T stage is determined by the largest tumor, the T2 stage is used.",T2,60.0
774,TCGA-AN-A0XS.D5C9D3FF-3799-4773-8A86-B000DBE42BD8,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. Stage: 1c N Stage: 1a M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,"The report does not provide a specific size for the primary tumor in centimeters or millimeters. However, it does mention that the cancer is infiltrative ductal carcinoma and the stage is 1c. According to the AJCC staging system for breast cancer, T1 tumors are 2 cm or less in size. Given that stage 1c is an early stage of breast cancer, it is reasonable to assume that the tumor size is within the T1 range.",T1,61.0
616,TCGA-A8-A06X.738B601A-24D8-4261-B000-198648213070,2,"Diagnosis: Invasive ductal breast carcinoma (maximum diameter 5.5 cm, malignancy grade. III) with angioinvasion and a mediocranial safety margin at least 3 mm wide. Tumor classification: G3 (L0, V0), pT3, Nx, Mx. Diagnosis: Tumor-free lymph nodes (total N = 11, pN0).",BRCA,0,"The report explicitly states that the maximum diameter of the primary tumor is 5.5 cm, which falls in the T3 range (T3: > 5 cm) according to the AJCC staging system for breast cancer. The rule used for this prediction is: 'Rule 6: The T stage should be determined according to the AJCC staging system for breast cancer' and 'Modified Rule 8: The maximum size of the tumor should be used to determine the T stage, even if it is given in centimeters or millimeters, converted to centimeters.'",T3,62.0
625,TCGA-A8-A07F.D1456192-83E7-4FC8-B783-90D615830156,1,"Diagnosis: 1. Ablated (left) breast sample with a moderately differentiated invasive ductal. carcinoma with an intraductal component (tumor diameter: 5.0 cm. Tumor classification: NOS, G II, pT2N1aLOVORO.",BRCA,1,"The report states that the tumor diameter is 5.0 cm, which falls in the T2 category (T2: > 2 cm but <= 5 cm) according to the AJCC staging system for breast cancer. This is in line with New Rule 19 and Modified Rule 8.",T2,63.0
1081,TCGA-BH-A1FJ.8169BE67-03C8-4F4D-9A60-200705B795AE,2,"Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE or LMP: AGE. DATE or LAST DELIVERY: PRB-OP DIAGNOSIS: RIGHT BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: RIGHT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: RIGHT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. and axillary contents. FINAL DIAGNOSIS: RIGHT MODIFIED RADICAL MASTECTONY: INTILTRATING AND INTRADUCTAL CARCINOMA WITH PROMINENT VASCULAR SPACE INVOLVEMENT AND INTERMEDIATE. NUCLEAR. GRADE, 6.0 CM. INTRADUCTAL CARCINOMA IS COMEDO TYPE AND COMPRISES APPROXIMATELY 20% OF TUMOR VOLUME. - MICROSCOPIC FOCI OF TUMOR IN VASCULAR SPACES INVOLVE RANDOM SECTIONS OF UPPER OUTER, LOWER INNER AND UPPER. INNER QUADRANTS. - METASTATIC CARCINOMA INVOLVES SIX or THIRTY-FIVI (6/35) AXILLARY LYMPH NODES. - NIPPLE, NEGATIVE FOR PAGET'S DISEASE. - SURGICAL MARGINS FREE OF TUMOR IN PLANES OF SECTION. - RANDOM SECTIONS OF LOWER OUTER QUADRANT SHOWING FIBROCYSTIC CHANGES WITH FOCAL SEVERELY ATYPICAL DUCTAL. EPITHELIAL HYPERFLASIA. NOTE: ER/PR immunoperoxidase assay will be performed on block A14. s U P P L E N E N T A L R P o R T. IMMUNOPEROXIDASE IDENTITICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE A14. DISTINCT. INTRANUCLEAR STAINING IS IDENTIFIED FOR PROGESTERONE RECEPTOR (80%) BUT ONLY RARELY FOR ESTROGEN RECEPTOR. (10%) THEREFORE, PROGESTERONE RECEPTOR IS INTERPRITED AS POSITIVE AND ESTROGEN AS NEGATIVE. My signature below is attestation that I have reviewed all slides and agree with the findings. as. noted. below.",BRCA,1,"The report states that the size of the primary tumor is 6.0 cm, which is larger than the maximum limit for T2 (> 5 cm) and falls within the range for T3. Therefore, the T stage for this patient is T3.",T3,64.0
875,TCGA-AR-A24P.0BF7CB67-49F1-42EA-8B41-988BD7E0DE61,0,"Breast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade II (of III), forming a 1.5 x 1.4 x 1.2 cm. mass. (AJCC pTlc). Associated ductal carcinoma in situ, intermediate nuclear grade, compromises approximately 20% of the tumor. Resection margins are free of tumor. Separately submitted lateral, deep, inferior and superior margins are free of tumor. Lymph nodes, left axillary sentinel Nos. 1, 2, and 3, excision: Multiple (3) left axillary sentinel lymph nodes without blue dye are. negative for tumor. [AJCCpNO(i-)] Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel. lymph node tissue and confirms the H&E impression.",BRCA,0,"Based on the report, the largest focus of the invasive component of the tumor is 1.5 x 1.4 x 1.2 cm. Using New Rule 13, we take the maximum value, which is 1.5 cm. According to New Rule 19, we convert millimeters to centimeters, resulting in a tumor size of 1.5 cm. This falls within the T1 range (T1: <= 2 cm) of the AJCC staging system for breast cancer.",T1,65.0
